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ABSTRACT

Mechanisms governing the release of drugs from controlled delivery systems are mainly
diffusion, osmosis and erosion. For poorly soluble drugs, the existing mechanisms are
limited to osmosis and/or matrix erosion. These mechanisms are commonly employed to
control drug release from single unit and multi-unit dosage forms. More recently, multiunit dosage forms have gained considerable popularity for controlled release technology
due to their advantages over single unit dosage forms. However, the mechanism of
polymer controlled surface erosion from a multi-unit dosage form has never been
reported in the literature. This study describes the development, characterization and
evaluation of a matrix pellet system which releases an insoluble drug via polymer
controlled surface erosion mechanism. Extrusion/Spheronization method was used to
formulate matrix pellets. The effect of various formulation and process parameters
affecting the drug release were characterized by analytical techniques such as Differential
Scanning Calorimetry, X-Ray Diffractometry, and Mercury Intrusion Porosimetry.
Different insoluble drugs were used as model drugs to demonstrate universal applicability
of this novel system. The effect of drug solubility was also investigated on the
mechanism of drug release from this system. Solid dispersions of the model insoluble
drug was formulated to increase its solubility. It was observed that when the drug
properties were changed towards increasing solubility in water, the release mechanism
and rate also changed from pure surface erosion to erosion/diffusion. Drug release of
nifedipine pellets in vivo occurred for more than 24 hours following zero order kinetics in
fasted dogs. Thus it was proved that the approach of controlling drug release by polymer

controlled surface erosion mechanism from a multi-unit pellet system is possible and
such a system may be beneficial than the current marketed dosage forms of insoluble
drugs such as nifedipine.
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PREFACE

This work has been prepared in accordance with the manuscript format option for
dissertation preparation, as outlined in section 11-3 of The Graduate Manual of the
University of Rhode Island. Contained within is a body of work divided in to three
sections.

Included within Section I is Introduction, which introduces the reader to the subject of
this dissertation, a statement of the hypothesis tested herein, and the specific objectives of
my research.

Section II is comprised of five manuscripts, containing the findings of the research

_.../

which comprises this dissertation. These five manuscripts are presented in the format
required by the journal to which they will, or have been, submitted.

Section ill contains appendices containing, ancillary data (information essential to, but
not usually included in published manuscripts) and other details pertinent to the
understanding of the concepts presented in Section II. This dissertation closes with a
complete listing of all the works cited in this dissertation, arranged in alphabetic order by
the author's last name.
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SECTION I

Introduction. A general introduction fo llowed by compilation of the specific
objectives of this research.

A statement of the hypothesis tested in this dissertation.

INTRODUCTION

Release of poorly soluble drugs in a controlled fashion is a challenging task for the
pharmaceutical scientist. The mechanisms that are utilized to control release of drugs are
mainly diffusion, osmosis and erosion. Alza Corporation has developed the GITS
(Gastro Intestinal Therapeutic Systems) system for the release of nifedipine, a sparingly
soluble drug, over a period of 24 hours. This is an "Oros" tablet that delivers drug under
osmotic pressure differences between the GI fluids and the drug formulation encapsulated
in the semi-permeable membrane surrounding the tablet. The release of the drug occurs
as a fine suspension from the laser drilled hole bored in the tablet (1, 2].

Other approaches used are matrix tablets which release the drug in a controlled fashion.
Low to moderate viscosity grade hydrophilic polymers such as hydroxy propyl cellulose,
hydroxy propyl methyl cellulose hydroxy ethyl cellulose, chitosans, alginates etc, have
been used for this purpose. One of the drawback of these matrices is that they are single
units and bioavailability from such matrices is dependent on gastric retention [3, 4] .

Single unit dosage forms of poorly soluble drugs that release the drug by osmosis or
erosion are commercially available. However in vivo drug release from such dosage
forms may not be predictable and complete due to physiological variations in the gastric
retention time and gastric emptying rates. Additionally, the frequency of bowel
movements is also a factor that seriously influences bioavailability of drugs from such
systems.
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During the past 20 years there has been a growing interest in multi-unit solid dosage
forms such as pellets for controlled drug delivery. Pellets offer significant therapeutic
advantages over the traditional single unit dosage forms. Since pellets disperse freely in
the GIT, they invariably maximize drug absorption, reduce peak plasma fluctuations, and
minimize potential side effects without appreciably lowering the bioavailability of the
drug. Pellets also reduce variations in gastric emptying rates and overall transit times.
Thus, intra and inter subject variations of plasma concentrations of the drug, which are
common for the single unit dosage forms, are minimized. Another advantage of pellets
over single unit dosage forms is that the high local concentrations of therapeutic agents,
which may inherently be irritant to the mucosa! membranes, can be avoided. Pellets,
when formulated as modified release dosage forms are less susceptible to dose dumping
than the reservoir-type single unit formulations [5].

During the early developmental phase of nifedipine GITS system, 20% of the population
in the clinical trials taking nifedipine GITS tablet expelled the tablet intact through the
GIT via fecal matter. The pellets on the other hand, due to their small size and large
number are dispersed rapidly in the GIT and thus avoid dose dumping or loss of dosage
form. Pellets also offer technological advantages over single units such as better flow
properties and ease of further processing during tablet compaction or coating for
controlled release. Table I shows a partial list of pellet products marketed in the US.

Traditionally coated pellets have been used for controlled release applications . Most of
the marketed controlled release pellets available today are coated. More recently, matrix

pellets have gained popularity in controlled release technology. Controlled release via
matrix pellets avoids the coating process and thus saves time and money. Pellets,
manufactured by the pharmaceutical industry, are sized between 500 and 2000 µm.
These can be produced in different ways such as spraying a solution or a suspension of a
binder and a drug onto an inert core, building the pellet layer after layer, spraying a melt
of fats and waxes from the top into a cold tower (spray congealing) forming pellets as the
result of the hardening of molten droplets and spraying a binder solution into the whirling
powder using fluidized bed [5]. The most popular method of producing pellets is the
Extrusion-Spheronization technique. This process was first reported by Reynolds (1970)
and by Conine and Hadley ( 1970) and involves four steps: preparation of the wet mass
(granulation), shaping the wet mass into cylinders (Extrusion), breaking up the extrudate
and rounding of the particles into spheres (Spheronization) and finally drying of the
pellets.

Traditionally, in the Extrusion-Spheronization technique, microcrystalline cellulose
(MCC) has been the excipient of choice to prepare matrix pellets. Due to its excellent
plasticity, it is widely used as a carrier or filler in the.Extrusion-Spheronization process.
However, MCC forms a non-disintegrating matrix and thus incorporation of a swelling or
disintegrating agent is necessary for drug release to occur from such a system. Drug
release from such matrices has been studied extensively by O'Conner et al. [6] and it was
concluded that drug release occurred by Higuchi' s square root of time equation and
followed first order kinetics. Incorporation of a poorly soluble drug in such a matrix
system would minimize drug release since the MCC matrix system is non-disintegrating.
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Therefore, such a system would be inappropriate to formulate controlled release pellets of
a poorly soluble drug. Additionally, since the drug is poorly soluble, diffusional release
will be negligible. Thus, the only choice remains is that of an eroding pellet, which is a
matrix pellet system that erodes from the surface as a function of time and releases the
drug which is homogeneously dispersed in the pellet matrix. There is no such system
reported in the literature.

Hellar et al. [7] prepared discs of poly (ortho esters) and studied in vitro and in vivo drug
release of the highly water insoluble levonorgestrel. Poly (ortho esters) are polymers that
erode due to pendent group hydrolysis of the ester groups, however; it is not generally
recognized as safe for pharmaceutical applications. Hellar et al. concluded from his
study that levonorgestrel release from surface-eroding polymer discs bas three important
consequences which are (1) The rate of drug release is directly proportional to drug
loading, (2) The lifetime of the delivery device is directly proportional to device
thickness, and (3) The rate of drug release is directly proportknal to the total surface
area of the disc.

The controlled release systems developed by Hellar et al. using poly (ortbo esters)
showed zero order release for months. Drug released in vitro was analyzed by measuring
the drug present in the device after periodic time intervals of dissolution and the polymer
erosion was detennined by gravimetry. This study demonstrated that an indirect method
such as measuring the drug left in the delivery device after dissolution may be employed

to quantify drug released and also the use of gravimetry to determine polymer erosion
profiles.

Based on the information given above, the specific objectives of this research were,

1. To search for a surface eroding "GRAS" (Generally Recognized As Safe) polymeric

system suitable for Extrusion-Spheronization technique.
2. To develop pellets of poorly soluble drugs for controlled release which releases the
drug following zero order kinetics for 12-24 hours.
3. To characterize and evaluate the release mechanisms by analytical techniques such as
differential scanning calorimetery, x-ray diffractometry, mercury intrusion
porosimetry, particle size distribution, microscopy and in vitro, in vivo analysis.
4. To test the universal application of the system developed initially by using another
poorly soluble drug.
5. If circumstances allow, to test the bioavailability in vivo of one of the model drugs
from the pellets tested in vitro.
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Table I.

Partial list of pellet products marketed in the U.S
Product
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Company

Sudafed S. A.

Glaxo-Wellcome

Theo-24

Searle Pharmaceuticals, Inc.

Theodur S. R.

Key Pharmaceuticals

Nitrostat S. R.

Parke-Davis

Bontril SR

Camrick Laboratories, Inc.

Compazine

Smith Kline & French

Hispril

Smith Kline & French

Nicobid T.S.

U.S. Vitamin

Papaverine HCL, T.D.

Lederle Laboratories

Russ-Tuss

Boots Pharmaceuticals

Slow-bid

Rorer

Theobid S. R.

Glaxo-Wellcome

Inderal L.A.

Ayerst Laboratories

Indocrin S .R.

Merck Sharp & Dohme

Xenical

Roche Pharmaceuticals

Novafed L.A.

Merrel-Dow

Fas tin

Beecham Laboratories

Catazyme S

Organon Pharmaceuticals

Source: Sellasie, L G.,"Pharmaceutical Pellitization Technology", Marcell Dekkar, Inc.,
New York, 12-14, (1989).

HYPOTHESIS TESTED HEREIN

It should be possible to develop a multi-unit controlled release matrix pellet system by

Extrusion/Spheronization technique without microcrystalline cellulose (MCC), which
can release an insoluble drug by polymer controlled surface erosion mechanism
following zero order kinetics for 12-24 hours.
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MANUSCRIPT I

DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF A NOVEL
MULTI-UNIT EROSION MATRIX FOR A POORLY SOLUBLE DRUG.
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Abstract

Mechanisms governing the release of drugs from controlled delivery systems are mainly
diffusion, osmosis and erosion. For poorly soluble drugs, the existing mechanisms are
limited to osmosis and/or matrix erosion, which are commonly employed via single unit
matrix dosage forms. More recently, multi-unit dosage forms have gained considerable
popularity for controlled release technology, because their rapid dispersion in the
gastrointestinal tract maximizes drug absorption and provides reduced peak plasma
fluctuations. Bioavailability from multi-unit dosage forms is affected the least by the
presence of food and gastric emptying rate. This study reports the development of a
novel multi-unit controlled release system for a model poorly soluble drug (thiazole
based leukotriene D4 antagonist, solubility in physiological pH < 1.3 µg/mL) by a
polymer controlled, surface erosion drug release mechanism. The drug, rate controlling
and pellet forming agents (Eudragit~ 100 55 and Eudragit® S 100) and a binder
(polyvinylpyrrolidone, Kollidon®K90F), were wet granulated, extruded and spheronized
to form uniform matrix pellets. In vitro matrix erosion and drug release from the pellets
were determined using USP Dissolution Apparatus I in pH 6.8 phosphate buffer by
gravimetry and UV spectrophotometry, respectively. Results showed that matrix erosion
and drug release from the pellets were well correlated. Pellets eroded with a consequent
reduction in size without any change in the pellet shape for over 12 hours.

Matrix

erosion and drug release followed zero order kinetics. Data obtained strongly suggested a
polymer controlled, surface erosion drug release mechanism.
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1.0

Introduction

Release of poorly soluble drugs from controlled delivery systems is a challenging task for
the pharmaceutical scientist.

Alza Corporation has developed a gastrointestinal

therapeutic system (GITS) for the release of nifedipine, a poorly soluble drug, over a
period of 24 hours. The system is an "Oros" tablet which releases the drug under osmotic
pressure differences between the GI fluids and drug concentration in the semi-permeable
membrane surrounding the tablet. The release of drug occurs as a fine suspension from
the laser drilled GITS device {l). Other approaches for the release of poorly soluble
drugs from controlled release erosion matrix tablets employing hydrophilic cellulosic
polymers are reported (2, 3). These matrices are generally single units and thus may be
associated with drawbacks such as irregular bioavailability due to presence of food and
dependence on gastric emptying time. Therefore, existing mechanisms for the release of
poorly soluble drugs by controlled release are limited to osmosis and/or erosion. Due to
their negligible aqueous solubility, diffusion has practically very little or no contribution
in the release of such drugs from the controlled delivery system.

More recently, multi-unit dosage forms have gained considerable popularity over
conventional single units for controlled release technology. Due to their rapid dispersion
in the gastrointestinal tract, they maximize drug absorption, reduce peak plasma
fluctuations, minimize potential side effects without lowering drug bioavailability. They
also reduce variations in gastric emptying rates and overall transit times. Thus, intra and
inter-subject variability of plasma profiles, which are common with single-unit regimens,
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are minimized. They are also less susceptible to dose dumping than the reservoir or
matrix type, single-unit dosage forms (4).

Controlled release of poorly soluble drugs such as nifedipine, ampicillin and isosorbide
dinitrate via pellets have been reported (5-9).

All these studies primarily employed

microcrystalline cellulose as a pellet forming agent. Due to its excellent pellet forming
properties, microcrystalline cellulose offers potential advantage in pellet manufacturing
by Extrusion/Spheronization technology.

Release from such pellets was extensively

studied by O'Connor et al (10). It was concluded that drug release follows first order
kinetics as described by Higuchi's square root of time equation from such pellets. Since
microcrystalline cellulose forms a non-disintegrating matrix when formulated as pellets,
incorporation of a poorly soluble drug in such a matrix would only intensify the problems
associated with its release. Such a matrix system would often provide no release of the
poorly soluble drug at all.

This paper reports the formulation of pellets which release a poor! y soluble drug as a
result of surface erosion of the matrix pellet. It was postulated that for drug release to
occur in zero order fashion, a matrix pellet must erode slowly as function of time from
the pellet surface. This will allow the release of homogeneously dispersed drug in the
matrix in constant increments as the erosion progresses in the pellets from the surface
thus controlling drug release. A schematic representation of such a delivery system is
shown in Figure I.
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2.0

Materials And Methods

The poorly soluble drug used as a model was a thiazole based leukotriene D4 antagonist
with a solubility less than 1.3 µg/mL at pH 6.8 (Hoffmann-La Roche Inc., Nutley, NJ).
Eudragit<!I L 100 55 and Eudragit<!I S LOO (Huls America, Inc., Somerset, NJ) were used
as release rate controlling polymers and matrix forming agents . Kollidon<!I 90 F (BASF
Inc., Parsipanny, NJ) was used as a binder.

Avicel<!I PH 101 (FMC Corporation,

Philadelphia, PA) was employed to prevent inter-pellet sticking during the spheronization
stage. Triethyl citrate (Morflex, Inc., Greensboro, NC) was used as a plasticizer for the
Eudragit® polymers. All other chemicals were used as received.

2.1

Formulation of Pellets:

Eudragit<!IL 100 55 and Eudragit<!IS LOO powders were mixed in a turbula mixer (Turbula
Mixer, Impandex Inc., Maywood, NJ, USA) for 30 minutes. Trietbyl citrate was added to
some formulations (Table- I) as a plasticizer and the resultant mixture was triturated in a
mortar for 5 minutes. Drug and polyvinyl pyrrolidone (Kollidon®K90F) as a binder were
added and mixed for 30 minutes in turbula mixer. This mixture was then granulated with
deionized water in a mortar and later extruded (LCI Xtruder, Model DG-Ll, Fuji Pauda!
Co., Lld., Japan) at 40 rpm screw speed. The extrudates were immediately transferred
into a rotating plate in the spheronizer (G.B. Caleva Ltd, Model 120, Dorset, England,
consisting of a stationary vertical cylinder with a friction plate (diameter 32 cm) of 2 mm
cross hatched pattern and a rotation speed of 200-3000 rpm).
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Spheronization was carried out for 20 minutes at 500-1000 rpm. During this period, 5%
w/w of total batch size Avicel® PH 101 was sprinkled over the rotating extrudates to
prevent the pellets from sticking. Pellets obtained were dried on trays at 50°C for 12
hours . Dried pellets were later sieved to obtain different particle size fractions (Rotap
Sieve Shaker, Model RX-29, W.S. Tyler, Inc., OH, fitted with sieve# 8, 10, 12, 14, 16,
18 and 20).

The pellets consisted of drug (10.0% w/w), Eudragit®L 100 55 and

Eudragit® S 100 (88.0% w/w) and Kollidon®K90F (2.0% w/w). A flow chart of the
manufacturing process is presented in Figure 2. The composition of formulations with
different polymer ratios is given in Table I.

2.2

Characterization of Pellets:

2.2.1

Determination of Glass Transition Temperature (Tg)

Polymer blends (Eudragit® L 100-55: Eudragit® S 100 in ratio of 1:3) with or without
triethyl citrate as a plasticizer were weighed in a DSC aluminium pan.

The DSC

(Differential Scanning Calorimeter, Seiko Instruments Inc. , Japan, Model SSC5200) was
programmed to perform a heat-cool-heat cycle from 0 - 200°C. Heating and cooling rates
of 10°C/minute was used.

2.2.2

Determination of Matrix Erosion

To study the erosion process of the pellet matrix, three criteria's were monitored, namely;
microscopic evaluation of pellets, matrix erosion after dissolution of pellets and volume
reduction by erosion of the pellets at different dissolution time intervals.
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Pellets were visually inspected, sized and photographed under an optical microscope
(Optical Microscope, Nikon HFX,IIA, Japan) before and after matrix erosion and drug
release studies. Ten pellets per time interval were evaluated.

Matrix erosion was evaluated by using standard USP dissolution system (Distek,
Dissolution System 2100A, USP Apparatus I ,Baskets). Matrix erosion was determined
by removing the baskets with pellets at intervals of 2, 4, 6, 8, 10, 12 hours and drying
them for 12 hours at 50°C to a constant weight. The difference between the initial and
final weight was calculated as percent matrix erosion.

Volume reduction due to erosion of pellets was calculated by using Equation 1.

V, = .1/6 7t 0 3

~ ··/

Equation l

Where, V, is volume (mm3) of a sphere and D is the diameter (mm) of a sphere.
Cumulative percent erosion volume was calculated by dividing the change in volume at
time 't' by original volume at time zero. The result of this was multiplied by 100 to
obtain percentages.

Rate of erosion volume (%/hr) was calculated by dividing

cumulative percent erosion volume with the time interval.

2.3

Dissolution Studies:
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Since the drug is poorly soluble, drug release from the pellets was determined by an
indirect procedure which involved determination of drug left in the pellets after
dissolution by UV analysis. The difference between initial and final amount of drug
present in the pellets after dissolution was calculated as percent drug release.

3.0

Results And Discussion

3.1

Pellet Processing by Extrusion/Spheronization:

Extrusion with Eudragit®L 100 55 and Eudragit®S 100 as pellet forming agents was
satisfactory and pellets of uniform shape and size were obtained (Figure 3).
Spheronization occurs by rotation of the extrudates at high speeds on a friction plate
within a vertical cylinder. During this stage each individual pellet rotates on its own axis
due to centrifugal force.

This action results in liquid migration from the interstices

between particles to the surface of the sphere which may be accompanied by migration of
ingredients in the formulation. lf the drug is soluble in the granulating liquid, then on
drying may lead to non homogeneous distribution of ingredients in the pellets (11).

The drug and the polymers used in this study were insoluble which prevented them from
solubilizing or retaining moisture within the pellet matrix, resulting in the migration of
moisture alone towards the pellet surface. This action created inter-pellet adherence
during the spheronization process. Inter-pellet adherence was eliminated by sprinkling
5% w/w of Avicel®PH I 0 I on the extrudates during the spheronization step.
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3.2

Characterization of Pellets:

Release profiles of the pellets ( 1.2 mm) prepared with and without Uiethyl citrate as
plasticizer is shown in Figure 4. It was observed that 70 to 100 % drug release was
obtained within six hours from these pellets. Pellets with 1: 1 and 1:3 ratios of Eudragit®
L 100 55: Eudragit® S 100 were formulated. Pellets within each of the two formulation
ratios containing plasticizer showed enhanced drug release rates when compared to
pellets without plasticizer. This effect was consistent when the polymer ratio of the
pellets were increased. The increased drug release from the pellets containing plasticizer
may be the result of increased dissolution rate of the polymers after plasticization.

This effect was investigated by determining the effect of plasticizer on the glass transition

temperature of the polymer (Figures SA thru D). Results obtained are tabulated in Table
2.

Polymer blends with plasticizer showed a significant reduction in glass transition

temperature and enthalpy.

Glass transition temperature of both the polymers were

reduced by about 60% indicating that the polymer blend became more amorphous after
plasticization, therefore its solubility was increased.

3.3

Characterization of Matrix Erosion and Mechanism_of Drug Release:

Microscopic studies showed that the pellets during drug release were reduced in size as a
function of time while maintaining a constant surface geometry (Figure 6A thru F). To
extend the release period to more than six hours, 2.0 mm pellets were formulated. Figure
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7 shows the extent of matrix erosion and drug release from the pellets. Matrix erosion
and drug release occurred simultaneously (Figure 7). This correlation of matrix erosion
with drug release holds true at stirring rates of 25, 50 and 100 rpm as demonstrated by
Figure 8. These findings prove that drug release was a direct consequence of matrix
erosion and was stirring rate independent.

Figure 9, shows the correlation of drug released with percent volume reduction by
erosion. It indicates a direct relationship between drug release and volume reduction by
erosion. Volume reduction depends on the diameter of the pellets. As the pellet erodes
with time the pellet diameter reduces due to which erosion volume increases to maintain
a constant rate of drug release (Table 3). Table 3 shows the changes in pellet volume,
cumulative % erosion volume and rate of erosion volume as a function of dissolution
time. The rate of erosion volume from Table 3 was observed to be constant up to 10
hours. This indicated that pellets eroded from the surface with consequent size reduction
without affecting the erosion volume. Thus drug release following zero order kinetics
was obtained.

These discussions explain the zero order release and matrix erosion profiles achieved
from pellets and provide strong evidence for a surface erosion mechanism and for
negligible diffusional release of the drug.

4.0

Conclusions
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Unifonn matrix pellets were obtained by using Eudragit®L 100 55 and Eudragit® S 100
as pellet forming agents. Pellets of satisfactory quality without microcrystalline cellulose
in the matrix can be fonnulated.

As hypothesized, multi-unit pellet system fonnulated for controlled release of a poorly
soluble drug by polymer controlled surface erosion mechanism were developed and
characterized. These pellets reduced in size as a result of polymer controlled surface
erosion of the drug and provided zero order controlled release up to 12 hours.
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Table 1:

t;:

Fonnulation of 1.2 mm and 2.0 mm pellets with different polymer ratios.

Eudragit® L 100 SS: Eudragit® S 100

Triethyl citrate

ratio

(% w/w of total Eudragits®)

1.0 : 1.0

15.0

1.0 : 1.0

-

1.0 : 3.0

15 .0

1.0 : 3.0

-

Table 2:

Effect of plasticizer (triethyl citrate) on Tg and t.H ofEudragit'" L JOO 55 and Eudragit'" S 100 polymers.

Polymer blends
l•IEudragit'" L I 00 55
Eudragit'" S 100
WEudragi~ L I 00 55

Eudragi t'" S I 00

T, (•C)

t. H (mJ/°C mg)

93.2

0.112

166.4

0.189

54.5

0.050

109.4

0.083

°''"
(a) Ratio of I :3 unplasticized polymer blend
(b) Ratio of I :3 plasticized wi th 15% w/w oftriethy l ci trate .

\

\

Detennination of the rate of erosion volume reduction from 2.0 mm pellets (n = 10).

Table 3:

0.0

Pellet
Diameter
(mm)
2.08

Pellet
Volume
(mm')
4.7118

'Volume
Change
(mm')
0.8889

2.0

1.94

3.8229

1.8573

18 .8654

9.4327

4.0

1.76

2.8545

3.6645

39.4180

9.8545

6.0

1.26

1.0473

4.1392

77.7728

12.9621

8.0

1.03

0.5721

4.6783

87.8581

10.9822

10.0

0.40

0.0335

4.7077

99.2890

9.9289

Time
(hours)

~

'Cumulative Percent l'Rate of Erosion
Erosion Volume
Volume
(mm'}
(%/hr)
0.0000
0.0000

I : Original Volume - Volume at time 't'.
2: Volume Change divided by 4.7118 (Volume at time zero).
3 : Cumulative Percent Erosion Volume divided by the time interval.

Schematic representation of a novel multi-ur.it erosion matrix for
controlled release of a poorly soluble drug.

0 to 24 hours
in vitro

matrix pellet

eroding layer

,'

''

_____ ...

(,,-,---------,,';
'' '
'

'

,,

-. - - - -...... 28

,'

'

intact matrix pellet

Flow chart of pellet manufacturing procedure .

Polymer blend (Eud L 100-55 + Eud S 100)

mixing in turbula mixer for 30 minutes

Addition of plasticizer (Triethyl citrate)
+ binder (PVP K90F) + Drug
mixing in turbula
granulation with

mixer for 30 minutes
deionized water

Extrusion at 40 rpm
Sprinkled with A vice! PH 101

to minimize inter-pellet sticking
(5% w/w of total batch size)

Spheronization at 500-1000 rpm

Drying at SO C for 12 hours

Pellet screening (Sieve fractions
collected 10/12 and 14/16 mesh)

29

Photomicrographs of p.:llcts (2 .0 mm) viewed under an optical microscope. magnification

sx.

~7'·
- ~ • .."}:• ·
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Effect of plasticizer on matrix erosion from pellets (pellet size: 1.2 mm, drug load: 10%
w/w, Eud L 100-55: Eud S 100 ratio of l: l and l :3)
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Figure SA

DSC thermogram showing the glass transition temperarures ofE udragit® L!00-55 .
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Figure 58

DSC thermo gram showing the glass transition temperatures of Eudragit® SI 00 .
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DSC thennogram showing the glass transition temperatures of Eudragit® L l 00-55 and
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Figure 50

DSC thennogram showing the glass transition temperatures ofEudragit® Ll00-55 and
Eudragit® S 100 mixed in ratio of l :3 and plasticized with 10% w/w triethyl citrate.
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Figure 6
Microscopical

°'"'

~valuation

of matrix erosion and size reduction of pellets (magnification: 5X).

A. Time: 0 hrs, Size: 2.0 mm

D. Time: 6 hrs, Size: 1.4 mm

B. Time: 2 hrs, Size: 1.75 mm

E. Time: I 0 hrs, Size: 0.8 mm

C. Time: 4 hrs, Size: 1.6 mm

F. Time: 12 hrs, Size: 0.2 mm

Correlation of matrix erosion(% w/w) with drug release(%) from pellets.
(pellet size: 2.0 mm, drug load: 10% w/w), Eud LI00-55 : Eud S 100 ratio of I :3, n =
5:tSE).
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Correlation of matrix erosion(% w/w) with drug release (%) at different stirring speeds.
(pellet size: 2.0 mm, drug load: 10% w/w), Eud Ll00-55: Eud S 100 ratio of 1:3, n =
4:tSE).
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EFFECT OF FORMULATION AND PROCESS VARIABLES ON MATRIX
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ABSTRACT

A novel multi-unit controlled delivery system for the release of a poorly soluble drug by a
polymer controlled, surface erosion mechanism was reported earlier. The present study
was undertaken to determine the effects of formulation variables (ratio of polymers used,
drug loading) and processing variables (water required for granulation, pellet size and
spheronization time) on matrix erosion and drug release. Powder mixtures containing
drug, different ratios of Eudragit®L 100 55 and Eudragit®S 100 were blended with
polyvinylpyrrolidone (PVP) and were extruded/spheronized to obtain homogeneous
matrix pellets. Drug release was predicted by matrix erosion studies. Matrix erosion was
determined using USP Dissolution Apparatus I in pH 6.8 phosphate buffer by gravimetry
and UV spectrophotometry, respectively.

Matrix erosion and drug release rates were

found to be a function of polymer ratio. Drug loading at 5, IO, and 20% w/w levels
demonstrated that drug release was predominantly matrix erosion controlled. At 30 and
40% w/w drug levels, matrix erosion and drug release rates decreased. Pellet size had a
profound effect on the total duration of matrix erosion and drug release from the pellets.
Thus, by optimizing the formulation and process variables, pellets can be prepared which
release a poorly soluble drug for 12-24 hours following zero order kinetics.
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1.0

Introduction

The design and evaluation of a novel multi-unit erosion matrix that releases a poorly
soluble drug by matrix erosion for 12 hours was reported earlier [ l]. Several authors
have reported factors such as polymer type, drug concentration, drug solubility,
pelletization technique used, influencing drug release rate [2-9]. All these factors were
evaluated for osmotically or diffusion controlled pellets employing microcrystalline
cellµlose as the principal pellet forming agent and release rate governing polymer in the
pellet.

The pellets used in this study were manufactured by Extrusion/Spheronization technique,
therefore any change in the formulation or process parameters may influence matrix
erosion and drug release from the pellets [10]. The aim of this study was to investigate
the influence of the most critical formulation variables (ratio of polymers used and drug
loading) and process variables (water required for granulation, pellet size and
spheronization time) on matrix erosion and drug release from the pellets. Previously, the
linear relationship between matrix erosion and drug release at various dissolution stirring
rates was described [I]. It was concluded that in such systems, matrix erosion and drug
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release occurred simultaneously, thus matrix erosion can be monitored to predict drug
release from the pellets.

2.0

Materials and methods

The poorly soluble drug used as a model was a thiazole based leukotriene 0 4 antagonist
with aqueous solubility < 1.3 µg/ml (Hoffmann-La Roche Inc., Nutley, NJ) . Eudragit® L
100 55, Eudragit® S 100 (Huls America, Inc., Somerset, NJ) were used as pellet fonning
and release rate controlling polymers. Kollidon® 90 F (BASF Inc., Parsipanny, NJ) was
used as a binder. Avicel® PH IOI (FMC Corporation, Philadelphia, PA) was used in the
spheronization stage to prevent inter-pellet sticking.

Triethyl citrate (Morflex, Inc.,

Greensboro, NC) was used as plasticizer for Eudragits®. All other chemicals were used
as received.

2.1

Formulation of Pellets:

Eudragit® L 100 55 and Eudragit® S 100 were dry mixed in a turbula mixer (Impandex
Inc., Maywood, NJ, USA) for 30 minutes. This dry mixture was triturated in a mortar for
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5 minutes with triethyl citrate (plasticizer). Drug and polyvinylpyrrolidone (PVP) as a
binder were added and mixed in a turbula mixer for 30 minutes. This mixture was then
granulated with deionized water in a mortar and later extruded (LCI Xtruder, Model DGLl, Fuji Paudal Co., Ltd., Japan) at 40 rpm screw speed. The extrudates obtained were
immediately transferred into a rotating plate in the spheronizer (G.B. Caleva Ltd , Model
120, Dorset, England). The spheronizer consisted of a stationary vertical cylinder with a
base friction plate (diameter 32 cm) with a 2 mm cross hatched friction pattern and a
rotational speed of 200-3000 rpm. Spheronization was carried out for either 2, 10 or 20
minutes at 500-1000 rpm. During this period, 5% w/w Avicel® PH IOI was sprinkled
over the rotating extrudates to prevent them from sticking. The pellets obtained were
dried on trays as a monolayer at 50°C for 12 hours. Pellets were later subjected to sieve
analysis to collect the desired particle size pellets in a Rotap Sieve Shaker, Model RX-29,

__.... W.S. Tyler, Inc., OH, USA, fitted with sieve# 8, 10, 12, 14, 16, 18 ,20 and 25.

2.2

Composition of pellets prepared to evaluate formulation variables:

Pellets of 2.0 mm size were formulated to determine the effects of polymer ratio and drug
loading. Pellet compositions are tabulated in Table 1.

2.3

Composition of pellets prepared to evaluate process variables:
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Pellets of 2.0 mm size were formulated to determine the effects of granulation water
level, pellet size and spheronization time. Pellet compositions for granulation water study
are tabulated in Table 1 Pellets of 0.8, 1.2 and 2.0 mm size were each formu lated at
spheronization times of 2, 10 and 20 minutes (Table 2) to determine the effect of pellet
size and the spheronization time on drug release and matrix erosion. The formulation
parameters maintained constant for this study were drug loading (10% w/w), polymer
ratio (Eudragit® L 100 55 : Eudragit® S 100 was 1:3), Kollidon® K 90F
(polyvinylpyrrolidone) as a binder (2% w/w), Triethyl citrate as plasticizer for Eudragits
( 15% w/w of total Eudragit content), deionized water for granulation (70% w/w).

2.4

In vitro release studies:

Drug release was performed using a standard USP Dissolution Apparatus I (Distek,
Dissolution System 2100A USP XXII). Pellets (100 mg) were immersed in 500 ml of pH
6.8 phosphate buffer maintained at and 37 .0 ± 0.5°C and stirred at 50 rpm. The baskets
were removed at intervals of2, 4, 6, 8, 10, 12 hours and were dried for 12 hours at 50° C
to achieve constant weight. The difference between the initial and final weight of the
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pellets was calculated to determine percent matrix erosion.

The matrix erosion was

determined to predict percent drug release [I].

3.0

Results and discussions

Several studies report the influence of formu lation and process variables on drug release
from pellets formulated by Extrusion/Spheronization process [2-9]. However, the results
of these studies are specific to the formulation and utilize either microcrystalline cellulose
(MCC) or MCC with various hydrophilic or hydrophobic in combination. Drug release
from such matrices is predominantly characterized by first order kinetics due to the
presence of microcrystalline cellulose used as the matrix [11]. Tapia et. al. [2] studied the
effect

of chitosan

on

drug

release

from

matrix

pellets

manufactured

by

Extrusion/Spheronization and concluded that drug delivery occurred by gel formation of
chitosan through diffusion process. Gel formation was found to be a direct function of
polymer ratio.

The rate controlling polymers used in this study were Eudragit® L 100 55 and Eudragit® S
100. These polymers dissolve above pH 5.5 and 7.0 respectively. Some of their popular
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commercial uses include tablet and pellet coatings to achieve controlled or sustained
release.

The effect of increased Eudragit® S 100 content on drug release from 2.0 mm pellets is
shown in Figure 1. It was observed that rate of drug relea3e decreased as the ratio of
Eudragit® S 100 increased in the formulation without any significant change in the release
kinetics.

Figure 2 shows the effect of drug loading on drug release. Matrix erosion data was used
to compare the effects of drug loading with that of placebo pellets. The same figure
demonstrates that drug release from pellets with 5, 10 and 20% w/w drug loading was
similar to that of placebo pellets which strongly indicated that the drug release
mechanism was matrix erosion controlled up to 20% w/w drug loading. However, above
20% w/w drug loading, the release rates were found to decrease as the drug load
increased up to 40% w/w. The reason for this finding may be hydrophobicity of the drug
incorporated into the matrix.

The influence of the amount of granulation liquid on the drug release rate from pellets
made by Extrusion/Spheronization has been the topic of many publications (Baert et al.
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[4], Jerwanska et al. [5]). Baert et al and his co workers demonstrated that slower release
rate was the result of increasing amounts of granulating liquid. They correlated the
effects of granulation liquid with the differences in hardness, density and structure of the
pellets, whereas Jerwanska et.al and his co-workers, through their study concluded that
rate of drug release increased with increasing granulation liquid level due to an increase
in porosity obtained after drying. They also correlated these results with differences in
hardness of the pellets.

The effect of the granulation water level on the matrix pellets prepared by employing
Eudragit® L 100 55 and Eudragit® S 100 as the rate controlling and pellet fonning agents
is shown in Figure-3. Increased granulation water levels had a direct effect on the drug
release rates. These findings are similar to the findings of Jerwanska et al [5]. However,
there seemed to be no significant difference in the release rates above 65% w/w
granulation water level. This can be explained by the effect of moisture content on the
degree of liquid saturation of the extrudates. Jerwanska et al [5], proposed that for a
continuous extrusion process, adequate water is required to bridge the particles together
until liquid saturation in the granulation is achieved. This is necessary to deform the
granulation to form extrudates and consequently shape them in to spheres by
spheronization. If the granulation water level is below the liquid saturation point the
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spheres obtained will be hard and less porous leading to decreased drug release rates.
Above the liquid saturation point the hardness and porosity of the pellets are not
significantly affected.

In order to investigate the most critical spheronization times which would have an effect

on drug release, pellets were spheronized for 2, 5, 8, 10, 20 and 40 minutes. The
hardness of pellets (n

= IO) was measured (Chatillon Force Measurement System, Model

TCD-200 attached with a 5 lb load cell, Greensboro, NC, USA). The results of pellet
hardness test of IO pellets per spheronization time are tabulated in Table 3. From Table 3,
the pellet hardness changes with spheronization time up to about IO minutes with
maximum hardness recorded for pellets spheronized at 8 minutes, where after the
hardness decreases up to 20 minutes. No significant difference in the pellet hardness
from 20 to 40 minutes was observed. This may be explained by the densification process
occurring during the spheronization step. As spheronization time progresses from zero to
time 't', the extrudates are cut into uniform particles and shaped into spheres due to the
centrifugal and frictional forces present in the spheronizer during operation. These forces
act on each and every particle making them more dense and more spherical with time.
However, after a critical period no further densification occurs with increase in
spheronization time. Data from Table 3 indicates that the pellet densification process
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talces about 10 minutes above which very minor changes in densification occur. Thus a
spheroinzation time of 2, I 0 and 20 minutes was selected to study the effects of time on
drug release.

Figure 4 shows the effect of spheronization time on the drug release rate from 0.8, 1.2,
and 2.0 mm pellets. Spheronization time appears to effect drug release rates at the 2 and
10 minute processing times for l.2 and 2.0 mm pellets.

This effect became less

pronounced when the pellet size increased from 0.8 to 2.0 mm. However, there is no
significant difference in the drug release profile of l.2 and 2.0 mm pellets above JO
minute processing time. It was also observed that the duration of drug release increased
as the pellet size increased without any change in release kinetics above 1.2 mm pellet
size.

4.0

Conclusions

This study shows the effects of various formulation (ratio of polymers used and drug
loading) and process (granulation water level, pellet size and spheronization time)
parameters on drug release by surface erosion from multi-unit matrix pellets.

Each

parameter evaluated, demonstrated a change in drug release from the pellets. Increased
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amounts of Eudragit® S 100 retarded the rate of matrix erosion and drug release from the
pellets. The drug loading had no influence on drug release mechanism up to the 20%
w/w level above which increasing levels of drug up to 40% w/w retarded matrix erosion.
Granulation water level at 65 % w/w had a significant effect on the rate of matrix erosion
and drug release as compared to the formulation with 60% w/w granulation water level.
Above 65% w/w, there was no significant effect on the rate of matrix erosion and drug
release.

Matrix erosion and drug release rates can be optimized by processing the pellets at
different spheronization times.

Thus, by optimizing the formulation and process

variables pellets that can release a poorly soluble drug by polymer controlled, surface
erosion mechanism for 12 hours following zero order kinetics.
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Table I.

Ingredients
(% w/w)

V•

"'

Composition of pellets fonnulated with different polymer ratios, drug loadings and granulation water levels.

Pellet Compositions with Different Drug
Loadings

Pellet Compositions with
Different Polymer Ratios

Pellet Composition
with different
Granulation Water

Drug

10.00

10.00

0.00

5.00

10.00

20.00

30.00

40.00

10.00

10.00

10.00

Kollidon®
90F
Eudragit®L
100-55
Eudragit®S
100
• Plasticizer

2.00

2.00

2.00

2.00

2.00

2.00

2.00

2.00

2.00

2.00

2.00

35.20

22.00

22.00

22.00

22.00

22.00

22.00

22.00

22.00

22.00

22.00

52.18

66.00

66.00

66.00

66.00

66.00

66.00

66.00

66.00

66.00

66.00

15.00

15.00

15.00

15.00

15 .00

15.00

15.00

15.00

15.00

15.00

15.00

60.00

60.00

77.90

70.00

70.00

62.00

60.00

65.00

60.00

65.00

70.00

Granulation
Water

* Tri ethyl citrate (% w/w based on total Eudragit®L I 00 55 + Eudragit®S 100 contents in the fonn ulation).

\

\,

Table 2.

Pellets of different size prepared at different spheronization times.

Pellet Size (mm)

0.8

1.2

...,
~

2.0

Spheronization Time (minutes)
2.0
10.0
20.0
2.0
. 10.0
20.0
2.0
10.0
20.0

r-

Table 3.

Effect of spheronization time on pellet hardness.

Spheronization Time
2.00

Pellet Hardness (grams)
J..Mean+SDl
1091±139.39

5.00

1383 ± 177.14

8.00

1511±157.12

IO.OD

I 259 ± 170.25

20.00

1034 ± 177.40

40.00

1110 ± 146.06

J..minute~

..,,
00

Effect ofvaryi.ng polymer ratios on drug released(%) from pellets.
(pellet size: 2.0 mm, drug load: l 0% w/w, n ; 3±SE)

100

~

80

Q
t.l

"'<
t.l

60

...l

~

(.)

;;;;>

Cl::

40

Q
~ ·'

,

20
0
0

2

4

6
TIME (hours)

59

8

10

12

Effect of different drug loading(% wlw) on drug released(%) from pellets.
(pe llet size: 2.0 mm, n ~ 4:!:SE)

100
~

80
0

Q
~

en

<

~

60

..l

~

{J
~

~
Q

40
20
0
0

4

12

8

16

TIME (hours)

60

rn
0

.6.

5

0

10

"V

20

<>

30

D

40

20

24

Effect of granulation water level (% wlw) on drug released(%) from pellets.
(pellet size: 2.0 mm, drug load: 10% w/w, n; 4:tSE)

100
~
Q
l.J

"'<
l.J

80
60

..l
l.J

c::

'-'

:::i

40

c::

Q

,.../

20
0
0

2

4

6

TIME (hours)

61

8

10

12

Effect of pellet size and spheronization time on drug release rate from pellets.
(drug load: 10% w/w, n = 4±SE)
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•
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0

.

40
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30
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w
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w

"'w
~
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MANUSCRIPT Ill

EFFECT OF FORMULATION AND PROCESS VARIABLES ON POROSITY
PARAMETERS AND RELEASE RATES FROM A MULTI UNIT EROSION
MA TRIX OF A POORLY SOLUBLE DRUG
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ABSTRACT

Controlled release erosion matrix pellets were prepared by a Extrusion/Spheronization
technique. The effect of drug loading, water required for granulation and spheronization
time- on porosity parameters (intrusion-extrusion isotherms, pore size distribution, total
pore surface area, mean pore diameter, shape and morphology of pores) and drug release
rates were investigated. Porosity parameters were detennined by using mercury intrusion
porosimetry. In vitro release was performed in phosphate buffer pH 6.8 using USP XXIl
Apparatus I (baskets, at 50 rpm) by UV spectrophotometery. The drug loading was found
to have a profound effect on the porosity parameters. Pellets with low drug loading
showed increased pore surface area, with small mean pore diameters and an increased
number of total pores. Whereas pellets with high drug loading had decreased pore
surface area with bigger mean pore diameters and a decrease in the total number of pores.
With high drug loading, drug release rate was found to be decreased. Water required for
granulation had a direct effect on the total porosity of the pellets. Dissolution studies
showed that release rates were directly related to the water required for granulation.
Spheronization time from 2 to 10 minutes had a pronounced effect on porosity parameters
and release rates. No changes in porosity parameters and release rates were observed
from lO to 20 minutes of spheronization time. It was shown that each porosity parameter
investigated was well correlated with drug release rates and thus it is important to study
the effect of porosity parameters in evaluating the In vitro performance of multi-unit
erosion matrix for controlled release of a poorly soluble drug.
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INTRODUCTION

Porosity is a measure of void spaces in a material and can be generally calculated by
using a number of techniques such as density, gas adsorption, water displacement and
porosimetry (I).

Determination of pore structures of solids can provide important

information on disintegration, dissolution, adsorption and diffusion of drugs (2). Pore
size measurements provide information on the actual pore structures, including pore
diameter and volume, and can be determined by gas adsorption and mercury porosimetry.
The gas adsorption method is limited to pore diameters smaller than 2000 Angstroms,
whereas mercury porosimetry is capable of measuring larger pores and inter-particle
spaces (3). Thus mercury porosimetry is a suitable technique to determine a broad range
of pores of a sample.

The method is based on intrusion of mercury into the pores of a solid sample and is
quantified by the Washburn Equation (4).

Pr= -2 yCos 0

where P =pressure (psi), r =pore radius (µm), y =surface tension of mercury (dynes/cm)
and 0 = the contact angle of mercury. This equation holds true only when the surface
tension and contact angle of mercury are kept constant and shape of the pores is assumed
to be circular.
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By mercury penetration under pressure, one can determine the size and quantity of void
spaces and pores in porous materials.

In addition, mercury expelled from pores as a

function of decreasing pressure provides information about the shape and structure of the
pores (5). In porosimetry, voids are defined as spaces between particles or the several
pieces constituting the specimen, whereas cracks, crevices, holes and fissures within the
specimen, whether a single piece or a powder, are termed as pores (6).

Mercury porosimetry has been extensively used in porosity determination of granules (7II) , tablets ( 12-17) and pharmaceutical powders ( 18, 19).

The development,

characterization and evaluation of a novel multi-unit erosion matrix for a poorly soluble
drug was reported in our previous study (20). In which, matrix pellets of a model poorly
soluble drug (thiazole based leukotriene antagonist, aqueous solubility < 1.23 µg/mL) was
pelletized with Eudragit® L 100 55 and S 100 used as release rate controlling polymers.
The pellets were prepared by Extrusion/Spheronization technique and the effect of
formulation (drug load, water required for granulation) and process (spheronization time)
variables on drug release were studied (21). In this paper we have used mercury intrusion
porosimetry to understand the effect of formulation and process variables on drug release
behavior relative to the changes in porosity parameters.

MATERIALS AND METHODS

A thiazole based leukotriene D 4 antagonist (Hoffmann-La Roche Inc ., Nutley, NJ) was
used as a model poorly soluble drug.

Eudragit® L 100 55, Eudragit® S 100 (Huls
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America, Inc., Somerset, NJ) were employed as matrix forming and release rate
governing polymers. Kollidon® 90 F (BASF, Inc., Parsipanny, NJ) was used as a binder
in the formulation . Avicel® PH 101 (FMC Corporation, Philadelphia, PA) was used to
prevent inter-pellet sticking during the spheronization stage. Triethyl citrate (Morflex,
Inc. , Greensboro, NC) was used as a plasticizer for Eudragit® polymers.

All other

chemicals were used as received.

Preparation of Matrix Pellets by Extrusion/Spheronization:

Eudragit® L 100 55 and Eudragit® S 100 were dry mixed in a Turbula mixer (Impandex
Inc., Maywood, NJ, USA) for 30 minutes. This dry mixture was triturated in a mortar for

5 minutes with triethyl citrate used as a plasticizer. Drug and polyvinylpyrrolidone used
as a binder were added to this mixture and were mixed in the Turbula mixer for 30
minutes. The dry blend was transferred to a mortar and was granulated with deionized
water for 10 minutes. The wet granulate was later extruded at 40 rpm screw speed (LC!
Xtruder, Model DG-Ll, Fuji Pauda! Co., Ltd., Japan). The instrument used was a single
screw extruder capable of extruding at speeds upto 100 rpm.

The extrudates were

spheronized in a G.B. Caleva Ltd, Model 120, Dorset, England, at 600-800 rpm
spheronizer speed. The spheronizer consists of a stationary vertical cylinder which has at
the base a friction plate with a 2 mm cross hatched friction pattern and a rotation speed of
200-3000 rpm. Spheronization times used were 2, 10 and 20 minutes. Av1cel® PH 101
5% w/w was sprinkled over the rotating extrudates to prevent pellets from sticking. The
pellets obtained were dried at 50° C for 12 hours using a tray dryer and were later sieved
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through Rotap Sieve Shaker (Model RX-29, W.S. Tyler, Inc., OH, USA), fitted with sieve
number IO and 12 to obtain 2.0 mm size pellets.

Drug Loading:

Composition of pellets formulated to determine the effects of drug loading are given in
Table I.

Water required/or granulation:

Composition of pellets formulated to study the effects of granulation water level are given
in Table 2.

_../
Spheronization time:

Pellets were processed at 2, IO and 20 minutes spheronization times .

Formulation

composition maintained constant for this study were the drug load ( IO % w/w), polymer
ratio (I : 3) same as in Table 2, Kollidon® 90F as binder (2 % w/w), triethyl citrate as
plasticizer (15 % w/w of total Eudragit®L 100 55 and Eudragit®S 100) and water for
granulation (70 % w/w of the total batch size).

Drug release studies:
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It was shown in our previous study that pellets prepared with the model poorly soluble
drug, released the drug as a direct function of matrix erosion (20). In vitro drug release
was determined by using USP XXII Apparatus I with baskets at 50 rpm (Distek Inc., NJ,
USA) in 500 mL of pH 6.8 phosphate buffer at 37 .0 ± 0.5° C.

Mercury intrusion porosimetry:

Porosity parameters such as intrusion-extrusion isotherms, pore size distribution, total
pore surface area, mean pore diameters, shape and morphology of the pores were
determined by using a Micromeritics PoreSizer 9320 (Micromeritics Inc., Norcross, GA,
USA) .

Incremental intrusion volumes were plotted against pore diameters which

represented pore size distributions. The moisture content of pellets were determined with
an infra-red moisture analyzer at 105° C (Computrac, Model Max-50, Arizona Instrument
Corp., USA) prior to porosimetry studies. The moisture content of all the pellet samples
varied between 2.2-3.0 % w/w. The pore diameter was calculated by using Eq 2.

D = _-_4~r_co_s_e

2

p

where D = pore diameter (µm)

y =surface tension of mercury (485 dynes/cm).

e = contact angle ( 130 degrees)
P = pressure (psi)

70

The total pore surface area (S) was calculated by using Eq 3

l

Vtot

S=-l-£JI
ycos f PdV

3

0

where; P =pressure (psi)
V =the intruded volume of mercury (mllg)
V,01 = total intruded volume of mercury (mllg)

The mean pore diameter (D'mean) was calculated by Eq 4.

Vtot
D'mean=4s

4

Pore morphology was characterized from the intrusion-extrusion profiles of mercury in
the pellets as described by Orr et. al. (6).

RESULTS AND DISCUSSION

Effect of Drug Loading:
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The intrusion volume of mercury is a function of •total porosity.

In Figure 1 the

cumulative intrusion volume was plotted agai nst pore diameters showing the intrusionextrusion profile of pellets with different drug loading. The intrusion and extrusion
curves form a hysteresis indicating that majority of the pores present in the pellets were
ink-well type pores that had smal l openings with broad bases. Although no particular
trend was observed in the intrusion profiles with respect to drug loading, the intrusion
volume of mercury was significantly lower for 30 and 40% w/w than the 5, 10 and 20%
w/w drug loading (Figure !).

Figure 2 shows the incremental intrusion volume as a function of the pore diameter of the
pellets with increasing drug loading. From Figures I and 2, the number of pores and
mean pore diameters of the pellets can be characterized. The data indicates that as the
drug loading increased from 0-10% w/w, the mean pore diameter increased with the total
number of pores essentially remaining constant whereas, with 30 and 40% w/w drug
loads the mean pore diameters increased and the total number of pores decreased.

Figure 3 shows the effect of drug loading on the total pore surface area and mean pore
diameter of pellets; they seem to have an inverse relationship as expected.

Table 3 lists the calculated ranges of pore necks and pore bases as a function of increasing
drug loading as characterized from Figures 1 and 2. The data from Table 3 indicates that
pore bases were nearly twice the size of pore necks at all levels of drug loading;
indicating that all pores have large bases with relatively small necks. This difference
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becomes more apparent as drug loading increases above 30% w/w. This interpretation is
supported by the relation of drug loading, total pore surface area and the mean pore
diameters of the pellets as shown in Figure 3. The results indicate that with increasing
drug concentration the pores became wider with larger necks and thus reduced in number.
These changes are illustrated schematically in Figure 4.

Figure 5 shows the dissolution profiles of the pellets with different drug loading. Drug
release from these pellets occurred via surface erosion. Therefore theoretically, the nature
of pores present at the surface of the pellet must influence the erosion rate rather than the
total porosity of the pellet matrix during the dissolution process. In pellets with high drug
loads, the total polymer content is relatively low. Since the weight fraction of drug per
unit weight of the drug-polymer mixture is high, the drug particles associate to form drug
agglomerates (22) and this agglomeration tendency of the drug at high drug loads will
reduce the number of pores and thus total pore surface area is reduced. Such a system
during dissolution will have a low contact surface area with the dissolution media.
However, in pellets with low drug loads, the weight fraction of polymer per unit weight
of the drug-polymer mixture is high, therefore chances of drug agglomeration are less
resulting in more pores with smaller mean pore diameters and increased total pore surface
area. Thus, the increase in mean pore diameter and decrease in total pore surface area of
pellets with high drug loading were primarily due to agglomeration of the drug particles.
As it is discussed above, because of the existence of larger pores, the surface area of
contact between the dissolution medium and pellets with high drug load is reduced, which

73

reduces pellet hydration and consequently the erosion rates. This was confirmed by the
dissolution profiles .given in Figure 5.

Effect of Water Required for Granulation:

The intrusion-extrusion profiles of mercury for the percent water added to the granulation
are shown by plotting cumulative intrusion volume against pore diameter in Figure 6.
The total intrusion volume was found to be a direct function of granulation water level.
This indicated that total porosity of the pellets increased with the addition of water for
granulation from 60-70% w/w. These findings are similar to the results obtained by other
researchers (23-26).

Figure 7 is a plot of incremental intrusion volume against pore diameter which shows the
pore size distribution of pellets with different granulation water levels. All pores present
are between 0.01-0.l µmin size. Table 4 summarizes the results of granulation water
level on the range of pore necks and pore bases. The pore base being the average width
of the ink-well type pores inside the pellet matrix. From Figure 7 and Table 4 it is
evident that increasing the granulation water level from 60 to 65% w/w increased the total
number of pores, but the pore necks and bases were not affected indicating that the water
levels used in the study increases the porosity without affecting the morphology of pores.
When the granulation water level was increased from 65 to 70% w/w, the pore neck and
pore base ranges remain narrow but the number of pores increase, resulting in overall
increase in the porosity of the pellets.
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Figure 8 shows the effect of total pore surface area and mean pore diameters against
granulation water levels. The data indicate that the total pore surface area increases
without any significant change in the mean pore diameter as a function of increased
granulation water levels. This finding also strongly supports the fact that with the
addition of more granulation water, the number of pores increased without any change in
the mean pore diameters.

These changes are illustrated schematically in Figure 9.

Fujiwara and Kato et al. reported similar findings with the increase in granulation water
level on pore structure and porosity of sucrose and lactose granules prepared by wet
granulation (9).

The dissolution profile of pellets formulated at different granulation water levels are
given in Figure 10. The dissolution rates increase with the increase in porosity and total
pore surface area of the pellets with 60, 65 and 70% w/w water for granulation. This
increase in the porosity and total pore surface area of the pellets increased the dissolution
contact area of the medium with the pellet surface resulting in faster hydration and
consequently caused higher erosion rates.

Spheronization Time:

The sphericity of a pellet is a function of spheronization time. The longer they are
spheronized more spherical pellets are produced. The circular motion of the friction plate
in the spheronizer, shape the sphagetti like extrudates into smal ler and uniform granu les.
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Eventually, the collision of these granules with the friction plate and the walls of the
spheronizer change their shape into small spheres or pellets as a function of time. This
transformation may be analogous to tablet compaction. "The term compactability is the
abi lity of the bed of particles to cohere into or form a compact of a defined mechanical
strength"(26). In compacting a tablet, the force applied by the upper punch has a direct
relation with the compactability of the tablet. It is also generally observed that after a
critical force no further increase can change the degree of compaction. Similarly, during
spheronization, the pellet is compacted up to a critical strength above which no more
compaction is observed. The change in porosity parameters of tablets as a function of
compaction force are reported (12-17). However, for pellets no information showing the
changes in porosity parameters as a function of spheronization time is reported.
Therefore, it was important to elucidate this process with respect to the change in porosity
parameters, particularly because the dissolution rates of the pellet were a function of
spheronization time.

To understand the changes occurring in porosity with spheronization, the pellets were
processed at three different spheronization times, 2, 10 and 20 minutes. Figure 11 shows
the total intrusion volume against pore diameters as a function of spheronization time.
The data indicate that porosity was not significantly affected by spheronization at 2, l O
and 20 minutes.

Figure 12 shows the plot of incremental intrusion volume against pore diameters which
demonstrates that the pores increased with 2 to 10 minute spheronization time. However,
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after 10 minutes, no change in the pore size distribution was observed upto 20 minutes.
Figure 13 confirms these findings by demonstrating no change in the total pore surface
area and mean pore diameter from 10 to 20 minutes.

In summary, following the argument given earlier, processing period from 2 to 10
minutes increased the pores, total pore surface area and decreased pore diameters, beyond
this time up to 20 minutes none of the porosity parameters changed. Figure 14 shows the
effect of spheronization time on dissolution profiles of pellets which were processed for
2, 10 and 20 minutes. The dissolution rates of pellets processed at 10 and 20 minutes
were same. However, pellets processed at 2 minutes spheronization time showed faster
dissolution rates. Figure 15 shows a schematic representation of the effect of
spheronization time on the porosity of the pellets.

CONCLUSIONS

This study demonstrated that the changes in porosity parameters (intrusion-extrusion
isotherms, pore size distribution, total pore surface area, mean pore diameter, pore shape
and morphology) of pellets made with insoluble drug substance is affecting drug release
rates with erosion controlled mechanism when the drug loading, granulation water level
and spheronization time are modified.

By increasing the granulation water level, the number of pores are increased without
affecting the mean pore diameter. The total porosity of the pellets was increased with
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higher granulation water level. This increases the erosion rate of pellets leading to faster
dissolution of the drug.

With spheronization time, the porosity parameters are affected depending on the time.
Up to I0 minutes of spheronization time, the number of pores increased with total
increase in surface area and decrease in pore diameter. No significant increase in porosity
parameters was observed when the spheronization time was further increased from I 0 to
20 minutes. This difference is reflected by erosion rate and dissolution profiles.

Thus, the study of porosity parameters is important in characterizing and predicting the !!!
vitro performance of multi-unit matrix pellets.
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Table I:

Formulations prepared to determine the effects of drug loading.

Drug Load

Kollidon®90F

Eudragit®L 100

Eudragit®S 100

*Plasticizer

(% w/w)

(% w/w)

55 (% w/w)

(% w/w)

(% w/w)

0.00

2.00

24.50

73.50

15.00

5.00

2.00

23 .25

69.75

15.00

10.00

2.00

22.00

66.00

15.00

20.00

2.00

19.50

58.50

15 .00

30.00

2.00

17.00

51.00

15 .00

40 .00

2.00

14.50

43.50

15.00

"'

w

•

Triethyl citrate (% w/w based on total Eudragit®L I 00 55 + Eudragit®S I 00 contents in the

formulation) .

Table II:

Fonnulations prepared lo detennine the effect of granulation water
levels.

...

Drug Load

Kollidon®90F

Eudragit®L 100

Eudragit®S 100

• Plasticizer

Granulation Water

(%w/w)

(% w/w)

SS(% w/w)

(% w/w)

(% w/w)

Level (% w/w)

10.00

2.00

22.00

66.00

15.00

60.00

10.00

2.00

22.00

66.00

15.00

65.00

10.00

2.00

22.00

66.00

15.00

70.00

00

• Triethyl citrate(% w/w based on total Eudragit®L 100 55 + Eudragit®S JOO contents in the fonnul ation) .

\

i

Table III:

Effect of drug loading on the size of pore necks and pore bases as
characterized from the intrusion-extrusion profiles.

"'

~

Drug Load (% w/w)

Pore Necks (nm)

Pore Bases (nm)

0.00

15 - 90

50 - 200

5.00

18 - 60

70- 150

10.00

18 - 60

70- 150

20.00

18 - 70

40 - 150

30.00

18 - 90

40-150

40.00

15 -180

50 -300

\

\,

Table IV:

Effect of water required for granulation on pore necks and pore bases
as characterized from intrusion-extrusion curves of mercury.

"'
"'

Granulation Water Level

Pore Necks

Pore Bases

(% w/w)

(nm)

(nm)

60.00

15 - 90

50- 110

65.00

15 - 90

50- 110

70.00

20-60

60 - 100

Cwnulative intrusion volwne vs pore diameter of pellets with different drug loading(%
w/w). (pellet size: 2.0 mm, spheronization time: 10 minutes, n = 4±SE)
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Pore size distribution of pellets with different drug loading (% w/w). (pellet size: 2.0 mm,
spheronization time: 10 minutes, n = 3±SE)
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pellets. (pellet size: 2.0 mm, spheronization time : 10 minutes, n

.....~
.§,

60

<

50

50

• •

CZ::
;:i

~

•

•

~

rJJ

3:tSE)

60

CZ::

<
~
u
<
C<.

~

40

~

40

0

~

""'
""'

0
--~/

•

""'
::E
~

:sQ
~

..J

<

e
-=CZ::

30

30

0

~

:z:
<

~

::E

20

20
0

10

20

30

DRUG LOAD (% w/w)

89

40

50

~

Schematic surface representation of the effect of drug loading on
the pore diameters and total number of pores.
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Effect of drug loading(% w/w) on drug released(%) from pellets. (pellet size: 2.0 mm,
spheronization time: I 0 minutes, n = 4:tSE)
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Effect of granulation water level(% w/w) on cumulative intrusion volume of pellets.
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Effect of granulation water level (% w/w) on pore size distribution of pellets. (pellet size:
2.0 mm, drug load: 10% w/w, spheronization time: 20 minutes, n = 3±SE)
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Effect of granulation water level (% w/w) on total pore surface area nad mean pore
diameter of pellets. (pellet size : 2.0 mm, drug load: 10% wlw, spheronization time: 20
minutes, n = 3±SE)
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Effect of granulation water level (% w/w) on drug released from pellets. (pellet size: 2.0
mm, drug load: 10% w/w, spheronization time: 20 minutes, n = 4±SE)
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Effect of spheronizarion time on pore size distribution of pellets. (pellet size: 2.0 mm,
drug load: 10% w/w, n = 3±SE)
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Schematic representation of the effect of spheronization
time on the pore diameters and total number of pores.
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MANUSCRIPT IV

MULTI-UNIT CONTROLLED RELEASE SYSTEMS OF NIFEDIPINE AND
NIFEDIPINE:PLURONIC® F-68 SOLID DISPERSIONS: CHARACTERIZATION
OF RELEASE MECHANISMS
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Abstract

Nifedipine (N) and nifedipine:Pluronic® F-68 solid dispersion (SD) pellets were
characterized for drug release mechanisms from a multi-unit erosion matrix system for
controlled release. N was micronized using a jet mill. SD with Pluronic® F-68 was
prepared by the fusion method. N and SD were characterized by particle size analysis,
solubility, DSC and XRD studies. Samples were subsequently processed into matrix
pellets by Extrusion/Spheronization using Eudragit® L 100 SS and Eudragit® S 100 as
release rate controlling polymers.

Drug release mechanisms from pellets were

characterized by microscopy and mercury intrusion porosimetry. DSC and XRD studies
indicated no polymorphic changes in N after micronization and also confirmed the
formation of SD of N with Pluronic® F-68. Pellets of N showed a 24 hour drug release
profile following zero order kinetics. Pellets of SD showed a 12 hour release profile
following first order kinetics. Aqueous solubility of N after SD formation was found to
be increased by IO folds.

Due to increased solubility of N in SD, the drug release

mechanism was found to be changed from pure surface erosion to erosion/diffusion
mechanism thereby altering the release rate/kinetics.
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1.0

Introduction

Nifedipine is a poorly water-soluble drug and when administered orally in the crystalline
form has poor bioavailability. For poorly soluble drugs, dissolution is the rate-limiting
step for gastrointestinal absorption of the drug from solid dosage forms.

Since

dissolution rate is directly proportional to surface area, decreased particle size may
increase the dissolution rate.

Numerous attempts have been made to modify the

dissolution characteristics of drugs to attain more rapid and complete absoqition ( 1-5).

Controlled release Oros® tablets of nifedipine are commercially available. The drug
releases in the form of a microfine suspension through a laser drilled hole in the tablet via

(

osmosis following zero order kinetics for 24 hours. Osmotic controlled release multi-unit
pellets and granules of nifedipine have also been reported (6).

The mechanism of polymer controlled surface erosion that provides a constant delivery of
a poorly soluble drug via multi-unit erosion matrix was reported in our previous study (7).

In such a system the drug release was found to be proportional to matrix erosion. Hence,
matrix erosion could be used to predict drug release. This system consisted of Eudragit®
L 100 55 and Eudragit® S 100 which were used as matrix forming and release rate
controlling polymers.
methacrylic acid esters.

These are anionic polymers based on methacrylic acid and
The ratio of carboxyl groups to ester units is about 1: 1 in

Eudragit® L 100 55 and about 1:2 in Eudragit® S 100. These polymers are soluble above
pH 5.5 and 7.0 respectively.

The model drug (nifedipine), Eudragits® and

105

polyvinylpyrrolidone (binder) were wet granulated and later pelletized using an
Extrusion/Spheronization technique.

The effects of dissolution stirring rate, polymer

ratio, granulation water requirement, drug loading, pellet size and spheronization time on
the release patterns were reported earlier (8).

Solid dispersions of poorly soluble drugs provide alternatives to increasing drug solubility
and bioavailability. Law et al. (9) showed increased oral absorption and bioavailability of
nifedipine-polyethylene glycol and nifedipine-phosphatidylcholine-polyethylene glycol
solid dispersions in rats . Solid dispersions of nifedipine with different carriers such as
urea, lactose, PEG 4000, 6000, 10000 and PVP K-30, K-90 have been studied by Sumnu
et al. (10). However none of these solid dispersions were evaluated for their release
patterns from the final controlled drug deli very system, and there are no studies
determining the influence of solid dispersions on drug release mechanisms via solid
dosage forms.

Release mechanisms of a drug from solid dosage forms may be related to the porosity.
Porosity is a result of the presence of voids and pores in a sample where voids are the
inter particulate spaces and pores are typically the crevices, cracks and fissures located in
the particle (11). The porosity can be characterized by mercury porosimetry. The pore
structure of a solid can provide valuable information regarding its dissolution and
diffusion properties (12). Therefore, porosity and pore size distribution measurements
have been extensively used to study tablets ( 13- 18), granules (I 9-23) and pharmaceutical
powders (24,25).

Void porosity can be characterized by low pressure mercury

106

porosimetry (upto 30 psi) and is detemtined by calculating the pore volume diameter. In
contrast, pores are analyzed by high pressure mercury porosimetry (upto 30,000 psi).
According to this method, the cumulative volume of mercury intruded is a function of
porosity, increased volumes indicate an increased porosity.

The present study was undertaken to develop, characterize and evaluate the multi-unit
erosion matrix as described previously (7) with nifedipine and nifedipine:Pluronic® F-68
solid dispersion. A physical characterization of nifedipine solid dispersion by particle
size analysis, aqueous solubility, DSC and XRD studies were conducted before they were
pelletized.

Later, pellets containing nifedipine or nifedipine:Pluronic® F-68 solid

dispersions were prepared by a Extrusion/Spheronization technique.

The effect of

porosity parameters (cumulative intrusion volume, pore size distribution, pore volume
diameter, total intrusion volume and total pore surface area) on dissolution time of the
pelletized nifedipine and nifedipine:Pluronic® F-68 solid dispersion were detemtined to
better explain the mechanism of drug release from controlled release matrix pellets and to
detemtine the differences that were introduced by the nifedipine:Pluronic® F-68 solid
dispersions.

2.0

Materials and methods

Nifedipine (USP/BP) was purchased from Vinchem, Inc, (Chatham, NJ, USA) and was
micronized by using a Fluid Energy Aljet Mill (Plumsteadville, PA, USA).

Inlet air

pressure of 60 psig and grinding air pressure of 80 psig for micronization were used.
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Eudragit® L 100 55, Eudragit® S 100 (Huls America, Inc ., Somerset, NJ, USA),
Kollidon® 90 F (BASF, Inc., Parsipanny, NJ, USA), Avicel® PH IOI (FMC Corporation,
Philadelphia, PA, USA), Triethyl Citrate (Morflex, Inc., Greensboro, NC, USA) and
Pluronic® F-68 (BASF, Inc., Parsipanny, NJ, USA). All other chemicals were used as
received. Since nifedipine is sensitive to light, all experiments were performed under
yellow light.

2.1

Particle size detennination

Particle size determination was carried out with Master Sizer X, Malvern Instruments
Inc., Southborough, MA, USA. An excess amount of drug was suspended in 1.0 % v/v
Tween 80 in 100 mL of distilled water and was sonicated for 30 seconds for a thorough
dispersion. This suspension was circulated at medium speed for particle size distribution
studies.

2.2

Preparation of nifedipine: Pluronic® F-68 solid dispersions

Solid dispersion with different drug:pluronic ratios were prepared by the fusion method
(26). The required amount of Pluronic® F-68 was weighed accurately and heated to 100°
C until it formed a transparent melt. Nifedipine (mean particle size: 2.31 µm) was added
to this melt in small portions with a constant stirring rate of 750 rpm . The temperature of
the mixture was kept constant at 100° C. This mixture was stirred for 45 minutes until a
clear transparent melt was formed. The melt was then poured on to a glass plate and was
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allowed to solidify at room temperature. The solid mass was powdered and uniformly
mixed in a mortar and 80/100 mesh (150-180 µm) particles were used for pelletization.

2.3

Solubility of nifedipine and nifedipine in Pluronic 119 F-68 solid dispersion

Solubility of nifedipine alone and nifedipine in the Pluronic® F-68 solid dispersion ( 1: 1)
was determined by placing an excess amount of sample in amber glass vials with 10 mL
deionized water. The samples were then subsequently allowed to equilibrate at 25° C in
an incubator shaker for 24 hours. Samples were filtered and the filtrate was analyzed for
nifedipine by an HPLC method. A Waters 600E multi solvent delivery system (Waters
Corporation, Milford, MA, USA) connected with a variable wavelength absorbance
detector (Model Spectra 100, Spectra-Physics, USA) and a Waters 717 plus auto sampler
(Waters Corporation, Milford, MA, USA) was used. The stationary phase consisted of a
micro bondapak C 18 reverse phase column (3.9 x 300 mm, Waters Corporation, Milford,
MA, USA). Mobile phase used was acetonitrile : methanol : distilled water (2 : 3 : 5) and
the flow rate was 1.0 mIJmin with 30 minutes of total run time per injection. Nifedipine
was detected at a retention time of 15.8 minutes. The sensitivity of the assay was I
µg/mL. All studies were performed in triplicate.

2.4

Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies

DSC was carried out with a Seiko Instruments Inc., Japan, Model SSC5200 system.
Approximately 10 mg of sample was placed in a hermetically sealed aluminium pan and
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was scanned at the rate of 10° C/min from 0 to 200° C. Qualitative powder X-ray
diffraction was performed by a Scintag X-Ray Diffractometer System, CA, USA by using
nickel filtered copper potassium alpha radiation.

2.5

Preparation of pellets

Eudragit® L 100 55 and Eudragit® S 100 were mixed in a Turbula mixer (Impandex Inc.,
Maywood, NJ, USA) for 30 minutes. Triethyl citrate was added to this mixture as a
plasticizer by trituration in a mortar. Nifedipine or nifedipine solid dispersion was then
added followed by Kollidon® 90F used as a binder and they were mixed for 30 minutes in
a Turbula mixer. The resultant mixture was then granulated with deionized water in a
mortar. The granulate obtained was then fed through an extruder (LCI Xtruder, Model
DG-Ll by Fuji Pauda! Co., Ltd., Japan) which was equipped with a single screw and a
screen of 2.0 mm size. Extrusion was conducted at 40 rpm. Extrudates obtained were
immediately processed into pellets by spheronization (Spheronizer: Model 120, G.B.
Caleva Ltd, Dorset, England attached with a 2.0 mm cross hatched friction plate). The
spheronization speed was maintained within 800-1000 rpm and spheronization time was
limited to 10 minutes. During this p'rocess Avicel® PH 101 (5% w/w of total batch size)
was sprinkled on to the pellets to prevent inter pellet sticking. Pellets thus obtained were
dried on trays in a hot air convection oven for 12 hours at 50° C. They were then sieved
(Rotap Sieve Shaker, Model RX-29, W.S. Tyler, Inc., OH, USA) to obtain 2.0 mm sieve
fractions. The quantitative composition of the pellets formulated is given in Table I.
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2.6

Detemzination of In Vitro drug release

In vitro dissolution was performed using USP XXII Apparatus I in 500 mL of pH 6.8
phosphate buffer with ionic strength of 0.05 M, at 50 rpm and 37.0 ± 0.5° C (Distek Inc.,
NJ, USA) .

Pellets obtained after dissolution were characterized for their shape and

structure by an optical microscope by Nikon HFX, IA, Japan. Transverse sections of
pellets obtained after 2 and 4 hour dissolution times were analyzed for the distribution of
drug in the matrix.

2. 7

Determination of porosity parameters

Pellet dissolution time as a function of cumulative intrusion volume of mercury, pore size
distribution, pore volume diameter, total intrusion volume and total pore surface area
were determined by mercury intrusion porosimetry. A Micromeritics PoreSizer Model
9320, Micromeritics Inc., Norcross, GA, USA was used 1·or the determinations. Each
sample was measured in triplicate.

3.0

Results and discussion

Results of particle size determination are tabulated in Table II.

The solubility of

nifedipine and nifedipine in the nifedipine:Pluronic® F-68 (1: I) solid dispersion was
found to be 9.72±Q.13 and 103.06±0.07 µg/mL respectively demonstrating that Pluronic®
F-68 increased the solubility of nifedipine by approximately ten fold .

Ill

DSC thermograms and XRD pattern of micronized nifedipine indicated no changes in its
thermodynamic and crystalline behaviour (Figures la and lb). Data obtained indicates
that nifedipine remained the same after micronization.

Figures 2a and 2b are the

thermograms of nifedipine:Pluronic® F-68 solid dispersions that were prepared in ratios
of 1:0.5 w/w drug to polymer (Tm= 167.8° C, 6.H = 50.7 mJ/mg) and 1:1 w/w (Tm=
152.6° C, 6.H = 24.2 mJ/mg) respectively. From these thermograms it was clear that the
melting point of nifedipine was reduced in the solid dispersion with consequent reduction
in enthalpy Figures 3a and 3b are XRD patterns of nifedipine:Pluronic® F-68 solid
dispersions in ratios of 1:0.5 w/w and 1:1 w/w respectively. The characteristic nifedipine
peaks were found to be reduced with increased concentration of Pluronic® F-68 in the
solid dispersion. These results provide evidence of decreased drug crystallinity due to the
formation of a solid dispersion.

Similar results were reported for nifedipine solid

dispersions with various other substances (9, 10) such as polyethylene glycol, urea,
lactose, polyvinylpyrrolidone etc.

A linear relationship of drug release via matrix erosion of a poorly soluble drug, similar
to nifedipine, was described in our earlier study (7). The validity of this matrix erosion
hypothesis was tested with nifedipine and nifedipine:Pluronic® F-68 solid dispersion
pellets. The in vitro release profiles of nifedipine pellets before and after micronization
and nifedipine:Pluronic® F-68 solid dispersion pellets are shown in Figure 4. Pellets
prepared with nifedipine of three different particle sizes provided a zero order 24 hour
drug release profile. On the other hand, drug release from the pellets prepared with
nifedipine:Pluronic® F-68 solid dispersions was changed from zero to first order and the

112

release rates had significantly increased compared to the pellets prepared with nifedipine
alone. Drug release rates from the solid dispersion pellets was increased as Pluronic® F68 increased from 0.5 to 1.0 part in the solid dispersions. Dissolution from these pellets
followed first order kinetics for about 12 hours for both the strengths. From Figure 4 it
can also be concluded that particle size differences of nifedipine did not significantly
influence the release pattern and rates from nifedipine pellets.

In order to understand the underlying release mechanism, the pellets collected at different
time intervals during dissolution testing were analyzed under the microscope. Figure 5
shows pellets prepared with nifedipine:Pluronic® F-68 (I: 1) solid dispersion after 12
hours of dissolution.

The size of the pellets was decreased due to surface erosion.

Nifedipine pellets also eroded in a similar fashion over a period of 24 hours. Both these
pellets maintained their geometrical shape but were reduced in size. Furthermore, pellets
of nifedipine and nifedipine:Pluronic® F-68 (1:1) solid dispersion that were removed
from the dissolution medium on the 2 and 4 hours of dissolution were dried at 50° C for
12 hours and transverse sections of these pellets were investigated. After 4 hours the
pellets became very soft which made it impossible to obtain the transverse. Transverse
sections of nifedipine pellets (Figures 6a and 6b) showed that the drug remained
unifomtly distributed in the matrix at 2 and 4 hours, whereas nifedipine:Pluronic® F-68
( 1: 1) solid dispersion pellets showed release of the drug from the core by diffusion. The
increased aqueous solubility of drug in the solid dispersion explains the enhanced erosion
and release rates from nifedipine:Pluronic® F-68 solid dispersion pellets as compared to
nifedipine pellets. Increased aqueous solubility had also increased the release of drug
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from the pellets of solid dispersion which occurred by erosion and simultaneous diffusion
from the matrix. Whereas release of drug from nifedipine pellets was purely by erosion
mechanism.

To further confirm the release mechanisms of both the pellets, their porosity parameters
were measured and determined by mercury intrusion porosimetry. The porosities were
determined after the pellets were exposed to 2. 4, 6 and 8 hours of dissolution media.
Figures 7a and b show the cumulative intrusion volume of mercury against pore
diameters

obtained

at

different

dissolution

intervals

of

nifedipine

and

nifedipine:Pluronic® F-68 solid dispersion pellets, respectively. Figures 8a and b show
changes in the pore size distribution during dissolution.

Figure 7a shows that the

cumulative intrusion volumes of mercury for nifedipine pellets following dissolution at 2
to 8 hours mainly remain constant with minimal changes, whereas from Figure 7b, pellets
of nifedipine:Pluronic® F-68 solid dispersion showed increased pores as the dissolution
time increased from 2 to 8 hours.

Further from Figure 8a, a trimodular pore size

distribution is observed with maximum pores lying within the range of 0.1 to 0.01 µm
indicating that the voids and fine pores contribute to the overall porosity of the pellets
with the pores occupying a much higher volume than the voids. A reverse pore size
distribution was observed (Figure 8b) for pellets of nifedipine:Pluronic® F-68 (I: 1) solid
dispersion indicating that the overall porosity was due to the voids which were increasing
with dissolution time. Figure 9 shows the effect of dissolution time on the pore volume
diameter of the pellets.

No significant changes were observed in the pore volume

diameters of nifedipine pellets indicating no increase in void porosity during the
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dissolution period of 8 hours, whereas pore volume diameters of pellets formulated with
nifedipine:Pluronic® F-68 (I: 1) solid dispersions increased with dissolution time
indicating an increase in the void porosity which is the result of increased void diameters.
This increase may be due to the enhanced solubility of drug in the solid dispersion which
diffused out of the matrix.

Figure 10 shows the total intrusion volumes that were

obtained at different dissolution times that summarizes the overall effect of dissolution
time on pellet porosity. From this Figure the porosity of nifedipine:Pluronic® F-68 solid
dispersion pellets increased linearly with dissolution time whereas, the porosity of
nifedipine pellets did not change significantly. Total pore surface area is the cumulative
surface area of all the pores and voids present in a sample. Figure 11 shows the total pore
surface area against dissolution time. The total pore surface area of nifedipine:Pluronic®
F-68 solid dispersion pellets increased linearly from 2 to 8 hours of dissolution time.
This maybe due to the formation of voids and pores as nifedipine and pluronic was
diffusing out of the matrix. However, it is postulated that the total pore surface area is
being reduced during dissolution because the size of the pellets becomes smaller. Such a
phenomenon can only occur if surface erosion is the only mechanism of release which in
fact was observed with nifedipine pellets. Their total surface area decreased linearly with
dissolution time (Figure 11). This confirms that surface erosion is the release mechanism
of nifedipine pellets. In addition, the results demonstrated in Figure 11 strongly indicate
that upon incorporation of a poorly soluble drug like nifedipine in erosion matrix pellet
systems, a zero order release for 12-24 hours as described previously (7) is obtained.
However, a change in the physical properties and solubility of the drug as it occurs with
nifedipine: Pluronic® F-68 solid dispersions alters the release profile and kinetics.
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4.0

Conclusions

In conclusion, controlled release of nifedipine (poorly soluble drug) following zero order
kinetics for 24 hours from a multi-unit erosion matrix was achieved. It was proved that
multi-unit erosion matrix systems as described earlier (7) are universal in their application
for controlled release of poorly soluble drugs . Drug release from nifedipine pellets
occurred by matrix erosion. Whereas for pellets of nifedipine:Pluronic® F-68 solid
dispersion, release occurred by a combination of matrix erosion and diffusion
mechanisms for 12 hours following first order kinetics. The solubi lity of nifedipine was
increased by 10 times due to solid dispersion formation in I: I nifedipine:Pluronic® F-68
ratio. Porosity parameters studied by mercury intrusion porosimetry proved that drug
release was not influenced by the porosity for nifedipine pellets, however the drug release
was predominantly porosity controlled for nifedipine:Pluronic® F-68 solid dispersion
pellets.

Acknowledgments

This study was supported by Hoffman-La Roche Inc., Nutley, NJ, USA. Assistance from
Mr. Ashish Chatterjee and Mr. Maurice Munroe from Hoffmann-La Roche Inc., Nutley,

NJ, USA in performing XRD and particle size analysis is deeply appreciated.
Constructive suggestions from late Mr. Jaques Tossounion from Hofimann-La Roche
Inc., Nutley, NJ, USA while preparing this manuscript are acknowledged.

11 6

(

References

I.

R. M. Atkinson, C. Bedford, K. J. Child and E. G. Tomich, Effect of particle
size on blood griseofulvin level in man, Nature, 1983 , (1962) 588.

2.

G. Levy, Effect of particle size on dissolution and gastrointestinal absorption
rates of pharmaceuticals, American Journal of Phannacy., 135, ( 1963) 78.

3.

S.S . Kornblum and J. 0. Hirschom, Dissolution of poorly water-soluble drugs,

Journal of Pharmaceutical Sciences., 56, ( 1970), 606.
4.

S. L. Lin, J. Menig and L. Lachman, Interdependence of physiological
surfactant and drug particles on dissolution behavior of water-insoluble drugs,

Journal of Pharmaceutical Sciences., 57, ( 1968), 2 143.
5.

E. L. Parrot, Milling of pharmaceutical solids, Journal of Pharmaceutical

Sciences., 63, (1974), 813.
6.

T. Chandy and C. P. Sharma, Chitosan beads and granules for oral sustained
delivery of nifedipine: In vitro studies, Biomaterials., 13 ( 13), ( 1992), 949-52.

7.

K. A. Mehta, M. S. Kislalioglu, A. W. Malick, W. Phuapradit and N. H. Shah,
A novel multi-unit erosion matrix for a poorly soluble drug.

Part L

Phannaceutical Research (suppl), 13 (9), (1996), S314.
8.

K. A. Mehta, M. S. Kislalioglu, A. W. Malick, C. I. Patel and N. H. Shah, A
novel multi-unit erosion matrix for a poorly soluble drug. Part II. Phannaceutical

Research (suppl), 13(9), ( 1996), S294.
9.

S. L. Law, W. Y. Lo, F. M. Lin. and C.H. Chaing, Dissolution and absorption

117

of

nifedipine

in

polyethylene

glycol

solid

dispersion

containing

phosphatidylcholine, International Journal of Phannaceutics., 84, ( 1992), 161166.
l O.

M. Surnnu, Increasing dissolution rate and gastrointestinal absorption of
nifedipine via solid dispersion, S. T. P. Pharma. , 2 (14), (1986), 214-220.

11.

C. Jr. Orr, Application of mercury penetration to material analysis, Powder

Technology., 3 (1969nO) 117-123 .
12.

P. J. Dees and J. Polderman, Mercury porosimetry in pharmaceutical technology,

Powder Technology., 29 (1981). 187-197.
13.

M. Wikberg and G. Alderbom, Compression characteristics of granulated
materials II. Evaluation of granule fragmentation during compression by tablet
permeability

and

porosity

measurements,

International

Journal

of

Pharmaceutics., 62, (1990), 229-241.
14.

M. Wikberg and G. Alderbom, Compression characteristics of granulated
materials: VI. Pore size distributions, assessed by mercury penetration, of
compacts of two lactose granulations with different fragmentation propensities,

International Journal of Pharmaceutics., 84, (1992), 191-195.
15.

A. M. Juppo, Porosity parameters of lactose, glucose and mannitol tablets
obtained by mercury porosimetry, International Journal of Pharmaceutics., 129,
(1996), 1-12.

16.

A. B. Selkirk and D. Ganderton, The influence of wet and dry granulation
methods on the pore structure of lactose tablets, Journal of Pharmacy and

Phannacology., 22, Suppl, (1970), 86S-94S.

118

(

17.

A. B. Selkirk and D. Ganderton, An investigation of the pore structure of tablets
of sucrose and lactose by mercury porosimetry, Journal of Pharmacy and

Pharmacology., 22, Suppl, (1970), 79S-85S.
18.

F. Carl i, I. Colombo, L. Simioni and R. Bianchini, The effect of compression
on

the capillary microstructure of tablets,

Journal of Pharmacy and

Phannacology., 33, (1981), 129-135.
19.

A. M. Juppo, Change in porosity parameters of lactose, glucose and mannitol
granules

caused

by

low

compression

force,

International

Journal

of

Pharmaceutics., 130, (1996), 149-1 57.
20.

A. M. Juppo and J. Yliruusi, Effect of amount of granulation liquid on total pore
volume and pore size distribution of lactose, glucose and mannitol granules,

European Journal of Pharmaceutics and Biophamraceutics., 40 (5), (1994), 299309.
21.

H. Fujiwara, J. Toda and M. Kato, Studies on pore structure of granules by
mercury porosimetry, Chemical Pharmaceutical Julletin., 14 (6), (1966), 601607.

22.

G. L. Nicholson. and R. P. Enever, The influence of porosity upon the
distribution of reserpine in calcium sulphate granules, Journal of Pharmacy and

Pharmacology., 26, (1974), 420-426.
23.

K. Zuurman, K. A. Riepma, G. K. Bolhuis, H. Vromans and C. F. Lerk, The
relationship between bulk density and compactibility of lactose granulations,

International Journal of Pharmaceutics., 102, ( 1994), 1-9.
24.

H. K. Palmer and R. C. Rowe, The application of mercury porosimetry to porous

119

polymer powders, Powder Technology, 9, ( 1974), 18 1- 186.

(
25.

F. Carli and A. Motta, Particle size and surface area distributions of

pharmaceutical powders by micro computerized mercury porosimetry, Journal of

Phannaceutical Sciences., 73 (2), (1984), 197-203.
26.

E. A. Saers, Studies on solid dispersions for fast release and dissolution of drugs
with low aqueous solubility, Doctoral Thesis, Uppsala University, Sweden,
(1992), 13.

120

\

~.

\.

Composition of pellets prepared with nifedipine and nifedipine:Pluronic®

Table I :

F-68 solid dispersions.
Formulation

1J'.E_e
nifedipine pellets
DJ_v, 5Ql_= 7.06.l!._
nifedipine pellets
DJ_v, 5Ql_= 2.66.l!._
nifedipine pellets
Dj_v, 50)= 2.3 !J:I.
nifedipine:Pluronic®
F 68 SD_JJelletsJ..J :12_
nifedipine :Pluronic®
F 68 SD pellets

Nifcdipine
(% w/w)

Kollidon® 90F
J_%w/w_l

Eudragit® L 100 55 : S
100 ratioJ.% w/w_l

* Plasticizer

20.00

2.00

I :3

I 1.70

20.00

2.00

I :3

11.70

20.00

2.00

I :3

I 1.70

20.00

2.00

I :3

11.70

20.00

2.00

I :3

11.70

_D:O.~

• Triethyl citrate (15% w/w ofEudragit® L JOO 55 + Eudragit® S JOO)

(% w/'2

'

\

\

Table 2:

Results of Particle Size ofNifedipine and Nifedipine in Pluronic F-68
so lid dispersions.

SAMPLE
Nifed_!Eine
Nifed_!Eine micronized once
NifediIJine micronized twice

DJY,

O.~ (µ)

Nifed_!Eine:Pluronic® F-68 (1:1) SD

7.06
2.87
2.31
3.10

Nifedipine:Pluronic® F-68(1 :0.5) SD

2.66

1

•

• 50 h percentile mean volume particle size.

"''"

•• 90tltpercentile volume particle size.

D(V, 0.9) (u)
17 .29
8.72
6.96
12.93
8.40

••

Figure I a

(

Melting point endothenns of nifedipine before and after micronization

micronized

Tm= 174.7 •c

Ml= 103.5 mJ/mg

unmicronized
Tm= 174.7 •c

97 . !5

14!5

TacP c . IHutfnol
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192. !5

Ml • 103.3 mJ/mg

Figure I b

(

X-ray diffraction pattern of nifedipine before and after micronization.
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Figure 2 a

(

Melting point endotherm of nifedipine:pluronic F-68 solid dispersion (I :0.5)
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Figure 2 b

(

Melting point endotherm of nifedipine:pluronic F-68 so lid dispersion (I: I)
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, ; ' - - - - - - - - ____2_4~2_~.!1.18.l . ll

c

-e:.u.w

(

---,

St.l!I C

-Zi.M!!I ...

50

100
TEMP C (Heating)

126

150

Figure 3 a
X-ray diffraction pattern of n.ifedipine:pluronic F-68 solid dispersion (l :0.5)

29
./
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Figure 3 b
X-ray diffraction pattern of nifedipine:pluronic F-68 solid dispersion (I: I)
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31.

Effect ofnifedipine mean particle size and ratio of nifedipine:pluronic F-68 so lid
dispersion on the release profiles obtained with 2.0 mm pellets.
(spheronization time : I 0 minutes, n = 4±SE)
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•
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Y

2.31 um
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•

1: 1 (3 . IOum)

•

1:0.5 (2 .66 um)
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~! ic ru scop i ca l eval uat io n of ni f~ dip i ne: plu ro ni c F-68 ( I: I ) so lid d ispersion pelle ts after
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f.

Ill hn u r.1

Figure 6 a
Transverse section of nifedipine pellets after 2 and 4 hour dissolution time intervals
showing uniform drug distribution in the matrix.

l·
4boun
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Figure 6 b
Transverse section of nifedipine:pluronic F-68 (1: l) solid dispersion pellets after 2 and 4
hour dissolution time intervals showi ng drug diffusion through the matrix.
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Cwnulative intrusion profiles ofnifedipine and nifedipine:pluronic F-68 solid dispersion
pellets during dissolution.
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l.e-1

l.e-2

Pore size distribution of nifedipine and nifedipine:pluronic F-68 solid dispersion pellets
during dissolution. (spheronization time : I 0 minutes, n = 4±SE)
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Changes in the pore volwne diameter of pellets during dissolution.
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Changes in the total intrusion vo lume of pellets at various dissolution intervals .
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Effect of dissolution time on the changes in total pore surface area of the pellets.
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ABSTRACT

The development, characterization and in vitro evaluation of a novel multi-unit erosion
matrix pellet system of nifedipine was described earlier. The purpose of this study was to
evaluate in vivo performance of the erosion matrix pellets prepared with nifedipine and
compare their bioavailability with nifedipine irrunediate release soft gelatin capsules
(Adalat® !Omg and 20 mg gelcaps administered togethe: as one dosage form) in fasted
dogs .

A randomized two way comparative cross-over design was employed for

bioavailability studies and four dogs were used. Blood samples were collected over
predetermined time intervals up to 12 or 24 hours and analyzed for nifedipine plasma
concentrations by an HPLC method for both the dosage forms. Data obtained was fitted
to a non-compartmental pharmacokinetic model to determine parameters such as Cmax,
Tmax, AUYl-24

h.

and MRT0- 24

h·

Results indicated that the bioavailability of nifedipine

erosion matrix pellets was four times higher than Adalat® gel caps.

Nifedipine was

detected in plasma within one hour of administration of erosion matrix pellets, thus no
significant lag time was observed. Nifedipine multi-unit erosion matrix pellets showed
controlled release for more than 24 hours following zero order kinetics.
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1.0

Introduction

Nifedipine is a calcium antagonist which is widely used as a coronary dilator in
hypertension. Clinical studies have shown that the hypotensive effect of this drug could
be correlated with the plasma nifedipine [l] . It is therefore important to prolong the
plasma concentrations so as to control and regulate the therapeutic effects of nifedipine
over a longer duration. Nifedipine is a poorly soluble drug and its absorption in GIT is
rate limited. It has a short biological half life of about 2.3 hours. When administered
orally via solid dosage forms, absorption of nifedipine is poor.

Nifedipine is commercially available as soft gelatin capsules and tablets for short term
and extended treatments. Controlled release nifedipine is available as an extended release
film coated tablet and also as a GITS system. The extended release film coated tablet
contains a tablet core coated by a slow releasing layer comprising of the drug and the
hydrophilic polymers such as hydroxypropylcellulose and hydroxypropylmethylcellulose.
The outer slow releasing layer provides the initial drug release followed by rapid drug
release from the tablet core. Drug release from such a tablet typically follows first order
kinetics. One of the most desirable outcome in controlled drug delivery is to achieve zero
order kinetics in vivo so as to obtain a constant therapeutic effect of the drug for a
maximum duration. This is achieved by the nifedipine GITS system for controlled
delivery.
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The GITS system releases finely powdered nifedipine in a suspension form into the
gastrointestinal lumen at a controlled rate over a 24 hour period. The release mechanism
involves a "push-pull" process.

As water is absorbed across the semi-permeable

membrane surrounding the bilayer tablet, nifedipine particles become suspended in
solution and are then "pushed" into the intestinal tract as the osmotically active polymers
expand. Hydration of the GITS tablet occurs for approximately 2 hours before substantial
amounts of nifedipine is detected in plasma. Dose dumping of nifedipine does not occur
from the GITS system however approximately 10% of the total GITS tablet content
remains unabsorbed after the tablet is emptied [2]. The dosage forms described above are
examples to current nifedipine formulations that are available commercially for
controlled delivery.

The development, characterization and evaluation of a novel multi-unit erosion matrix
pellet system of nifedipine was described elsewhere [3]. It was designed to release a
poorly soluble drug by surface erosion as a consequence of the polymer erosion from the
matrix pellets. The drug release mechanism from this system is illustrated schematically
in Figure !. In vitro evaluation of this system in pH 6.8 phosphate buffer demonstrated
zero order drug release in 24 hours [4].

The purpose of this study was to determine the bioavailability and pharmacokinetic
parameters such as Cmax. T """'' AUC

0-24 h·

and MRT

0-24 h

of nifedipine from this novel

erosion matrix pellet system and compare the bioavailability with Adalat® immediate
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release soft gelatin capsules used as a control in a randomized two way cross over design
in four fasted dogs.

2.0

Materials and methods

Nifedipine was purchased from Vinchem Inc., Chatham, NJ. Eudragit® L 100 55 and
Eudragit® S 100 (polymethacrylic acid esters) were provided as samples by Huls America
Inc., Somerset, NJ. Kollidon® 90 F (polyvinylpyrrolidone) was obtained from BASF Inc.,
Parsipanny, NJ . Avicel® PH 101 (microcrystalline cellulose) was purchased from FMC
Corporation, Philadelphia, NJ. Triethyl citrate was provided as a sample by Morflex Inc.,
Greensboro, NC. Butamben (n-butyl-p-amino benzoate) was provided as a free gift by
Abbott Laboratories, North Chicago, IL.

Methanol and acetonitrile (HPLC grade),

chloroform, acetone, 0-phosphoric acid (80% v/v) were purchased from Fisher Scientific.,
Springfield, NJ. All the chemicals were used as received.

All work was carried out under yellow light. Turbula mixer (lmpandex Inc., Maywood,
NJ, USA) was used for mixing dry powders. Extruder utilized was LCI Xtruder, Model
DG-Ll, Fuji Pauda! Co., Ltd., Japan. (Single screw extruder, capable of extruding at
speeds upto 100 rpm, with variable screens to obtain extrudates of different size). The
Spheronizer used was a G.B. Caleva Ltd, Model 120, Dorset, England. [It consists of a
stationary vertical cylinder which has at the base a friction plate (diameter 32 cm) with a
2 mm cross hatched friction pattern and a rotation speed of 200-3000 rpm]. Rotap Sieve
Shaker, Model RX-29, W.S. Tyler, Inc., OH (Fitted with sieve# 8, 10, 12, 14, 16, 18 and
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20) was utilized to collect pellets of the desired particle size. In vitro analysis of the
pellets was performed in a Hewlett Packard 8452A Diode Array Spectrophotometer
(Hewlett Packard Company, Paramus, NJ).

A vortex Mixer with 40 test tube holding capacity Model Typ VX 2V (IKA®Works, Inc.,
Cincinnati, OH) was used to equilibrate the frozen blood samples at room temperature
prior to analysis .

Fisher Vortex Genie 2™ with 40 micro-centrifuge tube holding

capacity (Scientific Industries, Inc., Bohemia, NY) was utilized for sample processing. A
Centrifuge, Model HN-S II (International Equipment Company, Needham Heights, MA)
for separation of plasma proteins after drug extraction from the blood samples was used.
TurboYap® LV Evaporator with nitrogen gas pressure of 1.0 bar (Zymark Corporation,
Hopkinton, MA) was used as a sample concentrator for the assay.

2.1

Formulation of pellets

Eudragit®L 100 55 and Eudragit®S 100 powders were mixed in a turbula mixer for 30
minutes.

Triethyl citrate was added as a plasticizer and the resultant mixture was

triturated in a mortar for 5 minutes. Drug and polyvinyl pyrrolidone (Kollidon®K90F)
used as a binder, were added and mixed for 30 minutes in a turbula mixer. This mixture
was then granulated in a mortar with deionized water and later extruded at 40 rpm screw
speed.

The extrudates were immediately transferred into a rotating plate in the

spheronizer. Spheronization was carried out for 10 minutes at 800-1000 rpm. During
this period, 5% w/w of total batch size Avicel® PH 101 was sprinkled over the rotating
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extrudates to prevent pellets from sticking. Pellets obtained were dried on trays at 50°C
for 12 hours. The pellets consisted of nifedipine (20.0% w/w), Eudragit®L 100 55 and
Eudragit® S 100 (78.0% w/w total in ratio of 1:3 respectively) and Kollidon®K90F (2.0%
w/w). Granulation water level used was 58% w/w of the total batch size. Pellets (150
mg) were filled in a size 2 blue colored capsule before they were administered to the
animals.

2.2

Assay of nifedipine in pellets

Nifedipine content of the pellets was determined by UV spectrophotometry. The pellets
(100 mg) were dissolved in 100 mL of methanol and the resultant solution was diluted to
obtain

10

ug/mL

nifedipine

concentration.

This

solution

was

analyzed

spectrophotometrically at 237 nm and nifedipine content of 100 mg of pellets was
determined

2.3

In vivo absorption study design and protocol

2.3./

Test animals

The bioavailability of nifedipine pellets was tested on beagle dogs using a randomized
two way comparative cross-over design.

Dogs were supplied by Marshall Farms, North Rose, NY. They were acclimatized for at
least two weeks prior to the study and were approximately 9-14 kg in weight and one year
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old in age. The study group consisted of two males and two females. Each dog had an
ear tattoo for identification and was housed individually in a stainless steel cage. Each
cage had an identification card showing the study number, dog number and sex. Room
temperature and humidity was maintained at approximately 72° ± 4° F and 50% ± 20%
respectively. During the experiments, the animal room was kept on an approximate 12
hour light/dark cycle. Each dog was exercised outside its cage at least three times a week
for at least 15 minutes.

2.3.2

Dosage forms administered, frequency and method of dosing

The bioavailability of nifedipine erosion matrix pellets, (30 mg capsules, Lot No. KM
280/2) was tested against an immediate release soft gelatin capsule (Adalat®. 10 mg
gelcaps, Lot No 6EAB and 20 mg, Lot No 5 HAX, manufactured by Bayer Corporation,
West Haven, CT).

All the test articles were stored in a locked area at ambient

temperature protected from light.

The dogs were fed with Harlan-Teklad certified 25 % lab dog diet (W). Approximately
800 grams diet (approximately 400 grams of dry dog food moistened with approximately
400 mL of water) was provided to the dogs 8 hours after dosing. Reverse osmosis (RO)
water was available Jill libitum by means of an automatic watering system. This RO
water supply for the animal room was monitored for bacterial contamination at least once
a month by the Department of Laboratory Animal Resources.

In addition, chemical

analysis of water was performed at approximately quarterly intervals by the

(
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Environmental Monitoring and Support Laboratory.

No contaminants expected to

interfere with the study were known to be present in the feed or water.

Each dog received one 30 mg nifedipine erosion matrix pellets capsule or IO plus 20 mg
Adalat® soft gelatin capsules in fasted state. Following a one week washout period, each
dog received a different formulation in phase two. The experimental protocol details are
given in Table I.

2.3.3

Blood sampling

Blood samples (6 mL) were taken from each dog at 0, 1, 2, 4, 6, 8, 12, 16, 20 and 24
hours after dosing for the nifedipine erosion matrix pellets. Blood samples from dogs
who received Adalat® soft gelatin capsules were collected at 0, 0.5, l, 2, 4, 6, 8 and 12
hours after dosing. The samples collected were transferred into test tubes containing
lithium heparin, used as an anticoagulant, and to prevent decomposition they were placed
in an ice bucket prior to centrifugation. Plasma was separated after cold centrifugation
and was frozen in amber glass vials at -20° C under yellow light before analysis.

2.4

Assay of Nifedipine in Plasma

Nifedipine in all samples was assayed using a modified version of the HPLC method
described by Miyazaki et al [5].

2.4.1

Processing Blood Samples for HPLC
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Methanol (I 00 µI) containing 2 µg/mL butamben , used as an internal standard and
acetonitrile (2 mL) were added to 0.5 mL of plasma in a test tube and were agitated in a
vortex mixer for 30 minutes. After centrifugation at 4000 rpm for 20 minutes, 2 mL of
the supernatant was transferred into a test tube containing l mL of distilled water, to this
solution 4.5 mL of acetone-chloroform mixture ( l: l v/v) was added. This mixture was
agitated for l hour on a vortex mixture to ensure complete extraction of nifedipine into
the organic phase and was then centrifuged at 4000 rpm for 20 minutes to separate the
organic and aqueous phases. The aqueous phase was discarded and 5 mL of the organic
phase was transferred to a fresh test tube, and was reduced to dryness in a sample
concentrator under nitrogen at 45° C for 30 minutes. The residue was dissolved in 100 µI
of the mobile phase and 20 µI of the solution was injected into the HPLC system.

2.4.2

Chromatographic Conditions

HPLC pump used was a Waters multi-solvent delivery system (Waters Corporation,
Milford, MA) with a Waters 717 plus auto-sampler (Waters Corporation, Milford, MA)
and a variable wavelength absorbance detector (Model Spectra-Physics, USA).

The

stationary phase used was a reverse phase Zorbax ODS, 4-6 microns 25 cm x 4.6 mm
column (I.D., Dupont Inc., Wilmington, DE). The column was warmed at 55° C using a
steel column heater {Model Code 600, Waters Corporation, Milford, MA). The mobile
phase consisted of 0.0 I M disodium hydrogen phosphate buffer-methanol (45:55).
Before mixing, the buffer was brought to pH 6.1 with 50% phosphoric acid. Run time
used was 30 minutes and the flow rate was 0.8 mL/min at column pressure of
approximately 1200 psi. The wavelength of detection was 237 nm.
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2.4.3

Calibration Graph

Standard solutions containing 0.05, 0.1, 0.2, 0.4, 0.6, 0 .8, 1.0 and 10.0 µg/rnL nifedipine
in methanol that contained 2 µg/rnL butamben (internal standard) were prepared under
yellow light. The standard solution (JOO µI) was added to 0.5 rnL of drug free plasma and
the samples were processed as described above.

The ratios of the peak height of

nifedipine to that of butamben were used to construct a calibration graph. Stock solutions
of both nifedipine and the internal standard ( 1 mg/rnL in methanol) were stored in
complete darkness; these solutions were freshly prepared every 2 weeks.

Precision

obtained using the described technique was ±5%.

2.5

Pharmacokinetic Analysis

The most suitable model to describe the pharmacokinetics of nifedipine was determined
by fitting the data to a hierarchy of models using WinNonlin software. The data most
appropriately fitted to a non-compartmental model and pharmacokinetic parameters such
as Cmu. T =• AUCo.24

h

and MRTo.24

h

(mean residence time) were calculated by a

computer using WinNonlin software by Scientific Consulting Incorporated (Lexington,
KY).

3.0

Results and Discussion
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The UV assay demonstrated that nifedipine erosion matrix pellets administered to the
dogs contained 98 - 102 % of the original nifedipine loading. The Adalat® soft gelatin
capsules were not assayed for nifedipine content.

Nifedipine plasma concentrations

obtained after dosing with Adalat® soft gelatin capsules and nifedipine matrix erosion
pellets are tabulated in Tables II and ill respectively.

Table IV shows the mean

pharmacok.inetic parameters (Cmax. T max. AUCo.24 h· MRT0.24 h) determined for both
dosage forms. Figure 2 shows the nifedipine plasma concentration profile for 24 hours
following administration of the pellets and the immediate release capsules. The mean
T max for nifedipine erosion matrix pellets from Table IV was 15.50 hours whereas for
Adalat® capsules was 0.5 hours.

This indicated that time taken to reach maximum

plasma nifedipine concentrations was 15.5 hours thus providing controlled release of the
drug. The MRT0_24

h

was 12.5 hours for the pellets and 1.72 for the Adalat® capsules,

indicating the presence of pellets in the GIT was prolonged. The mean AUCo. 24 h of the
pellets was four times higher than the conventional immediate release Adalat® soft gel
capsules.

Adalat® capsules contain nifedipine in the solubilized form in a polyethylene glycol based
co-solvent system. The bioavailability from Adalat® 20 mg soft gelatin capsules was
reported earlier by Sallam et.al. [6]. Accordingly, the lower AUC obtained with Adalat®
soft gelatin capsules might be due the precipitation of the poorly soluble nifedipine in the
gastric fluid. As a result the particle size of nifedipine may also have increased, which
can be the cause of reduced nifedipine absorption.
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Nifedipine release from the matrix pellets is governed by the polymer controlled surface
erosion process. In this mechanism, drug release occurs in a constant fashion in the form
of a microfine suspension in the gastrointestinal tract and thus is readily available for a
prolonged period.

lt is also interesting to observe that the nifedipine plasma

concentrations were obtained one hour after administration without any significant lag
time, Figure 2. The pellet matrix contains Eudragit® L 100 55 and Eudragit® S LOO
polymers which dissolve at pH 5.5 and pH 7.0 respectively. Considering that the pellets
were very small multi-unit systems (particle size: 2.00 mm), they are expected to have a
small gastric residence time after which exposure to pH 5.5 and higher pH's may have
caused the pellets to release the drug. The most significant effect that is shown in Figure
2 is that nifedipine release from the multi-unit pellets continued for over 24 hours. Thus,
the elimination rate constants could not be calculated for this period

4.0

Conclusions

Controlled delivery of nifedipine via polymer controlled surface erosion of nifedipine
provided zero-order drug release both in vitro and in vivo for 24 hours. Bioavailability
from the controlled release pellet system was four times more than the conventional
immediate release Adalat® soft gelation capsules of nifedipine.

Thus it was demonstrated that the surface erosion mechanism may be used in pellets to
obtain a controlled release system that delivers a poorly soluble drug like nifedipine
effectively and in a constant fashion .
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Table I:

Dosl!_g_e Form

In vivo absorption study protocol details

Condition

Dose
(mg/dog/day)

No. of
Tablets/Capsules

Males

Females

1-2

3-4

1-2

3-4

Phase I
Nifedipine
Erosion Matrix
Cl!.l!_sules

V>
A

Adalat® Soft
Gelatin
Cl!.l!_sules

Fasted

30

I

One week

Washout
Phase II

period

Fasted

30

2

\

\

Table II :

Nifedipine plasma concentrations (12 hours) obtained in dogs (n ~ 4) after administration of Adalat® soft gelatin
capsules (30 mg/dog/day).

V>
V>

Nifedipine

Plasma

Levels

(µg/mL)

Time (hours)

Dog I

Dog II

Dog III

Dog IV

Mean±SD

0.0

0.0000

0.0000

0.0000

0.0000

0.0000 ± 0.0000

0.5

0.2216

2.2628

0.6358

1.6288

1.1872 ± 0 9288

1.0

0.2079

0.6548

0.2530

0.7226

0.4595 ± 0.2666

2.0

0.2097

0.2387

0.0940

0.3394

0.2204 ± 0.1009

4.0

0.0897

0.0648

0.0518

0.1293

0.0839 ± 0.3410

6.0

0.0365

0.0321

0.0215

0.0494

0.0348 ± 0.0115

8.0

0.0243

0.0000

0.0307

0.0228

O.Ql 94 ± 0.0134

12.0

0.0387

0.0000

0.0239

0.0000

0.0156 ± 0.0190

Table Ill:

Nifedipine plasma concentrations (24 hours) obtained in dogs (n

=

4) after administration of matrix erosion pellets

capsule (30 mg/dog/day) .

"'

°'

Nifedipine

Plasma

Levels

(µg/mL)

Time (hours)

Dog I

Dog II

Dog III

Dog IV

Mean±SD

0.0

0.0000

0.0000

0.0000

0.0000

0.0000 :±: 0.0000

1.0

0.0000

0.1331

0.1536

0.3551

0.1604 :±: 0.1465

2.0

0.1333

0.0933

0.0699

0.4714

0.1919 :±: 0.1881

4.0

0.0586

0.0952

0.0867

0.3419

0.1456 :±: 0.1317

6.0

0.1454

0.1617

0.7161

0.0953

0.2796 :±: 0.2923

8.0

0.0727

0.0674

0.7945

0.1438

0.2696 :±: 0.3516

12.0

0.1252

0.1035

0.6778

0.0733

0.2449 :±: 0.2893

16.0

0.1636

0.1654

0.8409

0.0985

0.3171 :±: 0.3505

20.0

0.1869

0.1858

0.8629

0.1449

0.3466 :±: 0.3487

0.1192

0.1275

0.4665

0.0386

0.1879 :±: 0.1899

24.0

\

\

Table IV:

Mean phannacokinetic parameters of nifedipine matrix erosion pellets and Adalat® soft gelatin capsules obtained ny
non-compartmental analysison four beagle dogs.

Dosage Form

Cmu±SE

Tmu:!:SE

AUC0-24h :!: SE

MRT0.24 h :!: SE

(µg/mL)

(h)

(µg h/mL)

(h)

Nifedipine Matrix
Erosion Pellets

....
V>

0.4268

± 0.1602

15.5000 ± 4.5000

1. 1873

± 0.4644

0.5000

6.1123

± 2.8690

12.5561

± 1.2853

Adalat® Soft
Gelatin Capsules

± 0.0000

1.5049 ± 0.3980

1.7280 ± 0.2959

Schematic representation of a novel multi-unit erosion matrix for
controlled release of a poorly soluble drug.

0 to 24 hours
in vitro

matrix pellet

eroding layer
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SECTION III

Appendix !, 2 ,3a ,3b ,3c and 4.
Complete listing of references cited.
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APPENDICES

I. Solubility studies ofnifedipine and nifedipine:pluro nic® F-68 solid dispersion (I 1) in

water at 25°C.

2. Particle size determination of nifedipine samples before and after micronization and
after formation of solid dispersions with pluronic® F-68.

3. Determination of porosity parameters by mercury intrusion porosimetry.
(a)

Pellets formulated with different drug (D 4 Leukotriene antagonist) loads
and spheronized at different times .

(b)

Pellets formulated with different granulation water levels.

(c)

Nifedipine and nifedipine:pluronic® F-68 (I I) solid dispersion pellets after
different dissolution time intervals.

4. Determination of nifedipine in plasma after oral administration of nifedipine erosion
matrix pellet capsule and Adalat® soft gelatin capsule in fasted dogs.
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Appendix 1

Solubility studies ofnifedipine and nifedipine:pluronic® F-68 solid dispersion (1 I) in
water at 25 °C.
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HPLC METHOD VALIDATION:
SOLUBILITY DETERMINATION OF NIFEDIPINE AND NIFED IPINE:PLURONIC®
F-68 SOLID DISPERSION (1:1) IN WATER AT 25°C EQUILIBRATED FOR 24
HOURS

I.

SOURCE of STANDARD:

Nifedipine, Lot # 9S 1172, was purchased from Vinchem Inc., Chatham, NJ, USA.
Pluronic® F-68, Lot# 22415, was obtained as a gift from BASF Inc. , Parsipanny, NJ,
USA.

2.

HPLC METHOD:

System:
Pump:

Waters 600E Multi-Solvent Delivery System

Injector:

Waters 717 Plus Auto Sampler

Column:

Micro Bondapack C 18 Reverse Phase, 3.9 x 300 mm, Waters Corp.

Detector:

Model Spectra 100, Spectra-Physics,UVN IS

Parameters:
Flow Rate:

1.0 mUmin

Injection Vol: 20 µL
Temperature: Ambient
Detector:

A.max 237 run, 0.01 AUFS
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Solutions:
Mobile Phase:
In a suitable flask combine 200 mL ofacetonitrile, 300 mL of methanol and 500 mL of
distilled water. Mix well and degas under vacuum for l 0 minutes. Filter through a 0.5 µ
Millipore filter, or equivalent, before use.

3.

REPRESENTATIVE CHROMATOGRAMS:

Figures l through 3 are the chromatograms of nifedipine samples after injection. Figures
4 and 5 are the chromatograms ofnifedipine: pluronic® F-68 solid dispersion (l:l)
samples after injection.

4.

LINEARITY:

The linearity of nifedipine in the mobile phase was determined by simple linear
regression. Figure 6 depicts the standard curve and linear regression of nifedipine in
mobile phase.

The following concentrations were used for linearity determinations.

Solution#

Concentration in mobile phase (µg /mL)
1.0012

2

5.0024
10.0800

4

100.7600
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Correlation coefficient for linearity determinations in mobile phase was 1.0000.

5.

PRECISION:

Assay precision was determined by plotting the peak areas of triplicate injections of
nifedipine samples of known concentration against the standard curves generated in the
previous section. The mean % difference between the actual concentration of the
samples and that determined by the standard curve were below 4.0 %.
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Appendix 2

Particle size determination of nifedipine samples before and after rnicronization and after
formation of solid dispersions with pluronic® F-68 .
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Particle size distribution of unmicronized nifedipine
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Particle size distribution of once micronized nifedipine .
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Particle size distribution of twice micronized nifedipine
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Particle size distribution of nifedipine:pluronic® F-68 solid dispersion (1:1).
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Particle size distribution of nifedipine:pluronic® F-68 solid dispersion (I :0.5).
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Appendix 3a

Determination of porosity parameters by mercury intrusion porosimetry. Pellets
formulated with different drug (D 4 Leukotriene antagonist) loads and spheronized at
different times.
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Drug Load: 0 % w/w, Spheronization Time: 2.0 minutes. Run # l

POUSlZU 9320 ¥2 .07
166

SA,.,LE OUECTOltY/Hl.lft8Elt: OUA1

OPERATOR: l(eun ll<et\U

OJ:43:"3 02t2St97
HP 04 ;54;.}4 02/25/"7
UI" 04 :54: 34 02125197

SA.lll"LE 10: 'l•c:rbo2-Z• in11Ufill1
SU8"lnElt : (ctan ,._.,u

PEHET"°"ETU Hl.mafll : 13-Q241
PEHETltOflETU CtlHSTAHT :

AOVAHCIHG CONTACT AHG LE: 130 .0 deog

10. '1'9 11L/pF

UCEl>ING COHTACT AHGLE :

1'0 . 0 Hg

PEHETKlflETU llEIGl-IT :

68 . 9270 g

MEll:CUIY SUll:fACE TEHSIOH: 4aS .O dyn/u

STE" VOLIAIE:

0 . 4120 Ill

PIEllCUllTOVISITY :
SAllPLE \/EIGHT :

13 . S]JSg! -..
0 . 4022 g
SAllPLE•f'EH->Hg WEIGHT : 110.8710 g

IU.Ufl.#I HOO PllESSUllE: 4 . UQJ pt;

PEHETIKlflETU VOLUf!E:

3. 541.) Ill

LOii PllESSUU :
llOCUllYFILLlMGPltESSUltE:

0.1'il03ptit

LAST LOii l"ltESSUlE '°INT ; 2S.5791 pti•

HIGH PA.ESSUllE :
ltlJf4 TYPE:

AUTOMTIC

l\JN .llETHOO :

E<IJJLISAATU
10 tec:ondt

EClJILlBRATIOH TUIE:

lHTIUSIOfil OATA SUNU.ltY
TOTAL lHTltUSlON VOLUl'IE •

TOTAL l'Ofl:E HU. •

llEOIA/ol PORE OtAltETEll CVOUJlllE>
llEOlAM P<llE OIAl'IETElt CAllE.O
AYEAAGE l'OftE OIAllETU ( 4Y/A)
euuc :IENS lT'Y
A,,AltEHT CSKf LETAU 0£NSITI
l'OltOSlTY

•
•
•
•
•
•

ST£11 YOllllk USED •
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0 . 4'09 ..._/g

36.076 sq-•/g
0.0469 11•
0 . 0353 JI•

0 . 0444 11•
O.Mn g/llt.

1.2828 g/llt.
33 . 96 X
39 X

Drug Load: 0 % w/w. Spheronization Time: 2.0 minutes. Run # 2

SAIU'U 011ECT04tYll«JMSEI : OATA1

/67

06:15:38 02t ZS t97
HP 07:1 8 : 23 02 / ZS/97
llEI'' 2J :07: 41 02flS / 97

SU81'UTTER : ic:u .... 11..+ou

PEHETllOMETER NIJNIER: 1l-0Ma

AO\IAHCIHG CONTACT AHGLE :

no.a

PEH£TllOltETElt tottSTAllT :

llECEDU«f COIHACT AllGLE :

130.0 d.g

10 . 79 JIL/pf
68.4592 'ii

llEltCUllY SUltfACE TEHSJaot: 43S . 0

STEii YOLLl'IE :

0 . 4120 .._

llUCUllY OEl!stn :

PEHETllOltETU 'IOLLl'IE :

o.~g

SMl'LE lllEIGHT :

IU.lllU!HEAO,.ESSUllE: 4.6llOOpti

] . 6991 ml.

LOUPHSSUlE :
llERCUll:l' FILLJHG PltUSUllE :

1 . 0065 pti•

LASTLOllPllESSURE l'OIHT : 25.5541 p1h
HIGH PllESSUllE :

ltlJM TYPE :

10 neond•

lllTkUSION OATA 5'.ft\AllT

TOTAL INTlllJUOM YOlUflf •

TOTAL 'OlllE AlltEA •

0.]944 111.. / g

15 . 541 1q-•/ g

llEOUH l'O«E 01.&JIETEI (VOUME) •

0 . 0463 ll•

llEOUJI '°4tE OIAllETU (.U EA) •

o . ~o ~·

AVERAGE P'O«E OUJIETU

u.v/.O •

O.Q4.l.O JI•

8ULK 091S1TY •

0.6633 g / 91..

A,,.U:atT CSKELETAU OEMSlTY •

1.3099 g/-..

l'OltOSlTY •

}4 . 04 I

STEllYOUJHC:USED•

]91
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d9g

ctynl'•
1l . SllS g / .i..

l'EHETltOPIETElt WEIGHT :

(

Drug Load: 0 % w/w, Spheronization Time: 2.0 minutes. Run # 3

'Oll:ESIZER 9J20 Y2 .07

Of'UATOll :

'AGE

1

L' 06 : JS: la (1/.JlS /91
21 : 49 · 16 02 / 2S t 9?
ll:E' 23 : 49 : 17 02/25197

(etanll~U

AOYAHClHG COHTACT IJllGU : 130 . 0 d.g

'ENET!tOflHU COHST,Ullf :

'EHETltOftETU \lflGK T:
STEJll YOlUltE:
IU.XI~ HEAD 'RESSURE :
'EHETltOltETU V'OLUllE ;

10 . 7'9 11Llp'
69 . ooes 'ii
0.4120 Ill
4 . 6PJOJ psi
J.5541 -'..

1l0 . 0 "9
l\UCUlY SUUACf tatSl(lll : 48S . O dyn/c •
"UCUIT OOSlTI':
13 . SllS g/lll
S.ull'U WEIGHT :
O. l.0059
ltECEOlltG COHT.lCT ANGLE :

LCW PlUSUllllE :

l\UCUll T FILLIHG PIESSlHtE :

1.CJJ6S ps i •

UST LOW 'RESSUllE POINT : 25 . 5541 psh
HIGH "tUStJRE;
l\JlllfYPE :

AUTOMTI C

lt\M HETHOO :

EQUlLIPATEO

EQIJJll8RA TION TUtE :

10 HCondS

l NTR\JSION DATA SlM,U:Y

TOTAL lNTltUSIOH 't'OLIJ'IE •

TO UL l'OllE AAl.l •
llEDIAH JIOllE 01.IJIETU (VOl...U'IEJ •

0 . 3970 lll/ g

15.552 sq- • / 9
0.0461 , .

llEOIAH JIOllE Ol METU ( A':EA) •

0.0359 11•

.lYEllAGE l'OllE OIMETU ( 4Y/ U •

0 . 0447 ••

9U1..K DENSITY•
A,,ARENTCSltELETAL)OEHSJTY•
P'OftOSITY •
STDlvot..llf!fUSfD•

181

0 . 4574 9 / .C.
1 . 2'991Sg / 9L
}4 . 04 X
l9X

Drug Load: 0 % w/w. Spheronization Time: 10.0 minutes. Run # I

l'OoltfSIUJI 9l20 V2.a7

SAl.,LE OtUCTOlY/111.NEl : O-.TA1

/ 69

04 :05 : 15 02. /26/97

O'EU.TC>tt : l(•t¥tllM'IU

04 :43 : 20 02/ 26/"7

SAlll>Lf ID : ' l • t ir0ol•10. inlt\Mfi

Hf'

su•H TTU :

lEI' 04 : 43 : 21 02./ 26197

IC•ten l'lhtl

ADVMClNG a:iMTACT A*ilE : 130 .0
t>EMETllOl'tETU COHSTAHT : 10 . 7"9 "VpF
l'EMETAOl'ETU llUGHT:
68 . 0ISl.4 g
STEN VOLL.ltf :
0 . 4120 ._

0 ."116 g

IWllllUfll HEAD l'ltfSSUJIE : 4 .6800 p~li

l'ENIETllOMTU V'OUl'IE :

Wl~+l'Elttff;

3 . S&aS ..._

llt:IGHT : 111.'664 g

lOlll'lfSSUltE :
ltUCUlT 'ILll Ml l'JIUSOU: :
p•i•
U.ST LOW l'JIESSUJIE l'OINT: 25 . 5592 pa 1•

o.nn

Hl~l'ltESSUlE:

ltJN TYPE :
ti.Ill llETHOO :

EGUlllll.ATEO

ECIUILlBUTIOfl TlllE :

ff9

UCHlNG C091T.lCT .u.Gl.E : 130 .0 6M;I
llUOJIY SIJl:fACE TOtSIOlil : '8S . 0 ~ l e.
l'IHOJJIY ODSITY ;
1] . 5335 g } ._

10

•«One!'

IHTll\ISIOlllOATA~Y

TOTAL lln!tuSIOIC 'IOt...UlllE •
TOTAL l'Oll:E .UfA •

l'lf0 1AH l'Oll:E OINtEiEl ( \IOl.1.ltf ) •
llEOINt POllE OlN1£TU (.UEA) •
AVERAGE l'Oll:E 01.&llETU C4V/.l) •

!t.'LC eEMs : - .
ArP.t.llEIO' CSJCfLETAL) OVtSlTY •

0 . 382S 9l./ g
40. 193 .q-./ 9

O. CJ37a ,.
0 . 0114 , .
0 . 031'1 , .

C. 7Tl3
1 . SSOS

,1....

gt-.

~lfY.

l7.Zl x

STDt YOLUf'IE USEO •

37 X
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Drug Load: 0 % wlw. Spheronization Time: I 0.0 minutes. Run # 2

1'0llESIZU 9320 V2 . 07
f10

S.U.,LE Ol JIECTOllY/ NUMU : OATA1

°' :OS : 1S 02/26/97
06 : 19 : 40 02126/"7

Of'UATOfl : !CetM .... t8

I.I

SAlll'U: IO : Pl1ceOol-10.1nltUHl2

"'

SUM1nu : Ket., II.tit•

lf, 06 :19 : 41 02f26/97

l'EHETllO'ETU lilJfllU :

1]~41

l'atETltOf!ETU CONSTANT :

AOVAHCUG CONTACT AHGU: : U0 . 0

10 - ~

11L/pf

l'EHETll°'£TU VUGHT :

61 . 3061 i
0 . 4120 ....
IUJWUI KUO ,.USlJ•E : 4 . 6eCO p.. i
mitETllOl'IETU VOUJNE :
l . 544.J .i.

LOW l'lUSU•E :
llUC\lltY '1LL1Nli ,.UsutE :

UCUUG ct:IMTACT N«iU :

1Xl . 0

llUCUIY SUltFACE TalSlCN ; 41S . 0

11 . SJJS;l lll..
0 . 4C26 i

"UCUAY DENSITY :

S""'U VUGHT:

O. TTT2 p.s i 1

LAST LOW l'IUSUllE l'OIHT : ZS . 5592 p1 l 1

HIGH l'ltESSUllE:
JIUM TYPE :
Ill.I' llETHOO :
E<IUllllSAATJOH flllE:

fQlllLISAATEO

lHTltUSIOfll o.t.TA Sl..MAIT

TOTAL lllTtlJSION YOlUME •

TOTAL.

~E

U:EA •

0 . ]791

-. Jg

]9 . 202 tq ..... / g

AEOIAll l'Olf 01.METEll (YOl..t.IW:) •

0 . 0390 ~

M:DlAH '°4tE OlMETtl ( U:EO •

O.Cll17 11•

AVUMiE l"OltE OWtfT'U (4Y/ .O
II.A.JC OEMSlTY
A,,,U:EHT CSIC..ELETAL) OEHSlTY
il'OltOSlTY

•
•
•
•

STV!'IOU.M(USEO•
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~

cieoa
~/ ca

0 . 0387 ,_
0 . !5l.O g/ lt.
1.2~1 ; l .i..
12 . ]7 1
37%

Drug Load: 0 % w/ w, Spheronization Time: 10.0 minutes. Run # 3

l'OllESUEll 9320 \12 .07

171

SAPIPlE OIRECTORY / IUl8Ell: : OAU1
Of'UATOll : l:<ltan Kef'IU

SAllP LE 10 ; 'l • cetlo2• 10.inNlt.l

llt" 01 : 11 : "6 03 / 03 / 97

PVtETlel!ETIEll Hl.l'IBEll : 1]-Q'l]l

PEM£Tltclf!ETH COHSTAl4T :

00:3] ;56 03 103 197
01 : 11 ;4S 03103/97

HI'

SUBIH nEll: : ICU..., f'letit•

AOVAflC I HG CONTACT ANCM.E : 130 . 0 d..:;i

10. 7'9 Ill/ pf

ltECHING CtWTACT ANGLE :

1l0 . 0

~

POIETllOMTEI VflGHT :

67.llOTl g

llEICUIY SUUACE TEHSlOH : '8S . O rl'{n / eia

stEfl YOLUPIE :

0 . 4120 .._

"UCUl:Y OEMSlTY :

s..utPLf VElGHT :
0 . "IXl'S 'ii
SAltl'U .. PEH+Hg VfJGHT: 111 . 131] 'ii

ltAXI ..... HU.0 PllESSUltE : 4 . 6ll00 p1i
PEMETl!Of!fTU V'OLUPIE :

1l . 533S 'il l .._

] . Saas....

LOllPlESSUU :
llUC\Jlt'I' '1LLIHG Pll:ESSUltf. :
LAST LOii Pll:ESSUlllE

'°un:

HIGH PltESSUllE :
IMITYl'E ;
1M1 llETl«>O :

0 . 76'0 p1 1•
ZS . 6757 p1il

AUTOM.TtC
EQIJlll81lATEO

EQIHL181lAf10N TlllE :

10 HeondS

TOTAL IHTIUSION VOLLME •

TOTAL

~E

A.llEA •

0 . 3643 -.Jg

C.0. 1M sq-•/ g

1tEOUJ1 l'OlE OIAllETD '. YOlUPtEl •

0.034S ..-

PIEOIAll' l'OlE 01.u!ETUI (AlfA) •

o.m11 JI•

AVE!lAGE JIOlllE OloU1£TU C4V/A) •

0. ~

JI•

llllU: OVtSITY •

0 . 9608 g/ tlt..

A,,.U:EltT CSICEU:TAL ) 0£JfSITY •

1.5Zl1 9 / 91.

'°"°SITY •
STEll't'Olt.1"EUSED•
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36 . 92 X
] 7X

Drug Load: 0 % w/w, Spheronization Time: 20.0 minutes. Run # I

POllESllElt 9320 V2 . 07

m

SAllPLE OillECTOllY/Hlltl8ER : 0ATA1

LP
HP

00 :.33 : 56 Ol/0]/97
03 :01:05 03 103197

llEP 03 :01 :06

PENETROl'IETU ldleU: 13--0968
l'ENET9ClfllETH COHSTAHT;

l'fHETROfllETU WEIGHT :

10 . 79 ,wL/pf

AO'OJtCING CONTACT Al'IGL £:

no.a det01

ll:ECEOING COHTACT u.GU :

130 . 0 d~

llEICUltY SUUACE TENSlOH : 4&S . 0 dyn / c•

68 . 9255 ;

STEii VOLUllE:
0.4120 Iii.
IUilllUfl HE.AO PUSSUll:E : 4. 6800 p1i
l'EHETIKlllETElt YOU.HIE :

03103~7

~.699i "'-

llEICUAT DENSITY ;

13 . SllS 'il /.i,.

SAJl.,U WEIGHT :
0 . '-COJ 'ii
SAPIPLf•PEH++tg WEIGH T: 11l. 1216 11

LOW "l:ESSUllE :
11EllC1JllY flLllNG "l:fSSlJllE : 0.7640 pti•
LAST lOW PRESSURE '°INT : 25 . 6757 p1il
HIGK PRESSURE:
l\.IMTYl'E:

AUTOM.TJC

RUNllETM:>O:
ECUILJBAATIOH TUtf:

ECIUlLIBllATED

10 Heoncb

l NTl:USIOH OAT.I. SUPtltAllT
lHT~SlOH YCUJflf •
TOTAL POA" .OU•
llEOI>JI PORE OIMETEll (V'OLl.lflf) •

TOTAL

0.le04 llL / 9
39. 514 sq- • / 'il

0.03156 11•

llEOU.H l'OllE OIAl'IETU C.UEAI •

0.0315 11 •

AVERAGE il'ORE OlAflETU C4VfA) •

0.0385 11•

OfHSlTY"
A,,AREllT ( SK!LUAL) DOISITY •
9UlJ(

0.8640 'ill-*.
1 . 2!70 "1 191..

l'O!tOSITY •

32 . 157 1

STEPI YOLLME USED "

J7 1

18 5

Drug Load: 0 % w/w. Spheronization Time: 20.0 minutes. Run # 2

l'OllESIZU 9]20 V2 .07

PAlif:

Of'EU.Tott ; ltst.,, 11.nu
S·U"U JD : Pl•c~-2Q91nlt\JH2
sue1"1nu : 1teun "'"'u

05 : 00 : 46 Ol/OJ/91
MP 05 : 39 ; 49 Ol/OJ/91
llEP 05 : 39 :'9 Ol / Ql/97

PENEfltclftUElt IUllEI : 1].--005 4
PEHt:TllOflETElt COMSTAHT :

1

1n

$MPLE DlllECTOllY / HUftSU :

AD\llfllCIHCi COHTACT AllGU : 130. 0 d<f9

10 . '19 pL / p,

lfCED!MG COHTACT AllGU :

130. 0 " '

PVIETJIOftfTU WEIGHT :

68 . 5376 'ii

llUCUIT $UlfACE TUIS!OH : 48S . 0 tlyn/ c•

na.

o.n20 -..

11ucvn oatsin:

YOOJNE :

u .nu

91-..

O. t.aX> 'ii

P\AXUUI MUD PllESSUllE : 4 . 680:J p11

SA.llPLE VUGHT :

PfH£TllOflETU YOlt.l'IE :

SAAPLE•PEK+Hg \/EIGHT : 111 . 051] 'ii

l . SS41 111..

LOW "tESSUIE :
11.UCUltT FILllHG PllESSUltf :

0 . 7537 pti l

UST LOW PltESSUltf l'OlMT : 25 . S611 p•l 1
HIGM,.IESSUllE :

ltUHTY,E :

AUTOIU.TIC

ltUHllETltOO :
fQUILllllUTlOH Ttllf ;

10 nc:onds

l HTA USIOH OAU. SUMAll Y
TOTAL IM TlttJSIOH \'Oll.'IE •

TOTAi. ~E UL\ •
ltEDl.ul '<Mt£ 01.utETU CV'Ot..t.l'IE J •
MEDIA.II ~E OIMETElt CUU.l a
AV(lt,.U;f "<Ml:E OIMETElt C4V / A) •

0 . 3&]1 -.Jg
Q . 2'11 tq_.,/ g
O.OJ28 11•
0 . 0354,,.
0 . 0363 .W •

11UU: DEHSlT'T •

0 . 8654 ; I -..

-'"A.llVIT { SKfLETAL)OVISlT'T•

1.294.5;191..

." 'OllOSJT'T•

33.15%

STEii YOLIME USED •

37 X
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Drug Load: 0 % w / w, Spheronization Time: 20.0 minutes. Run # 3

POllESIZEll 9J20 V2 . 07

SAl'IPLE OlllfCTOll Y/N\R'IBElt ;

174
OS :00 : '6 0J /OJ ~7

OPERATOR : l(eun Pliri!U

LP

SA.. PLE 10 : Plu:d»Z-Z0.1nltUHll
SU91!lTTElt : Kt u n "etltl

HP 06 : 511 : 55 OJ /OJ /97
llEP 07 :06 : 47 Ol / Ol/97

PEllETROMETU HIJ"8U : 1J-Q241
PEHETllOf!ETU COflST.ulT :

AOYAJllCIHG COfilUCT ANGLE : 130 .0 deg

10.79 11L/ pf

no.ad~

u:cEOIHG COfilTACT NIGLE :

PEHETllOflETU WE!Gt4T :

68 . 6054 Q

ltEltCUll:T SUllH.CE TEHS!ON : 485 .0 dyl\/C •

STEii VOl..Ut!E:

0 . 4120 .._

"ERCUllY OEMSJTY:

13 . 5335 91-..

0 . 4012 9

llAllf'M'I HUD PllESSUllE : 4 . 680:) p1i

SJJll'LE llEll#IT ;

PEHETl!Of!ETER VOlUllE :

S.fJIPLE+Pfff+Kg llEJGHT : 110.7J14 9

l . 5443 ..._

LOV ntESSUltE :

ptfltCUllY FILLING PllESSUllE :

0.1'587 pti l

LAST LOV "l:ESSUllE l'OINT ; 2S . !611 p1i1

HIGH PRESSURE :

ltl#CTY,E :

AUTOMTIC

ll:UH llETltOO :

EQUILIMATEO

EQIJ1LJ8AAT10H TIME :

10 H«lt'ld l

lMTIWSlOH DATA SUNlAl'f
TOTAL lMTltUSlOH 't'Ol!Jf!E •
TOTAL l'ORE AREA •

0 . 3700 9'. /g
39.224 sq-1 /9

llEOUJt PORE OIA .. ETU (YOltnlf) •

0.0363 111

llED1J.M l'OtE DlAllETU (AltEAl •
AVEll:AGE l'OltE DI AllETD ~ 4V /I.).

0 . 0111 11•
o . 01n 11•

9UU DENSITY •
A,PAll:EHT <SKELETAL) DEJrlSln •
l'?"!OSITY •
STE!! VOl.UflE USED •
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0.8699 'iJI.,,_
1 . 2527 'iJ / el.

32. 19 t
J6 t

Drug Load: 5.0 % w/w, Spheronization Time: 2.0 minutes, Run# l

il'OREHZU 9120 Y2 .07

'AGE

5All,UOIRECTOll'f / ....aEll :

0'ERATOI : kct.,,
SA.11,LE 10 : 5X2-2• 1,.,llUH1
Sl.181UTTU ; tnan

05 ; "6 : '-0 11/19/96
H, 06 : ]7 : 45 11/19/96
ll:f, 06 : ]7; '6 11119196

,EllETllOflETU llUMEll: : 11-0131
'l:HETIOftlETU CONSTAllT :

'EHETllOftETU WEIGHT :

10 . M 11L/ pf

68. 659] g

0 . 4120 ...
IWllll.l'I HUD 'ltlESSUllE : 4 . 68CXI P•i

'fNETltCMETElt VOLUflE :

1

/ 1]

AOVAHClNG CONTACT AHGLf ; no.ode;
llE CEOIHG CONTACT .uc;U.: 130. 0 "°I
llEltCUllY SUltfACE TfHSiJM: "85 . 0 ctyn/n
llEllCUIY O(ltSlTY:
U.HJS 9 / ..._
S""'LE VUGHT :

0.'°27g

l . 6417 llL

LOlil,ll:ESSUll:f :

llEltCUtt'f Fili.ING ,IESSUllE :

0 . 57'M p1 h

UST LOW 'll:ESSURE il'OIHT: 26 . 0516 p1i •
HIGH PllESSIJllE :
ltuHfY,E :

AUTOfU.TlC

ltl.14 llETM:>O :

EQUILIPATU

EQUILUIAATIOlll TUIE :

1Q HCond l

INUIJ SIOH OAT.I. St.lllQlllUY
TOTAL lNTltUS!ON VOl\JllE •

TOTAL il'OltE AREA •

llED lAll l'OllE OUJtETU ( VQlt.llE) •

llEOIAH l'OllE OIAAETEll (.UE.O •
AVEIAGE il'Oll:E OIAllETEll '4V / 0

•

8UUC OEHSITY •
A,,AllVIT CSXELUALJ OE"SlTY •
JIOltOS1TY •
STEll'IOlUllEUSEO•

188

0 . t.236 llL /g

l9.a32 sq--..Jg

0 . 0491 If•

0 . 0412 If•
0.042S /19
0 . 8290 g/ llL
1.2777 g/"'35 . 12%

Drug Load : 5.0 % w/w, Spheronization Time : 2.0 minutes. Run# 2

POllESIZEll 9J20 '12 . 07
SAllPLE IHtECTOllYIHU"80: : OATA1
OPEil.i. TOR:

11!

.nu.

~et.,,

SAllPLEIO :

5%2-.Z 1 1n~

SU8" 1TTEll:

~•tllfl

05 : 46 : 40 11 /1 9 / 96
07 : 22 : ll 11 / 19 196
UP 07 : 22 : 24 11119 196

Nf'IU

PEl'IETltOl'IETU llUlftlEll: 13--0241

AOV.fJllCilllG CONTACT Al«>Lf : 130.0 d99

PENETAOf!ETEJI COHSTAHT:

68 .049] g

llECEOING CONTACT AllGLE : U0.0 dee;!
llERCUllY SUllFACE TOSIOM : 43S . 0 rtyrl / c1

0.4120 9l.

lllUCUllYOEHSITY :

PElllETIOftETEJI llEIGHT :

STEl'I VOLUPIE :

10. 79 flf-/pF

1l.5lJSg / .._

/Ulll'IUl'I HU.O PRUSUAE : 4 . 6800 pai

SMl'U I/EIGHT :

PEHETRMETU VOLUPIE :

SAlll'LE•l'EN+ttg llE1GHT ; 109.asoa

l .544J 91..

LOW PllESSUllE:

llUC\JJIY FtU.lNG "tUSUttE : 0.>188 ptia
LAST LOW PRESSUllE l'OIHT : 26 .0516 pail
HIGH PUSSUllE:

lttJNTYl'E:
EQLJILlUATEO

10

fQUlLISRATION Tll'IE:

HCondt

INTltUSlON DATA SUNUllY

TOTAL

IHT~SIOH

vot..lME •
TOTAL MflE .O:EA •

llEDIAH ~E 01.AJIETEI (vot..J,Mf) •

0. 4200 .Ug
40. Z91 ~·1/g
0.0491 tr•

llEDl.ul l'O«E OIAHETU (AIEA) •

0.0405 p

AVERAGE PORE OUllETEJI (4V/A) •

0.0417 11•

llUlJ( DENSITY•

0.82llO g/.t.

A,,AllEMT (SKfLfTAL) DEHSlTY •

1.269S g/ ._

l'OllOSITY •
STE" VOLl.IHE USED •

189

34.71 X

0 . 40'!8 g

g

Drug Load: 5.0 % w/w, Spheronization Time: 2.0 minutes, Run# 3

POAES U Elt 9]20 V2 .07
SAllPLEl)lltEC TOitT / ~Elt :

OAU.1

11 5

LP 06 :39 : 20 11 / 24196
HP 07 :ll : S1 11/24196
ltEP 07 : ZJ : S1 11124/%

OPElt.UOlt : kct.n .mu
SMPLElD : SI2• 1n2~

SU9fllTTElt : keun .mu

PEHETllOl'IETU 111,fllBElt : 1]-Q1J1

AOVAHCING COHTACT Al'IGU : U0 . 0 deg

PEHETllOflETU CONSTAf!IT : 10 . 7'9 JIL / pf
PEHETllOfl£TElt llElGHT :
68 . 70loS g

llEltCUAY SUUACE TEHSION : '4S . 0

UCEOIM& CONTACT AHl>LE:

130 .0

STEH YOluttE:
0 . 4120 Ill..
f'lAXUI._. HEAD l'ltESSIJllE : 4 . 6l!CO ps1

llERCUltYOEHSITY :

PEHETltef!ETU 't'OLUl'tE :

SAltl"U•PElf+Hg \/EIGHT : 1l1 . !J60

] . 5898 ._

SAltPlE WEIGHT :

LOU PllESSUllE :
llEllCUllT flll.lHG PltESSUllE :

0 . 71.91 pti •

LAST LOW PAESSUllE '°lllT : lS . 9651 P•l •
HIGH PltESSUltE:
lt\.lllTYPE :

.WTOtA.TIC

-'UN llETHOO :
£QUILI81lATIOH TillE :

ECllILlBlATEO
10 s..:onds

TOTAL lHU\JS l ON VOLIJflE •

TOTAL l'OllE AREA•

0. 4209 . ./g

'IJ . 245 1q-• /9

llEOIAH l'Oll.E 01.METEll: (VOUIPIE> •

0 . 0490 11•

llEOIJJI "1lltE OUJIETElt OREA) •

0 . 0412 11•

AVERAGE l"Otlf OIAltETU (4V / A) •

0.0418 11•

81JLX DVISITY •
Al'PAJ:EMT t S.:ELETAU :~MSITY •
f'()l:l()SlTY •

190

0 . 9J12 g / .C..
1.5312 g / .C..
39 . 19 X

d~
~le.•

1l . Sl1Sg/M.
0.4.QD g

g

Drug Load: 5.0 % w/ w. Spheronization Time: 10.0 minutes. Run# I

l'OllUilER 9120 Y1 . 07
SNl,LE

OllECTOllY /~llU :

0'fllATOll ; li::U9n
SM, L E

lO :

Oo\TA1

/16

...nu

06 : 39 : 20 11 / 24 / 96

~

H'

oe:oe:os

11124/<16

u, oe :oe :os 11n41'J6

SU8111tnu : k•ten ""u

AOVAllCING tc»ITACT .tJllGLE : 130 . 0 deQ

'EHETltOf!ETU COHSTAHT : 10. 79 Jrl/pF
'UfETltOl'IETU \/EIGHT :
61 . 0909 'ii
0 . 4120 ....
JU.II"°" HE.lO ,llUSUU : 4 . 68CD ps i
'EHET!tOftETEll YOLLME :
l . S'69 ._

llECEDUG COMTACT AHGLE :

130 .0 deg

l'IUClll:Y SUttfACE TUISIOH : '-'S . 0 ft'(n/ca
ltUCUltY DE!ilSlTY :

UIU'LE VUGHT :

1] . S]lS 'iJ / 91.

0 . t.016 g

SNll'l..E•'(IM4ig Vt:lGHT : 110 . 0900 !I

LOW "llfSSUU :

llUCUIY flll..lNG 'llESSUU : 0 . 72"17 p•l 1
UST LOW 'll:ESSUU '°!HT : 2S . 9681 J"lll

HIGH "tESSUU :

AUTO•tt.TIC
lt\Jtj

EQUI LlUATIED

ltfn«>O :

EQUlLJl!IAATIOH TlllE ;

10 seconds

UITltUSIOH OATA Sl.ll'UJtT

TOTAL lHUUS IOM \IOLUPIE •

TOTAL l'OllE AllEA.
llEDlAH l'ORE 01.utfTU tYOlUllt:l •

.llEDIAH l'Ollf DUll.ETU tAAEAl •
AVEll.AGE P'OlllE OIAllHU (4V/A) •

0 . 1955 9l../ 'i1

41 . 5n sq-af 9
0 . 0420 JI•
0 . 0354 111
O. OleO " '

euur; r.aistrY •

o.asos ; t .._

APPAIEHT ( SKELETAL) Da4S1TY •

1 . 2SZ1 g / 11111..

'°"°'lTY •

JJ . 64 J:

STUI YOll.lllE USEO •

)9 X

19 1

Drug Load: 5.0 % w / w, Spheronization Time: 10.0 minutes, Run # 2

l'OflESIZEI 9]20 '+'2 . 07
SAll,Lf OllUCTOtllT/HU!t8Elt : OATA1

117

OPUATOll : ht.n eeftu
S.utPU: ID: 5110.in2..itUH2
St.181!1TTEll:: tct., .tit•

LP
Kf'

PEHET.aPIETElt .-..aEll: 13--01]1
PElllETllOflETElt CONSTMIT ;
PCHETIONETU WEIGHT :

10: 47 : 16 11/24196
11 : 17 : 03 11/24/1J6

1.0 11 : ]7 : 0.C. 11 / 24 / 96

10 . 7'9 JfL/ pf
68 . 4074 g

Of9

l.fUOING COMTA CT AHGLE :

d°'9

130 . 0

llEllC\JllY DE,.SITY :
1l . Sl1S gl-..
SMl'LE llUCiHT :
0 . 4026 g
SAll.JllLE•,EN+Hg llE!GHT : 111 . 5960 g

0 . 4120 Ill.
STOI vot..l.11£ :
llA.ll"""' HEAD PIUSSUllE : 4 . 6800 p1i
PEHETllOIETU YOU.Ill( :
l .SMS ._

LOWPll:USUttE :
llUCUllY '1LltHG PllESSUltE :

AOYAHCJNG CONTACT .u<iLE : 130 . 0

llUCUIY SUUACE TUISIOM : 41S.0 dyn /c •

0 . 107l p1i •

LAST LOW PIESSUllE 1'0UH : 2S . aJJ7 P•• •

HJGHnusuu :
..._..TnE :

.tUTOflATIC

at.JNllETI«>O :
EQIJILIU.UION flllE :

EQUlllUATU

10 Heonch

umtuslOH DATA stNARY
TOTAL lHTRUStOM vot..~E •
TOTAL POll:E AllE.l •

llEDIAH l'OlE 01.utETU (vot..Ul'IEl •
llEOUH roll£ OIAltfTU ( AJIE.O

0. '°"1 114. / g
4] . 5]1 tq-• / g
0 . 0l99 11•

•

0 . 0351 11•

AVfUGE l'Oflf 01.utETU ( 4V / A) •

0 . 0311 11•

euu::

:IEHSlTY •
A,,.O:EJIT (5'i:ELfTAL) OE"SITY •
'OllOSITY •

ST"EJll'tOLUftcUSEO•

191

0 . 94]9 g / .i..
1 . 5259 g/ ml.
J.8 .15 1
]9t

Drug Load: 5.0 % w/ w, Spheronization Time: 10.0 minutes. Run # 3

S.l.1t,1.EOlllHTOAY/11Ult8Ell: O.l.TA1

115

O,UATOll : 'teten ..nu

10 :47: 16 11 124/ 96
12 : Z2 : 24 11 / 24 /96

SAlll"LE 10 :

5%1 0. 1~ .-AlMJ

HI"

SU~lTTU ;

'tu.,,

ltEl' 12: 22 : 2StlJ2t.~

~u

l"EHETlla.IHU f11Uf18Ell : 13--0241
1"£14ETllOftETElt CC»ISU.HT :

AOYAHCl!«i COHUCT ANGLE ; 130 . 0 de-;

10 . 79 11L / pf

.aaso

g
0.4120 ...
.UXIMUfl HUD l"llESSUllE : 4 . 68CXJ pt i
l .5"69 Iii.
l"E'IETllOftt:TU YOlUl'lE :
l"ENETll'OllETU llEIC>HT :

67

lf:CEOING CONTACT .t.HGL.f :

110 .0

ltEICUU DEHSITY:
SMl'LE WEIGHT :
SM~E+l"Ot+ttg

1l . Sl1S9/ "'0 .4.0'IO g

WEIGHT: 109 . 5288 g

LO!il"llESSUIU :

ltUCVI Y fllllMG l"USSUU :

d~

llEltCUllY SUUACE TEHSIOH : '85 . 0 dyt1 /c •

0 . 7'07) p•il

LAST LOW l"llESSUll:E l'OINT : 25 . &3]7 p$il

H!Gli "llUSUIU ;

"""'TYPE :

AUT°"4TIC

atJN llETMOO :

EQUIUIPATUI

EQUILIBUTIOI( THIE :

UfTltUSIOH DUA Sl.RtU:Y

TOTAL lHTNSIOH VOU.11tE •

TOTAL l'Ol\E .UU •
1muu l'OttE 01.utEl'Elt 1YOU1tU •
ltU lJJi 'OJIE OIA.llETU (AlllfA) •
AVERAGE '°41£ OIA.lt£TU (4V/U •

i!llJlX OEHSITY •
A,,.l.ltfHT ( Sl((L.fTAll OOIStTY •
'°"°StTY •
STEMVOUlltlEUSIEO•

193

0 . 3973 91../g

42 . 097 ~-1 /g
0 .°'°6 . .
0 . 0353 ,,_
0 . 0378 lfS

0 .8410 g/ m_
1 . 2630 <; / ._
33 . 41 :Z:
39X

Drug Load: 5.0 % w/w. Spheronization Time: 20.0 minutes. Run# l

l'Oll:ESIZU 9120 '12 . 07
SAAl'LE OltECTOtlY/HUfeU : 0AU1

l>'UATOI : l(n .... Menu

03 : S2 :07 11125 196

SJJlll'LE 10 : SX20llin2-'Mf1

04 : 19 :15 11125196

SU9ftlfTU: l(nan II.nu

eu :

l'ENETlllOftETU .....

AOV.lltCING CQNU.CT AHGLE : 130 . 0 ~

13-01]1

PENETllOftETU COHSTAltT :

l'EtlETltOIUTt:Jt llflGHT :
STEii 'IOLLltE :

ltfl' ()t. ; ]9; S6 11/25196

10 . 7'9 11L / pf

RECEDING CONTACT .tHGLf :

130.0 89

llUCUlY SIJUACE t£NS!OH : '85 . 0 ctyn/a

67 . 906l 11
0 . ,12'0 .._

llUCUlY ODISlTY :

1l.S364 g / 111..

llAXUllf'I 11EAO l'ltfSSUll:E : 4 . 6a00 p 1 1

SA.l'll'LE \/EIGHT :

l'EHfTIKlltETU YOt..LltE :

SAIUl'LE•l'Elt+Hg WEIGHT : 111 . 2415 g

l . 5885 ._

LOii l'USSUIE :
llUCUltY '1LLING ,IUSSUl.E :

0.4007 II

0.7293 p1i a

L.ASTlOlill'ltESSUltE P'OINT : 26 . 10'l4p1h

HIGH l'll:ESSUtE :
llUNT'Yl'E :
l(llfl

AUTOfU.TIC

EQIJIL18AATED

llEntoO:

EQIJlll81U TIOH TillE :

IHTllUSl<»I OATA SUVUU

TOTAL IJHftUSIOI' V'OLU..E •
TOTAL POii~ UEA •

llEOl.IJI P'O':E OUJtETU (\'ClLltE ) •

0 . 3&60 91. /g
19 . 525 tq- • /g
0.0419 JI•

llEOIAH l'OllE OI NIETEll UIE.l) •

O.OJ61, Jr•

AVUACiE l'OllE OI AllETEll (4V/A) •

0.0391 11•

llUU: OUISITY •

0.9616 9 /9'.

A,,AUIH (SUUTAU DEMSIT'Y •

1 . S290 9/ lll

l'OROSIT'Y •

]7 . 11 %

STEii YOLUl'IE USED •

)& %

194

Drug Load: 5.0 % wlw. Spheronization Time: 20.0 minutes. Run# 2

l>ORESIHI 9120 '12 . 07

SAll.PLE D11ECTOIY/HU"8U : OATA1
OfiEHTOll : (IUn "ef'lta
St2()91n2..itl.IN2
SlJ81HTTU : (eten "9hta

120
0] : S2 : 07 1112'/96
HP 05 : 11 : 2] 11 125 196
UP 05 : 31 : 24 11/25/96

AOV~lHCii

PEHUltOftfTU NUl't&U : ll . 0241

JllEH£TaotlETU CONSTANT ;

10. 19 A.Jpl

CCMTACT 4"GL£ : 1]0. 0 d199

•EcEDUG CONTACT Al'IGLE :

110 .0

ff9

PENETllOl'IETU llElGHT ;
64 . 3124 ;
STEii YOl.UflE :
0.4120 IL
ft.lllPIUfl HEAO PllESSUIU: : 4 . 6900 p•i

llUCUIY SURFACE TEllSlOfll : 1.35 .0 clyn /ca
ltUCVIT OEMSlT'I' :
1l . S]64 9 / .C..
S-"'L'U llUGHT :
0 . 4011 9

'EMETJl'Of!fT£JI YOlUllE :

SAllPU•P~

l . S44l ml.

11EIQ1T : 110 . 3415 9

Lo.IPltESSIJllE :

. llUCUltY HLLIHG PllESstHtf :

0 . 7293 p1 i 1

UST LOW PIESSUllE f"OINT : 26.1014 p1 i 1

HIGH PllESSUU :

WM TYPE:

AUTOMTIC

ltUM ltfll«>O :

EQUillPATEO

ECllJILIBMTlOH TtME :

10 second s

urntuSlOfll DAU Sl..R'IAAT

TOTAL lHTltuUOfll '/Cl.I.'!£ •
TOTAL POiit£ AIEA •

O. JaS2 .U;
]9 . 498 1q-. / 9

llEDU.M l"Oltf DlAltETH (VOUMU •

0 . 0438 • •

l'IEOIAH P'Ollf 01 .....mlt UREA) •

O. Ol6J • •

AVEIUGE l'Olf OIME'TEI (4V/Al •
11M..K OEHSITY •

0 . 0390 • •

Al'PAAfl(T CSKELETAll OEMSlTT •

0.8552 g f9L
1. 27S2 g/ 9L

l'OltOStT'f•

12:.9"%

STU VOUll'IE USEO •

14:

195

Drug Load: 5.0 % wlw. Spheronization Time: 20.0 minutes, Run# 3

'<lllESIZEll 932() V2 . 07
SAll,LE OUECTOA1'/NUfl8HI : OAT.1.1

121

MEllATOll : Kn .... 11.nu
$AllPU ID : $120io1"'2~
SUMt n u : l(eUn ~u

LP 09 : 18 : 22 11/25/96
"' 11 : 12 : l3 11/l5/96
U:P 11 : 12 : 14 11/25196

PEJrlETllOl!ETU Hl.llfJEll : U-0241
PV•ETAOflETU COHSTAHT :

AOVAHCU«i COHTACT AllGU : 130. 0 cl..;

10. 79 111../ pf
68 . 1909 g

PEHETltOftfTU llUGHT :

STVI 'IOluPIE :
0 . 4120 111..
MXIM.111 HUD PllESSIJllE : 4 . 6800 psi

J . S44J .._

PEllETROllETU YOLLl'IE :

IECEDIHli COHTACT N«>Lf:

ll . $:!64 9/"'0 . '-008 g
SAlll'LE+PfH+Mg \IEIGHT : 110. 0498 g

"UCUllT OENSlTY :
SMPU \/EIGHT :

LOW PllUSIJllE :
llEJICUltY Fii.UNG ,.ESSURE :

0 . 744] psia

LAST lOlil PltESSUl.E l'OINT : 26 . 0912 ps i a

HlGH "'ESSUU :
AUHTYl'E ;

AUTOftATlC

lttMltEtltOO :

ECIU1Ll8lAT10H Tll•E:

10 HC:ondt

,.. -,,.·
TOTAL IHTlt\JSIOH VOll.ME •
TOTAL l'Ol:E AltU •

"EDIAH POllE OlAllETElt (VOU.lltU •
llEDU.11 il'OflE OIAllETU CHEA) •

AVERAGE

~E

130.0 Mg

llEJICUllY SUllFACE TEHSIOH : 48$ .0 lf'fn/ca

OVJIETEll (4'1/A) •
8UtJ( DENSITY •

A"UEHT CSKELHALl OOIStTY •

l'OAOSlT"r • ,
STEl!VOlUflEUno.

196

0.l862 .U9
39 . 090 ~- •/g

O. Ot.SO ,_
0.03n ir•
O.Ol9S 11•
0.43Z2 g/91.
1.2265 9 f 9l
32.14X

lat

Drug Load: 10.0 % w/w, Spheronization Time: 2.0 minutes. Run# I

'°"ESllU 9120 Vl . 01

122

S.utPLE OIRECTOlt'ffNUllllU : OATl1

v

08 : 111 : 22 11/25 / 96
HJll 11 : 59 : 57 1112S/96
IEP 11 : 59: $7 11/ZS / 96

OPERATOlt : IC•tan lletlta

SAHl"LE lO : 10X2• 1n2..-ut11

su&111nu : .:et enit.n t a

AD'IA14CUG CONTACT AllGlE :

PEltETIDIETElt CONSTAHT:

10.79 ~/pf

IEC£Ot"6 COIHACT Al«iLE :

no .a O<t9
no .a deo;i

PEMETIKll"IETU WEIGHT :

6& . 6221 g

lt(ltCUll:Y SOllUCE TEHSION : 485 .0 Oyn/c •

STEii 'IOLLlllE :

0.t.120 ._

"Ell:C\ll:Y OOSITY :

13.5:561. Q/91.

Mllf'\Ufl HUD 'llESSUllE: 4.6800 p• i

PEHET1t0f!ETU YOLUllE :

l.SMS tll

LOW f'llESSUllE :

ftUCUll:T '1U1HG PllUSUJI! :

0.7443 p1 ia

LAST LOii/ PltESSU•E l'OJMT : 26 . 0932 p1i a

HICOH PllUSUllE :
ltUN T'Y1E :

AUTOIU.TtC

EQIJILIPATED

ltUHl'IETl100 :
EQUlllllllUIOfll TUIE:

1Q HUJndl

TOTAL IHTllUSION 'tOU.lltf •
TOTAL~'!:

.t.ltU. •

0 . UOJ k /9

]7 . 712 ,q-a / g

llEDlAH l'OllE OIAllfTU (VOUMEl •

0 . 0609

ftEDIAM l'OllE OIME'TU ( AIEA l •
AVERAGE ~E OlMETU (4V/A) •
&UU: '""MSlTY •
APPARENT (SXELETAL) DENSITY •
l'OllOSITY •
ST£1t VOUJP1£ USED•

0.0412
0.°'61
0 . 9101
1.5184
40 .07

197

J•

¥"'

11•
g/ 111..
g/"'%

'3 I

Drug Load: 10.0 % w/w, Spheronization Time: 2.0 minutes, Run# 2

12~

SAl\PLE Ollll!CTOU/Nt,NU : OATA1

LP
HP

00 : 27 : 56 11/26/96
01 ; 11 ; 11 11/26 / 96
llEP 01 : 11 : 19 11126/96

Of'EIUTOll : ICetMA<ttlt•

SAl"lE 10 : 10%2•11'\2..it\MZ
SUMlrTH : ic.un "-"U

AO'OJllCllllG CONTACT AHGU :

P9'ETJIOf!ETll CONSTIMT :
PatETllOflETH \llEIGHf :

10.7' •L/pf
67.1749 II

STE" VOlt.N: :
0 . 4120 .._
IWlll'l.ll' HEAD PllESSUllE: 4. 61JOO p1 i
PENETJIOflETU YOlUltE :
J . WS ..._

130.0 dit;

.c.as .o rtyn/u

PIUCUllY DatSITY :

13 . S:s.M g / ._

LOW Pll:USUIE :
MllCUltY llUIJIG

.n:USUllE:

o .• ~10 p•i•

UST LOW Pl.ESSUU l'OIMT : 25.P19 p1 i 1
HIGH PHSSl.nl( :

llllltTYPE :
lllllt llEntOO :
EQIJlllWTtON TUIE :

no.a ff9

IECEOIHG CONTACT AHGU: :
llUCUllY SIJllfACE TENSION :

.WT°"""TIC

EQIJIL!Wf£0

10 utond•

lNTltUSlON OAU. Sl.IUU.IT

TOTl.L UITltUSlON VCllJf!E •
TOTAL l'OllE AllfA •
l'IEDlA.lt l'OlE DlA.ltETD ('tOl.J.ME) •

0 . "3SS

.Ug

]7 . 09e .,q-.i/ g
0 . 0606

.r•

llEOlAH l'OllE Ol.UETU CUU) •

0.0410 11•

AVEAAGE l'OllE 01.IJIUU (4V/0 •

0 . 0410 11•

91.JU:: DENSITY•
A,,UENT (SU:LETAl> DEJilSITY •
l'OltOS1TY •
STEii YOlllftE USED •

198

0 . 9Zl!
1. S456
t.Q.23
4.2

gt-..
g/ IM..
X
X

Drug Load: l 0.0 % w/w, Spheronization Time: 2.0 minutes, Run # 3

l'O•E SIZElt 93 20 V2.07

l' AGE

SMPLE OIREC TORY / HOPISEll : OAT.1.1

OfERATOf: : (etati l'lef'IU
SMPLE ID: 10X2• i "'2-lllJIO
Sl.IMITTU : K•t.tn l'lenu

U' 00 :27 : 56 11 /l6 / 96
01 : Sl : OIS 11/26196
REP 01 : 53 : 09 11/l6/ 96

l'ENETltOflETER Hl.'"8U : 13--0241

ADVAllCIHG CONTACT ANGLE : 130 . 0 d"9

'EllfUOflUU C°"STAIH :

ltECE OI HG CONTACT AHGLE :

l'EllETllOl'IETU WEIGHT:
STU! 'IOlUltE :

10, -,q 11L / pF

] . 5443

«.

LOW l'llESSUltE :

llEllCURY FIUU«i PRESSURE :

0 . 6510 ps i •

l.lST LOW l'llESStJllE '°Utf : lS . 8919 p11•
HIGH "lESSUllE :
WM TYi'£ :

AUTOMTIC

Rl#ll'IETl«)() :

EQUILIWTEO
10 tecond•

EQJIL I BIUTIOH TUtE :

130 . 0 deg

llUCUR'f' SURFACE TEHSIOH : '85 . 0 ctyn/ u
llUCUllY OEllSITY :
13 . 5364 !1 1._
S.tJIH.E llEICOHT :
0 . 4003 !1
S.tlll'LE•l'fH+Hg WEIGHT : 1l0 . 69S7 !1

6a . 9'17l !1
0 . 4120 «.

llAXlllJM HUD Pll:ESSURE : 4 . 6800 ps1

l'EMETROltETU YOllll'tE :

1

124

TOTAL l HTRIJSUlH

VOL~E

•

TOTAL l'ORE .UEA •

llEDIM l'OllE 01.utETU (VOUJPIEJ •
llEO I AH l'Oll:E OIAl'IETU ( .U:E.l) •
AVUAGE 1'011£ OlAJllETEll

1

4V/A) •

BUU: D£HSITY •
A,,ARElil T ( st.ElEUl) DEJISITY •
STEii YOl°"E USED •

199

0 . 4355

._,!I

37 . 260 .q-•/ g
0 . 0607 ll•

0.0409 ,,_
0 . 0468 _.

0 . 1211 ;/&
1.27&3 g / &

35 . 761
42: l

Drug Load: 10.0 % w/w. Spheronization Time: 10.0 minutes Run# l

}(;1£SllU 9320 Y2 .07
/~

SAllPlE OllE CTOllT/ NUflBU : OAfA1

LI' or. : S6 : 4l 11/26 196
HP OS : l9 : 1S 11/26/ 96
UP OS : l9 :15 11/26196

Of'EIUT041 : K1tt...,l'l«lt •

SAlt'U: lO : 10X10.i n2..mN1

SUM tn u : Ket.,, 11ct1u

•ovAMCIHG CONTACT AllGU : 1:50 . 0 d~

'f:tlETllOflETU HUftUlt : 1]-()'131
l'afETIOflfTEI CONSTAlllT ;

130. 0 ~

ltt:CfOlHG C.ONfACT AJtGU :

10 . 79 '1./pf

1'£HETllOf!ETU WE I GHT ;

67 . 9940 9

llUC\MT SUUACIE T£HSIOH : 485 .0

STVI VOLIME :

0 . 4120 ._

AEllCUAT 0£Hst1'Y:

0 . '°12 9
SNU"\.f+l'EH+Ho; \!EIGHT : 111.1876 g

SNll'U lfflCOHT :

AAJ:llU'I HEAO 'U:SSUU: : 4 . 6ll(X) p1.i
1'£HEU0fl(TU VOLLllE :

J.saas ....

LOIJl'llUSUllE:

llUCVJl:T 'lLllHG "IUSUIE : 0 . 7328 p1h1
LAST LOW nusuu '°'"T : 25 . 9104 p• i•
HlGH l'llESSUllE:

111.NfYl'E :

AUTC!ft'.TIC

ltlMllETl400 :

£CIUlLIBAATED

EQUlll8AATtON TUIE :

~/u

13 . 5364 g / lll.

10

•eccind•

lHTllUSlOH OAU. Sl.....U Y

TOTAL UCTllUSION VOlt.1"E •
TOTAL il'Oll:E .UE.l •

HEDI.AH l'Ollf OUJIETU (VOl.UfllE} •
l'IED IAM l'Oaf Ol.METU (.U:EAl •
AYfu.6£ l'Ol:E Ol.ulETU (4V/A) •

0.4189 llL./ 9
la . 994 sq- • / 9

llULK OfHSlTY •

0 . 0La4 /19
0 . 0428 jl •
0.000 11•
0 . 939'1 91-..

Arl'AltEHT ( SICELETAl) D£HStTY •

1 . 5.cal 9 / -..

rottOStTY •
ST£1'VOLI.llEUSEO•

100

39 . :n

t

Drug Load: 10.0 % w/w, Spheronization Time: 10.0 minutes. Run # 2

SA.ltPLE OIREC TORY / NUf!8E ll: 0AU1
O,UATOi!. : ICet.., "ttH•
10:10. t n2- lllJH2
SU8"1 TT Elt ; Keun ,.<ef'IU

l'Zl

04 : S6 : 4l 11/26/ 96
HP 06 :1 11 :09 11 / 26 / 96
REP 06 : 111 : 10 11/26 / 96

PEHETltOftETU HUMEll : 11-02.41

PEHETltOMETER COtlSTAHT :
PEHETltOllETU I/EIGHT :

AOVAHClNG COltU.CT AHGU : 130. 0 de<J

10 . 'T'i 11l/ pl

RECEDING COftT.l.CT AH:iLE ;

68 . nJO 9

STEJ'f YOt.\Jf!E :
0. 4120 .._
PLUHIUfl HEAD PRESSURE : 4.6l!QJ ps i
PEHETltOltETU 'IOlllf!E:
3. 544] • l

LOW PRESSURE :
ltEltCURY flLLING PRESSURE:

llERCUU OUIStTY:

1l . S164 g / lll
SA.ltl'LE VEIGHT :
0 . 4020 g
SA.ltl'lE•PE,..Hg WEIGHT : 110. 5390 g

0 . 1'1211 pa i •

LAST LOW Pll:ESSURE '°1111 : 25 . 9'104 p1 i •

HIGH PRESSURE :
lttMTYPE :

AUTO.U.T1C

ltUHllETl400 :

EQU I LIBUTED

10 ucooda

EOUILISAATlOH TlllE :

- ·'

130. 0 d"'J

llUC\lltY SURFACE TUISION : "35 . 0 lfyn/ e•

/
TOTAL IHUUSIOM YOl.Uf\E •

TOU.Ll'O«E.U:EA•
.llEDIAH POU 01.utETER ( VOUJf1E> •

llEOI.1.14 l'OllE OIA.ltETER ( Allf.O •
.1.VUAGE l"Oltf DIA.ltETElt ( t,V/ A) •

0 . 4185 .._/ g

l9 . 416s.q-• / g
O. Qt.Q 11 •

O. Ot.29

,1111

0.Ql.25 11 •

OEHSITY •

0 . !291 g / ml

.l"'UENT ( SKELETAL) OEMSlTY •

1.2697 g / .i.

!tJU(

l'O«OS l TY •

34 . 70 X

useo •

41 x

STEN vou mE

201

Drug Load: I 0.0 % wlw. Spheronization Time: I 0.0 minutes. Run # 3

SAllnE 011.ECTORY/MIJflBU; OAU.1

/27

MUATOll : tu .... ..tin
10X10.11'\2-.AUHJ
w&l'ltnu : 11;.can ect\U

03 :09 :15 12102 / 96
"' Ol : Sl : 27 12102/96
U, Ol : Sl :29 12102196

AOVAHClHG COtHA CT AHGLE : 130 .0 o~

'EMETllOflETU II.NU: 1]-Q241

PEHETllOftETU COHST.ulT :

10 . 79 ~Ip'

llECEOING CONTACT J.HGLf :

130 .0 deg

lllUC\llllY SURFACE TEJtSI°" : 485 .0

o.nzo-..

STEl'I VOUlllE :

llUClJll Y OEHSlT'I' :

it.ull'Mt HUD PltESSUU : 4 . 6800 pa i

'VIETltoi.ETU VOUllE :

SAll"-f llflGHT :

l . S4'J ._

LOW "tESSUll:E:
lllUCUllY FILllNG PllUSUltf : 0 . 6190 p1il
U.st LOW 'llESSUl.E P'OlHT : 25 . 907'9 ptl •
HIGH ,ltESSIJllE :
AUTOMTtC

11Ut1

EGUlllWTEO

,.ETMOO :

EQIJ1LIBUTIOt4 TllllE:

IHTlllJS10H DATA Sl.lf•.UY
TOTAL IH TlllJSlOM VOllll'E •

TOTALl'OllE AllE.l •

0.4170 lll /9

]9.SSl sq-•/9

lllEDl"'4 l'Olf DUJlfTU <VOUMEl •

0.048'1 , .

lllEOIAH ~E OIAl'ETU (.U O. l •

0.0422 .J•

AVEIUGE l'OllE 01.ulETU (4V/A)

11

llUUC DENSITY •
"''U.EMT (SICELETJ.L) OEHSlTY •

"°"°SITY •
STE" VOLIME USED 11

202

0 .042.2 JI•

0.IU69 9/111..
1.2SSS 9 / ._

Y..90 ::r;

rt>fn/c•

Drug Load: 10.0 % w/w, Spheronization Time: 20.0 minutes. Run# l

l'OUSIZU 9320 V2 . 07
128

SAMPLE 01UCTOllY/HU"8Ell : OATA 1

°'UATOI : ket.,, wf\U

03 :09 : 15 12/02/96
HP 04 : 41 : 16 12/02/ 96
IEP 04 : 41 : 17 12102/ 96

WPLE 10: 10U0.11'\2- llUN1

SUlll'l lTTEll: ketMI lleflU

PEHETllOflETEll Nll"8Ell : 1]-0131

AOVAllC l HG COHTACT AHGLE :

no.a

d ....

U CEO IHG CONTACT AHCiU :

130 . 0

d~

PfHETltOf!ETEll llUCOHT :

10. 7'9 •Llpl
6a . 6.ll8 g

ltEll CUAY SUlilfACE TOfSIOH: 48S . O

~le•

STEJll VOlt.l'IE :

0 . 4120 ._

ltEll CURT OVISlTY:

gt-.

PENETllOflfTU COHST.tHT :

ltAlllU'I lfEAO PIUSUl:E : 4 . 6800 p•1
PVIETltOPIETU 'IOl.Uf!E :
3 . 6417 111..

1l . S41l
0. ~

g
SAlll'lf•PE.N<-Hg llUGHT ; 111 . 8144 1J
SA.l'"LE WEIGHT :

LOW,1£S5Ull.E :

llEllCUllY '1U.JHG Pl:ESSUllE :

0 .6790 p1h
LAST LOW ntESSUllE 'OUIT : 2S . 9'1"'9 p1 i •

HJGH "ll:ESSUllE :
ll:IJHT'YPE :

AUTOflATt C

llUN llETMOO :

EQIJlLlllUTEO

fQIJILlllU.TlOH TIPIE :

10 uconcls

TOTAL IHTltUSlOH 'fOt..lME
TOTAL l'Oltf All:U
llEOtNI POfl:E OlAAETU ('IOl.Uftf)
llEOl.t.11 l'OllE OIAAETU CAllU )

•

0.4094 -.19

•

3a . 662 lq-•/g

•

•

0.°'41 JI•
0.0f.26 1•

AVEIUGE l'Oll:E 01.utETEl C4V / A) •

O.Ot.24 JI•

9JUC OEHSITY •
"'''4UMT CSX.ELETAl) Of:MSITY •
l'OlllOSlTY •

STEii VOUJfltE USEO •

203

0.&l'oO g/ ._
1.2664 g / 91..

34.14 l

4oO I

Drug Load: I 0.0 % w!w. Spheronization Time: 20.0 minutes. Run # 2

SJJll'U OIUCTO.Y/HLNER : OATA1

11.9

OPEIUTOll : k•Un ..nu
1CIX20iiin2.-tuie2
SUllllHTTU : ktt*"' eetita

06: ,9 :22 12/02/ 96
HI' 07: 35 : 4' 12/02/ 96
llEt 09 : 19 : 21 12102/ 96

l'EHETllCflfTH -....Ell : 13-0131

l'EHET.ctlETU CONSTAHT:

AOVAHCIHG CONTACT A.NGLE : 130 . 0 deg

lECUIMG CONTACT A.MGU: :

10 . 7'9 'LIP'

130 . 0 cM'Q

l'EHET~TU llEl!OMT ;

67 . 6SSO 9

lllEllC\JllY stJU.lCE TV4S1t.ft : 485 . 0 ~It•

STEii VOlt.llE :

0.4120 ._

llUC~Y
SM~

llAXI"'-'" HOO l'llUSUIE : 4.6800 pt, i
l'EHETllOflETU VOLIJllE ;
] . 6417 .._

OEHSIT'l :

13 . S41] 9 / .._

llElGHT:

0 . '°10 9

s..utl"l.f•l'V..+41; \IElGHT: 110 . &876 9

LOW l'ltUSIJIE :

llUCUll:Y 'ILL.ING l'ltESSIJllE :
l.AST LOW l'ltESSURE '°INT:

0 . ma pa l •
~ . 1911

paia

Hl!OMl'ltESSUltE :
1U1

mt: :

AUTI'lflATJC

!Ml llETMOO :

EQU1L18U.TEO

E<ILllLIHATIOlf TUE :

.,.,.

10

a..:onda

l HTltUSlait OATA SUIMAJIT

TOTAL umruSJOM VOLUltE •

TOTAL P'O«E .U£A •
llEOIAN l"OlE OIAllETU (VOU#tf) •
llEOIAH l'OllE DIAIUTElt UltfA) •
Al/HAGE l'OllE DIAlfETEll: (41//Al •

0 . 4059 . .,9

le.266 tq-•/9
0.04&1 ...
0.0Q6 .11•
0 . 0'.24 , .

OU4SITY •

o.cn ,,..

.ll'PAIEMT (Sl(f:UTAI...) OE>tSITY •

1 . 2695 9 / W.

8lJU(

"°"°11TY •
STOI VOllll'tf USED •

._

204

34 .01 I

l.O %

Drug Load: I 0.0 % w/w, Spheronization Time: 20.0 minutes. Run # 3

HGE

l>OIESllU 9120 V2 .07
UJll'Lf OUECTOll:Y / M.1'8£11 : OAU.1

1

/ 30

L' 06 : 49 : U 12/0Z/96
HI' 10 :00 : 45 lZ/02196
t:EI' 10:00: 46 12102/96

O' EIUTOlt : ltetan 91tt\U
10"'..2Cla1n2~

SU&llnut : keun -.eflu

AOVAllCl/llG CONTACT AltGlf : 130 . 0 d<f9

l'OIETIKlflUU IUISElt : 1l--OZ41
l'DIETllOl'IETU COfilSUJIT : 10 . 7'9 11L/ p,

tECEDUCi ctlHTACT AHGU :

l'VIETIOPIETU VUGHT :

69 . 1096 9

llUCUU SUWfACE TVtSIOM : '85 . 0 etyn / e•

STVI YOUME :

0 . 4120 ..

"UC\llT004SITY :

IV.XI,._.. HUD l'ltESSIJlf: : 4 . 68CXI pa;
nHETltOflETU: VOlUftE :

l . S44] llll..

LOlill'llESSUltE :

flUCUltT flLllHG l'ltfSSUlf: :

0 . 1"95a pt i •

U.STl.OW"l:ESSUltfl'OIHT : 25 . 8911ptle
HIGH l'lfSSUU :
AUN

nn: :

ltlJN llETHOO :

ECIU1llWT£0

EQUILUIAATION TlllE :

130 . 0 dotg

13 . 541]9/ eL
Ultl'lE WEIGHT :
O.t.022 9
SA.M'lf•I'~ llEIQtT : 110 . 80!0 9

10 1K.Ord•

TOTAL ll'lftuSlON YOU.t!E •

TOTAL '°"E AUA •
llEDIAM l'OIE OlAltETUI ('tOl,..IM() •
llEOIAll '°'E OI AllETUI ( AltU) •
OlAAETt~ { 4V/A) •
8UUC OOStTY •
A,,UOO (SULlTALl OUISITY •
l'OltOSITY •
STOIV'OU.MEUSED •

AVEllAGf l'OltE

205

0 . l.OS6 ._/ g
34 . 603 .q_./ 9
0 . °'80 ,,_
0 .04l1 ,.

0 . °"'20 ,.

0 . 1111 9 / ._
1 . 2H1 g/ ._
32 . 98 X
40%

Drug Load: 20.0 % w/w, Spheronization Time: 2.0 minutes. Run# I

"°RESllER 9]20 V2 . 07
SAllPLf OlRECTORY/ HONIU : OAU.1

OPEU.TOlt : (nan

Ill

OS :2J : '6 12101 196
06 :08 : 29 12/03/ 96
UI' 06 :08 :30 12101196

LI'

~t•

UJtl'LE 10 : 20X.2• 1n2.itUH1
SU&llTTU : .::etan Plel'IU

AOVAllC.lNG C.ONTA CT ANGLE : 130. 0 cl..;

l'EMETltOllETU CON STAHT ;
l'fHETllOMETEl WEIGHT :

10 . 7'9 JL / pf

0 . 4120 ...
KA.I I"°" HEAD 'IESSUltf ; , .. 68CXI p•i
l'fNETltOllETU VOLUPIE :

t:ECEDING CONTACT AHl>LE :

130 . 0 4cg

llUCUllT SIJllFACE TEMSIOM : '&S . 0 tlyn / u

67.80l6;

1l . 5"64g/ ..
0 . 4022 g

llUCUIY 0£/llSITI :

SAlll'LE WEIGHT :

J . 544] 9l.

LOW "tESSUltf:
llUCUll:T FILLUllG l' RESSUllE :

0 .5768 psia

LAST LOW ,ll:ESSUt:E ,-OINT: 26 . 0094 ps 1a

HIGH l'IESSURE :
ltl.INTYPE :

AUTOl'IA TIC

ltlJH llff'MOll :

ECIU 1LJBAATEO

EQJlUWTIOM TU•E :

11') seconds

IHTll:USIOH OAT.I. SUMAltY

TO TAL l NTl:USION VOLl.lflf •

TOTAL '°'9:£ AREA "
llEDIAM l'Of!E DIAl'IETU (VOLIJflE> "
!tEOlAM l'OllE OlAltETU UREA) •
AVERAGE il'ORE O!AllETU ( 4V / A> •

0.31114 -..l g

32 . 887

~-a/g

0.0580 11•
0 . 0414

.n

0 . °"6411•

8ULX DOISITY •

0.85'7 g / ._

Al'l' .O:EMT ( Sl(flETAU Oft4SITY •

1 . 267'9 g / .._

POflOSlTY •

l2 .S9 1

STE" VOlLME USEO •

37 t

206

Drug Load : 20.0 % wlw. Spheronization Time: 2.0 minute.

l'OllESUEt 9l20 V2 . 07
/Jl

SAl!P Lf OIIECTOllTllU'tSU : 0ATA1

05 : 21:46 12 103/'96
HP 06: 49 : 20 12/0J/96
IEP 06 : ,9 : 21 12/0l/96

Of'UATOll ; KttM llet\U

SA.llPlf. 10: 20%2a1"2.-n.ti2

SUMlnn : K•tll'I llef'lt•

AOVAltCllllG COftT"ACT AICOLE : 130 . 0 deog
aECEOUIG COMTAU .u«ilf : 130 . 0 "9
ltUCUlY SUUACE TEHSIOM : "" -0 rtyn /c •
llUClllY OOISITY:
s.utf'lf VEJCOHT :
UIU'lE+PVt+Hg VEIGHT : 112 . 0378 g

PEHETltOf!ETEI CC»ISTAMT: 10.79 1tL/pf
PEllHJIOflmJ \/EIGHT :
68 . 7225 9
sro 'tOllME :
0 . 4120 ....
Kill ..... HE.AD PllESSUl:E : 4 , 6800 pt i

Ulli/PIESSUllE :

llUCUll:Y fll.1.U«i ,.ESSUll:E :

0 . 5768 P•h1

un LOW PllUSUllf. l'OlllT : l6 . t::c94 P• i •
Hl~

Pltf.Ssutlf.:

IMIT't'Pt: :

AUTOAATlC

IMI MTMOO ;

EQUJllUAT£0

f.QJll18lATIOM TIHE :

10 1eccrci&

TOTAl IMTltlJSlOM VOLUl'IE •
TOTAL. l'OllE .UEA •

llEDIAH

~E

01.u!ETU (YOl.1.1110 •

llfOtM l'OllE DllJIETU (Allf.A) •
AVEl!MiE l'Oll:E OIAl!ml {4V/A> •

1!1UUt OOISlTY •
APP.lllEHT (Uflf:TAl) OOISITY •

l'OltO$ITT •
STEii 'ICl.Ul'IE

207

vn:o .

0 . 34.lS "'-19
l l . 729 11iq-a/9

O.OS45 Jf9
0.°'"20 119
0.0455 ~

0 . 9606 91111.
1.5210 9 / 111..

36 . M %
l7

J;

Drug Load: 20.0 % w!w . Spheronization Time: 2.0 minutes. Run # 3

....

l"ORESIZEll 93 20 V2 .07

Ol'flt.A TOll : btan

1

/ JJ

SAlll'lE OllUC TOltY / HUtBU : OAT.1.1
~ta

U'

01 : 27:1 6 12/09196

S.l.ftl'Lf I D: 20X.2 a 1n.Z..it\.IJIO

141'

02 : 09 : 50 12/09196

SUMITTU : r:.et#'I AconU

ltEI' 02 : 09 : 51 12/09196

l'f/rlETllOftETU HlNU : U-0131

AOVA/llCll«i CONTACT ANGLE : 130. 0 d199

l'fHETllCflETU CONST AMT :

lfClOIMG CONTACT .uGl.f :

l'fHETIOltETU WEIGHT :
IU.XI~

10 . 79 l'Ll pf

ltUCVllT Sl.lltfA(f T£NSICH : 4aS . 0 dyfl / ea

0 . 4120 ._

l'IUCUIY OEHSITT :

KU.D l'ltESSUU : 4 . 6800 P•i

l'EMETJIOl'IETU YOllMf :

130. 0 d99

68 . 1041 Q

13 . S36l ;I-.

S.UWU WElGHT:

l . SMS Iii..

0 . '015 9

s.ull'Lf•l'Vt+ttg WEIGHT : 111 . 20Za 9

LOW l'llESSUltf :

llEllCUIY flLLll«> l'llESSUlf ; 0 . 6&23 pa i l
UST LOW PltESSUH l'OINT : 2'.7'69 paia
HIGH l'llESSIJll.f :
RUN mE :
IUN ltfll«)O ;

AUTOftATt C

EOJ1LISA.t.n:o

ECl.llLIWTJOH TUtf :

10

•KO"ld•

IHTR\JSIOM DATA SIMU.lT
TOTAL IHUtJSIOH YOlLME •

TOTAL l'Oltf AIU •

0 . 3a2S ._/ 9

:SJ . 54) tq-1/ 9

!1£01.&M l'OltE OIAl'IETU ('+'OIJ.lllU •

0 . 0558 , .

llEDIAlil l'Oltf OJAJ'IETU (HEAi •

0.0412 • •

AVEIUGE POll:E OINIETU ( 4V/ A} •

0.0452 Jtl

auut OENSlTY •

0 . 92'6 9 / .._

A"All:EHT (SICELflAl) OEHStn •

1.4304 g/ ._

f'OIOSlTY •

JS.J6

STEJll VOlUJllE USEO •

J7

208

t
t

Drug Load: 20.0 % w/w, Spheronization Time: 10.0 minutes. Run# I

'1)1tESIZU 9320 V2 .07
SAl!PU: OlllECTCHIT I NOM8U : OATA1

/ }4

01 : 27 : 16 12/09/ 96
03 : Z3 : 3a 12/09196
UP 03 : 2J : ]9 12/09196

Ol'fltATOll : IC•tM1'ent •

S.U.l'U ID : 20%10.in2-"\IH1
SU81'HTTU : IC1tan l'l«lu

l'EHETllOMETU "'-"M:I :

U~41

l'EHETllOltt:TEI COMSTAHT :
l'EMETIKlftETD '11£1GHT ;

AOVolHClNG COITAC T All:illE : 1JO. O deg

10 , 79 •L / pl

0 .4120 ..

MUC\llT OEJilstTY:
1l . 5l64 i / 9l
s.utrU WEIGHT :
0 . 4031 g
SAIU'U•I'~ V!JGMT : 110. 1447 g

l . 5443 Ill

LOI.I l'll:ESSUU :
llUtulY 11Lll/llG l'IUSUllE : 0 . 6323 p1 i 1
LAST LOW l'ltUSUU l'OIHT : 2S . 7469pa i e
Hl~l'llESSUllE :

NH TYl'E :
~

130 .0 ~

llUCUllT SUUACE TEHstOH : 44S . 0 dyn/ t •

MAXI ..... HEAO l'l!:USUIE : 4 , 6800 p1 i

l'EHETltOltETU vot.LWIE :

llE CEOIHG CONTACT NGU :

68. 6317 g

AUTOPU.TI C

11Ell400 :

EQIJILlSAATEO

EOJIUUATJOM TUI( :

10 Ueondl

TOTAL JMTlttJSION YCU.lfllE •
TOTAL l"OlE AltEA •
ltfDUH l'OllE DIAllETU \ \IOl.UJIEl •

0 . 3522 -.Jg
D . 215 sq-. / 'il
0 . 0497 ,_

llEDUM POJE DI METU (AJIEA ) •

0 . 0419 1•

AVUAGE '°'9:E OIMETU ( 4V/ A) •

0 . 0424 ,_

u.JC OEMSlTY •

0 . 8707 9 / 9'.

Al'l'U:EHT ( SKILETALJ DENSITY •

1. 2557 g/ ._

FOltOSITY •
STEii VOLIJl'IE USED •

209

30 .66 I
Y. I

Drug Load: 20.0 % w/w, Spheronization Time: 10.0 minutes, Run# 2

"<>ti!ESUU 9]20 V2 . 07
SAllPLE OUECTOSY/!UttlEll ; OATA1

f lS

v

OPERA TOlt : l(nan lletltl

05:47 : 56 12/09/96
HP 06 : 3.2:51 12/09/96
IEP 06:57:21 12/09196

SAllPLE 10: 20X10.11'1l9dl.IM2
SOMITTU :

.:.n_,

llel'IU

l'ENETllOflETU HI.NEii : U-0131
PEHETllOflETU «*STA.MT :

ADVAHClNG CCfllTACT AJIGU : 130.0 ~

10.7'9 11L/pf

ltfCEOlHG CCfllTACT AHGU :

130.0 deg

l'ENETllOltETU \/EIGHT :

64. 1160 g

llUCUllY SUllFACE ftHSICfll: 485 . 0 ctyn/u

STEii VOl.UftE:

0 . 4120 fll.

MllCUIY OVISlTY :

AAXI~

HEAD l'llESSUl.E : 4 . 6eOJ p1i

l'EHETROflETU 'IOll.llE:

l.SMS fll.

13 . 5364 g/ .._

SAl'll'U llftGHT :
SAAPLf.,.pflt+~

0.t.OZJ g
\/EIGHT : 111 . 6Jl0 g

LOlill'llESSUllE:

llUCUltY FILLUCi l'llESSUllE:

0.6992 p1i1

UST LOW PRESSURE JOINT: 25.7719p.a11
HIGH l'IU:SSUllE :
inMT'Yl'E :

AUTOMTJC

lttW llETHOO :

EQJlllUATED

fQUILl!UTICfll flllE:

10 Heondl

UHllUSION OATA SUlf'IAll'r
TOTAL IHTltUSION "'ot.1.11£ •

TOTAL l'OllE UU •
llEDIAM l'OllE OIAl'IETU ('t'Ol.UflEl •

0.3551 1111../ g

lJ .578 aq-1/g
0.0496 ,_

llEDIAH H>llE OUJIETH (UEA) •

0.0419 11•

AVERAGE l'OllE DIAl!ETUI (4V/A) •

0.0423 11•

IM.JC DENSITY •

0 . 9973 9/ lll

'"'AllEMT (SICELETAL) OEHSITY •

1 .5440 9/ml

"°"°SITY •
STVl'IOl.UltEUSEO•
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35.41 X
l5X

Drug Load: 20.0 % wlw. Spheronization Time: 10.0 minutes. Run# 3

~ESllfll

9J20 '12 . 07

'AGE

t..r

Ol"EUTOfl ;

IC.ttMt lt.+IU
SNll'LE 10 : 21lZ10.1n2-"UK3
Sllel!ITTU: IC.•tM llehU

05 : 47 : 56 12/09/ 96
Hr 07:39:58 12/09/96
U:, 07:]9:SI 12/09/96

,VtETtlOflf.TU ,.,..0 : 1]-GZ.41
l'EMETllOMTH COMST.MT :
POiHJIOllETU llEIGHT :

10 . 79 11\../pf
65 . m4 !1

AOVAJK: I HG COHTACT AllGLE :

no.o d99

IUCEOIHG COfilTACT ,.,,..U :

110. 0 Mo;

ltUCVltY SUll:FACE TUSl<ll ; 445 . 0

STEii \IOLtME :
0 . 4120 ._
IWl:UUI HEAO l'IESSUU : 4 . 65X> p11
l'fMETllORfTU 't'OllME :
] . 54"] ._

llUC\lltY fILLIHG "IESSUU: :
LOW "IESSUltE KllMT :

0 . 6992 p11•

25 .n19 P•,.

HlGH l'ltESSUll:E :
M.INT'f'l'E :

AUT~TI C

lttM llEnt:>O :

EQU:LIBAATEO

EOUILl8UT10N TUIE :

dytl/~

llUCUltY O~SUY :
13 . 5364 9 / lli.
S.lftl'U VEIGHT :
0 . 4019 g
SA.11,U•l'Ef"Ho; VEIGHT : 110 . 9042 g

t..Olil,.ESSUl:E :

usr

1

/J6

SAN'LE OlltECTOflY/NlNU: OATA1

10 Hccn;l1

TOTAL UtTlt\JSICI( VOllME •
TOTAL l'OlE AJ:f.l •
llEOl,l,111 POltE OIMETU ( \IOLIMEl •
PIEIHAH PORE 01.t.llETU <AIU) •

A.VU.AGE l'OllE OIAltETU U oV/ 0

•

i!lllJUC OatSlTY •
Al'l'.U:EHT ($KILETAL) DUISlTY •

0 . ]516 ._1';!
l2 . ti77 aq-• l !I
0 . 049S p
0.0425 ,_

O. Ol.28 JI•

0 . 8701 g/ "1 . 2'37 gt -..
:5C>.S9I

STEllvot.UftEUSED •

2 11

:54I

Drug Load: 20.0 % w /w, Spheronization Time: 20.0 minutes. Run # l

l'Oll:ESIZU 9l20 Y2 .07

'.I.GE

Of'ERAtol: KetWlfl.ehta

OJ :07: 26 12/10/96
H' Ol : S7 : 40 12110/ 96
ltEI' 0J : 57 : 41 12/10/ 96

SUMITTER : ICetWI llehu

PENETllOfllETU COHSTA.HT:
'fKETltelf'ETElt VflGt4T :

10. 79 11L/ pf
67 . ao50 g

AOVAHClH!i tOfilTACT AHGlE : ll0.0 d"'iJ
lfCEDlWO OONTACT AllGU : 130 . 0 d"'iJ
PIEltCUIY ~fACE TUISlOH: 4aS . O dyn l c•

1l.s:564 g f lt.
O.lo021 'ii

llEltCUltY DDISlTY:

IU.XI*'" HU.0 'ltESSUltE ; 4 . 6l!OO psi

'fHETltOfllETEll VOll..lftE:

SAl'll'U WEIGHT:

l . 544] ..._

LOW PllESSUllE :
llERCU«T IIUIHG PllESSUltE :

0.8010 pti •

L.lSf LOii PltESSUltE fl'OUtT : lS.8091 pai a
HlGHPllESSUll:E :

NM T'"E :

AUTOfllATIC

ECIUlLISAATED
EQUILIMATIOH Tll'tE :

10 Heondt

IHTltUS!OH DATA SllflllU.ltY
TOTAL lNTltUSlOH YOUME •

llEOIAH

1

m

SAllPLE OlltE CTOIY / ff.MBU:

~E

TOTAL l'Ot!E UEA •
OIIJllETU ( YOl.UltU •

MEDIIJf lf'OltE DUJIETU CAllEA) •
AVEltAGE P'OIE 01.U.ETU. (4V/0 •
8UlJC DENSITY •
A'l'UEJIT ( SkELETAll DEHSITY •

0.3259 .C../g

30. 785 sq-• / 9
0 . 0495 119

0 . 0411 1•
0 . 0423

~

0.89SO -;i/lli.
1.2635 g/ ._

POlllOSITY •

1.9 . 16 X

STEii YOUME USED•

32 X
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Drug Load: 20.0 % w/w, Spheronization Time: 20.0 minutes. Run # 2

POllESUEll 9320 "2 . 07

,,.

SAl'.,LfDIUCTOltY/~11:

Ol'ElATOlt : ICn .... ..-.u

lJ

S.ut,LE U : 20%20ainl..itll'l2

'lNET~ETU

OJ :07 :26 12/10196

05 :10 : S2 12110196

sua1unu : «•t"" ...nu

UP OS : 10 : 5J 12110/ 96

Ml.IW:ll : 13-0'131

PEMETllOflETU VElGHT :

68 . n74 9

AOVA.llClHG CONTACT AHGLE : 130 . 0 OeQ
ltECEOIHG CONTACT AHGLE :
130 . 0 0.,..
llHCutY SUllUCE TENSIOH : 4aS . 0 ttyri/u

STEPI YOlUflE :

0 .4120 ..

llUC\Jl'f OENS1TY:

PVIETllOflttU toHST.tJIT :

10. 1'9 ,iL / pf

13 . 5364 g/M.

l'All,... HIEAD PllESSUlf : 4 .68CXI pa l

S.vlflf WEIGHT :

PEHETllOIUTH 'IOl.UflE :

SAlll't.(•P~llEIGHT :

J.SMS M.

0 . l.008 9
112 . 13'09

LOW PllESSUlf :
llUCVllY fJLLIN:i PllESSUU :

0 . 8010 pa 1•

U.S1' LOW PllESSUllE l'OINT : 25 . 8091 pa,.
HUiH PllESSUllE:

ltllHTYPE :

AIJTCAATIC
EQUllllltATU

EQUILIBAATlOH TUIE :

10 u concll

llHltUSU::W DATA Sl,JfMAA1'

TOTAL INTIUSICN YOt.UflE •
TOTAL l'OllE AIU. •

O.JD9 .._, ,
]1 . 783

~-•/g

PIEO I A.H ..oll:E DlAl'IETU (\IOLUflD •

0.0495 ,_

NEOIJJt l'OllE OINIETU (AllLO •

0 . 0411 11•

A\IU.AGE P'Ollf OIMETU (4\1/A) •

0 . 0420 11•

BtJU( OVISITY •

IJIPAUMT ( SIC!UTAL)

~"JtSITT

•
l"l*)SITT .

STEJlt'IOl...UflfUSU •

213

1. 0104 g / tll..

1.52"3 9 / ._

n .n

I

l2 I

Drug Load: 20.0 % wlw . Spheronization Time: 20.0 minutes Run # 3

'°41£SJZU 9320 V2 .07

, AGE

1

02 :2S : 4S 12116/ 96
H, 03 :05 :51 12/1 6196
llEI' 03 :09 : 58 1211 6196

I.I

l'EHETJIOl'IETU NUNSO : U--0241
l'EHETJIOl'IETU COHSTAHT:

l'EHETl!OflETU llEIGflT :

ADYA.MCl/llG COHTACT AHGLE : 130 . 0 d99

10. 79 11L / pJ

UCEOIHCi CONTACT Afi!Glf :

67 . 6SJO 'ii

130 . 0 dev

llEICUllY SURFACE TEMStOM : 481 . 0

STEA vot..Uf!E :
0.4120 ..
AAJINUfl HEAD l'llESSUllE : 4 . 6800 pti
l'EHt:TJIOl'IETU 'IOll.l'IE :
l . S44J ._

llEICVltY OEHS11'Y :

0. 'IXX> 'ii

SIJl,U WEIGHT :
SAN'U•l'E~

VUGHT : 109 . 9712 g

LOW "IUSIJllE :
0 . 6843 p.. h

llUCUltY '1LLIHG l'llESSUllE :

LAST LOii l'llESSURE l'OINT : 25 . 8344 p1i a
HIGl'l"IESSUltf :
ltl.IMTYl'E :

AUTOfU.TlC

ltuHltEll400:

f<lllLIUATf:O
~o

EQJIL J.!ltATtCN TU'l.E :

•KOf"ld•

lNTlt\JSIOM DATA Sl.11'1..U Y
TOTAL UtTlt!JSlClt VOLL.ME •
TOTAL l'Of!E AllU •

11£01.fJll '°41£ OINIETU

(V'Ot,.IJllE) •

O.Jln llL/9
31.498 tq-• / g
0.0l.95,,.

ltEOIAH "°4tE OlM£TEL (Al.EA ) •

0.°"20 , .

AVEIUGE "°41.E OllJIETU (4V/ A> •

0.0429 _.

11UU: OfHSITY •
Al'l'HOfT ( SXlLETAl) DENSITY •

0 . 1937 g / lli.
1. 2Sl) gJ-..

"<>llOSITY •

JO. 18 1

STEJlvot..Ul'IEUSEO•

]]%
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ftyn/~ •

U . Sl64 gt -.

Drug Load: 30.0 % wlw. Spheronization Time: 2.0 minutes. Run # I

SAllPU: OUECTOllY/.......U:R : OATA1

/40

Of'EU.To« : l(.et..,llmu
SAMLE 10 : 30X.2•1n2..aurn

02 : 2S : 4S 12116 / 96
HP 01 : 49 : 28 12 116 / 96
llH03 : 49 : 21112116196

SIJ6fllnU : ICRtWll'l«lt•

AOVMCING (OflUCT AHGLE : U0 . 0

PEMETllCflETU CONSTANT :
PEHETICll£TU WEIGHT :

10. 7'9 11t../pF
611.5499;

0 . 4120 ....
ltAXllU'I HOO PllESSUU: : 4 . UOJ p1i
PVIETAOllETU V'Ollll'lf :

] . ~5 Ill

ltUC\lllY SUU ACE TEJISJOll : '4S.0 ltyrl/u

"ucun

OEMStTY :
SAllPU VUGHT ;

13 . Sl64 OlllL
0. ~ 0

SAlll'Lf+P£1+4-H; llUGHT : 111 . 9406 O

LOlril PltESSUll:E :

llUC1JltY 'ILLJHG PlESSUH :

0 . 6841 p1i•

LAST LOW l'ltESSUllE '°!NT: ZS . o.544 p11•

HIGH PllESSUllE :
ll:UN T',,E :

AUTON.TIC

1tUH llETHOO:

fQUlLlllUTEO

fQUILlMATIOH TlllE :

d~

130. 0 de;

l:ECEDtHG CONTACT AHGlf :

10 Ueondl

TOTAL lKTlVSION VOlUfllf •
TOTAL '°llE UU •
JltEOIAH l'Ollf OIMETU (\'OU#lf) •

O.J6Z8 111... / ;
]1 . 031 .q-•/O
0.0644 11•

llEOLUI l'OllE DIAltfT!l (.UEA) •

0 . °"-0 #•

AVEAAGE l'Olf OIAltfTU ( 4\1/A) •

0.°'68 11 •

1!1UUt DENSITY•

0 . 9TH ; I -.

.VP.O:DfT (SICELfTALl ioEHSITY •

1.4999 ; / Ill

'°"°SITY•
STEllV'Olll'IEUSEO•

2 15

JS . 24%
lSX

Drug Load: 30.0 % wlw. Spheronization Time: 2.0 minutes, Run # 2

SAll, LE Dl ltECTOU / HUMEll : OATA1

/ 41

OPEUTOlt: ICeten"ft\U

07 : 15:40 12116/%

SJ.Jlt'LE 10 : XJ12• o'2-'IUMZ

"' 07 : S8 : l4 12116/%

SU81UTIU : ICeten ""'1U

ltEP 07 : Sl : 34 12/16/ 96

AD'IAMCIHG CONTACT AHGU : 130 . 0
'ENETJIOftETU COMSTAIH :

10 . 1'9 t1L / pf

IECUlNG CONTACT AMGLf :

deoa

1l0 . 0 d eog

'ENfTJlOftETU llUGHT :

67 . 89}(. g

llUCU ll Y SUltfACE TPISIOJt : "3S . O dyn lt •

STlllYOLl.flE :

0 . 4120 ....

llUCUllY OUISITY:

IU.IUUI HEAO jl'ltESSUltE : 4 . 6SXI p1 i

l"EHETl!Of!ETEll YOt..Uf!E :

ll . Sl64 " ' .._
0."°6g

SIJll'l.E \lflGHT :

l . 541.] .._

LOW PllESSIJllE :

"UCUllT '1LLING PltESSUltE :

0 . 69]] p1il

LAST LOW 'ltESSUltE l'OlHT : ZS . &376 p 1 i a
HIGH "IESSUltE :

ltUH TY,E:

AUTOIU.TlC

ltUH llEnc>o :

EOJlLIUATEO

EOJlUUATION TUtE :

10 H Cond l

lHUUSlON DATA SUMAAT
TOTAL INTll'\JSIOH 'tOLLl'IE •
TOTAL f'OllE .lll:E.A •

O. Jseo .C./ 9
30 .1 47 tq-.Jg

llEDIAH l'Oll:E OI AltETU ( Y'OLUl'IE> •

0 . 06Ja .-

llfDIA.lt f'OllE OlAllETU CAAU.) •

0.0406 11•

AVUAGE !'ORE OIAllETU (4Vf A) •

0.0475 , .

8lllJ( GDISITY •
... ,,.U!JolT (SIU:.. EU L) OO!SITY .

"°~SIT'!' •

STE,. VOLLltlE USED •

216

0.87'S4 g/ ._

1.zn;;

~ / 91.

]1 . 34I
35 I

Drug Load: 30.0 % w/w, Spheronization Time: 2.0 minutes. Run # 3

PO AESllEit 9 320 V2.07
IQ

SAMPLE OUECTOltT / HUl'!BElt ; OATA1

Of'UATOll : (ttan l'let!tl

07 : 15 : 40 12116 / 96

SAllPLE 10 : J.J%2 • •n2~

HI'

SU8" 1TTER : (etan lletlt•

ltEP OIS : S6 : 00 12/16/ 96

AOVMICU«'.i COtHACT AHGLE : 130 . 0 d119

PEHET"°"ETU !U18U: 13--0131

l'EHETROl'IETU COHSTAHT;

08 : 55 : 59 12 / 16/ 96

110 . 0

10 . 7'9 11L/pf
68 . 6191 g

llUCURT SUllFACE TENSION : 435 . 0 dytl / c•

STEii VOLUltE :

0 . 4120 Ill..

llUCU«T OEJISITY :

llAXUtlfl HEAO f'RESSUllE : 4 . 6800 p11
PENETllOflETU 'tOl.llftE :

l . SMS 11t.

UCEOIHG COllUCT ANGLE :

d~

PEHETllOflETU llEJGHT :

tl . 5364 9 / 9L

0 . 4006 'i

5.ull'LE I/EIGHT ;

SAlll'LE•f'Elt*"Q llEl~T ; 112 . 0IS18 g

LOW f'USSUU :
llEllCUll'I' FlLLJHG f'llESSURIE :

0.6933 p 1 i •

LAST LOW PllESSURE '°lNT : 2S.8J ( 6 ps i •
HIG!ol PIESSUU :
111.#!Tll'E :
~/11£nil00:

fQUOLIWTEO

EQUILIBlATJOH TU•E :

10 1-=r>d1

UITJIUSlOH DATA Sllf!MlT
TOTAL. llHRUSJOH YOlLlllE •

TOTAL P'OttE HEA •

llEOIAH l'OlllE OIAAETElt (VO!.Uf'lf) •
llEOIA.I( 'ORE OIAllUElt (AREA) •
AVEltAGE l'Otl:f OtMETElt (4VI AJ •

A,,UENT CSICELETAl l OENSITY •

0.]595 lll,. / g

30 . 107 sq-•/g
0 . 0640 11•
0 . 0410 11•
0.0478 11•

1 . 52169 / 111..

l'OROSITY•

JS . 36:

STEKV'Ol~'lUSEO•

3S X:

2 17

Drug Load: 30.0 % w/w, Spheron.ization Time: 10.0 minutes. Run# 1

POllESIZU 9320 V2 . 07
SAll,LE OlllECTOflT / HtJ"8EJI :

00: 4]:22 12117/96
HI' 01:44:25 12117196
llEI' 01:44:26 12/17196

MEUTOft : IC•U..'I l'lenu
SAJllPLE lO : }(JX10111n2-.AUK1

SIJBIUTTEI : ltetenllehU

PEHETROftETU l«JM&EJI : 1J-01l1
PEHETllOflETEJI COHSTAllT :

10 . 79 1L/ pF

AO¥Al'IC1HG COtlTACT AHGLE: 130.0

ffo;I

llECUlHG COtlTACT AHGLE:

~

130.0

PEMETllOflETEll WEIGHT :

67 . 7465 <J

llUCUU SUll:fACE TENSION; 485 .0 dytl/c•

STEI' VOUJflE :

0 . 41<!0 el.

llEJICURT OVISJn:
SAll'LE WEIGHT:

ltAI1Pl.ll'IHEAOPllESSUll:E : 4 . 61JCOps i
PEHETltOflETU V'Ol.UIU :
l . 5885 el.

13.5364 g/._
O.t.aJSg

LOli/PRESSUAE :

llEJIC\JR'I" FILLIHG. PllESSUtllf :

0 . 6858 psi1

UST LOW PllESSURE il'OlNT : 25 . 718'9 psi1
HlGM PRESSURE :
lt!.MTYl'E :

AUTOl'\.HIC

lllJHllETI«XI :

EQUILIBAATED

EQUtLIUATtC»I HllE:

10 HCOf"dl

TOTAL UITRIJSlOtl VOLUl'IE •

0.]41.Q Ill.lg

30.610 -.q-• /g
0.0593 . .

TOTAL POllE AREA •
11£01.ul !'ORE OIMETU ;'t'Ot..UftE> •
llEOUH l'OllE IHA.llETU ;.ue.o •

0.041] ..

AVUAGE POftE DlAl'IETER (4V/Al •

0.0449 11•

llUU:: OEJISJTY •
A,,AllEHT (SULETAL) DOISJn

~

1.0COS g/._
1.S261 g/11i.

34.42
STEii VQLL/flE USED "

2 18

x

ll X

(

Drug Load : 30.0 % wlw, Spheronization Time: 10.0 minutes, Run# 2

IOOll ESIZEI 9320 Vl . 07

JU.

S.utl'LE OlllECTOllY/,._U : OAU.1
OPE il.i. TOii:

C:~tWI

LI' 00 : 43 : 22 12 117196
Ol :l2 : 44 12/17196
llEI' 03 : l2 : 45 12/17/96

llef'IU

S.t.l'l, L£10:30%1 0. i n2~

SU8fHnn :

(UM!

lleht•

l'EMETIK»'IETU NUIBU : 1]..Q241
l'fHETltOf!ETU COHSUMT ;
l'EHETllOf!ETElt YEtGHT :

ADVA.llClNG COHTACT Af!CiU : 110. 0 d119

u:ct:ou«;

10 . 19 ,Up#
68 . llOO g

0 . 4120 ...
M.XIIUI HEAD l'llESSUU: 4 . 6800 ps i
l'ENETll<WIETU YOlUllE :
l . 541.J L

LOW ,.ES$UJIE:
llEllCVlT FllllMCi "IESSUllE :

1l0.0 o...i

COHTACT AJIGU :

!IEllCUttT SIJIFACIE TENSIOH : 41S . 0 tlyft / u

!IEllCUU OEHSITY:

11 . 5364

llEtGHT : 11l .Q81.0 'ii

0 . 68S& pti1

US T LOW l'ltESSUAE l'OIMT : lS . 7189 ps i •
HIGH l'ltESSUU:

.-UHTYl'E :

AUTOIU.TIC

EQU ILl lllATEO

10 s-=nds

EQUILIP.ATlOH TUIE :

IHTRIJSIOH OATA $UM.UY
TOTAL I MTa!JSIOH VOUlf!E •
TOTAl. l'OltE AllEA •
llEDlA.N l"O«E OIAMETtl ('tOUM El •
ltEOIA.11 l'OI E 01.u!ETU CUE.A ) •
.l\lfllAGE l'OAE OIAK(T'EI {4Y / .l ) •

auu::

O. l4J9 .t./ g
29 . 707 sq-sf g
0 . 0623 • •
0 . °'24 11•
O. Ot.63 11•

OOISlTY •

O. M43 g/ 111..

A,,AUHT Cst:ELETAL) DENSITY •

1.2707 g/ ml

l'OftOSlTY •
STEii

g/ ..._

0 . 4COJ g
SIJll'lE+l'E~Hg

VOl~E

USEO •

219

](). 41 l
ll l

Drug Load: 30.0 % wlw. Spheronization Time: 10.0 minutes. Run# 3

'AGE

POllESIZER 9320 Y2 .07

SAl'l'LE l>t•ECTOllY/N.NElt : OATA1

U'

OPEUTOl : IC<tUt'I Jl<ttlt•
SA.11,LE 10: JOt10.1nZ-.ltUM3
SU81'1InU: ICH.n Jleht•

10: 4l : 17 12/17/ 96

11 : 26 :31 12/17/ 96
RE' 11 : 26 :12 12/17/96

AOVAHClMG CONTA CT .fJllOLE : 130. 0 ~

'fKETIOflETElt -...Ell : 13-0Z41
'EHETllOf!ETU CONSTAHT:

10. 79 111...lp,

130. 0 deojl

llECEOIHG COHTACT" AMGLE :

'fMETltOf!ETU llUGKT:

68 . oeo9 g

llUC\JRY SURFACE TEMSIOH : 485 . 0 rtyn / u

STEii VOl.t.l'lE :

0.4120 ._

ltEltCUll1' OEHSITY:

1wmut HEAD ,.ESSUltE : 4.6800 pa i
'EHETAOl!ETU YOLLll'E :
3.5443 ._

13 . 5364 g/ ..

SAll,LE llEIGHT :
0.4007 9
S.u!PLE .. ,V..Hg llEJGHT : 110 . l'J1 g

LOW 'RESSUllE :
ltfltCUJIY flUlHG 'RESSUllE :
UST LOW PllESSURE l'O l NT ;

0.6758 pti 1
ZS.~961

pa; •

HIGH PJIESSURE:
111.M TYP'E :
1tUN llETHOO :

EOUlLl!M.TlON TJJIE:

,,. •..-

1

145

AUTO.....Tt C
EOUlllHATtD
10 1KOl"d1

l HTRUS JON OA U. SUMARY
TOTAL JHT.VSIOM VOLUPIE •
TOTAL l'OIE AlllEA •

llEOlAK l'OIE 01.U.ETU (\l'OC.1.111 £ ) •

llfOIAH l'OlE 01.u!ETEJI ~ AREA ) "
AVEiv.GE PORE 01.U.ETU {411/A) •

0. 1'-87 Ill. l g
l0 . 897 aq-1 / g

0. 0605 111
0.0414 111
0.()l.51 11•

llUUC OOISlTY •

0.8869 9/91.

.l1PAllEMT ( SltELETAl l OOS ITY •

1 . 2840 g/.t.

~-:OSITY

•

STEM VOlUflE USEO •
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30.92 X

Y.

t

Drug Load: 30.0 % w/w, Spheronization Time: 20.0 minutes Run # l

PORESIZER 9320 '12 . 07
SAl.,LE OI RECT0Rl' / IMl8ER : OATAl

Ol'EllATOR :

/ 40

.:.un...nu

10 : 43 : 17 12/17/ 96
H, 00: 20 : 4a 1Z/18/ 96
IEI" 00 : 20 : 4a 1Z/18/ 96

3CX2CM1n2-"'-"11

SUSlll nU: ICet.,,llet>t•

AO'IA.ltCIMG COHTACT NIGLE : 110 .0 deog

'UIETllOllETUNl..IMMR : 1]-Q131
'ENETllOllETU CONSTANT :

10. 1'9 jri./pF

RECEDING CONTACT AHGLf :

130. 0 dev

l"EllETltalETU WEIGHT ;

64.3199 i

"UCUltY SURFACE T£HSIOflt : 43'5.0 dyn lc•

STEii VOl.IJllE :

0 . 4120 llL

"UCURT OEHSlTY:
SM,LE VUGHT :

ltUlllUfl HEAD 'ltfSSURE : 4 . 6e00 p• i

'EHETllOllETElt VOLLl'I E:

l . SMS 11L

1J . S36' g/ 111..
0.4014 g
S.u!'1.f+'ff'f+f49 WEIGHT : 112 .0143 g

LOV PllESSUll:f:
llEllC\IU HLLl NG l'RUSUllllE :

0 . 6'758 p 1 i1

LAST LOW l'RUSUllE l'CHNT ; 2S . S961 p1i1

ltUHllETI<IO :

EQJILl!ltAT!O

fOUlLISltATION THIE :

10 11condt

TOTAL INTltUSlON VOL\#lf •

TOTAL l'Ol:E Al:EA •

0.J19S llL/ g

28. 143 sq-• / g

llfOlAll il'OtE OUJtETU (VOlL.1'1£> •

0 . 0584 JI•

llEOIM '°llE DIMETEll: (AllEA) •

O.Ql.06 JI•

AYfllAGE il'Otf OIAllETU (4Y/ A) •

0.04$4 111

&IJU: DENSITY •
APPAAENT (SKELETAL) OEHSITY •

l'OllOSITY •
STUI 'IOll.lllE USEO •

22 1

1.0289 gt -.
1 . Sll7 g/ .i..
ll . 87 X
31 X

Drug Load: 30.0 % w / w, Spheronization Time: 20.0 minutes. Run # 2

l"OllESUU 9]20 V2 . 07
SAllPU OUtECTOllY/IQIBElt : OATo\1

/ Sl

04 : 20 : 19 Q2 / 18/97
04 : Sl : '-O QU18197
IE' 04 : 58: 1.ll 02 / 18/ 97

OPEIU.TOW : ICETAH llEHTA
SAlll'Lf 10 :

10%20.1~.-lt\JK2

SUM1nu : UTAH llatTA

PEHETllCJllETUllJNU:ll : 1l-<Ml1
PENUllOl'IETU ((INSTAllT:

'EMETJIOltETU \IUGHT:
STElt VOUME :

AOV.+JIClHG CONTACT AHGU : 1l0. 0 d9Q

10. 79 •I. I P'

IECEOlHG COl'ITACT AHGU :

11.Ul!U' KOO ,llESSUllE : 4.68CX> pai

'EHETltOltfTH YOL.UflE :

0. '°36 g

SNU'U llEIGHT:

l . SMS -..

LOW,lESSUltE :

1tncu11r ftLLIHG "tusuu: a.sass

pa i•

LAST LCN l'llESSUltE l'OIMT : 25 . 4901 psh
HIGH "IESSUllE:

1'1.JHTYPE :

AUTOftATIC

1'1.14 llEntOO :

EQUIL18AATEO

EQUlllBlt.l.TIOH r:11E :

_.. •..-

10 uecnd•

IHTlt\JSlOH OATA SUNUllY

TOTAL l MTlt\JSlOfl \IOLl.lltE •

TOTAL l'OllE .U:U. •
ltEOlAM P'OflE 01.lllETElt (YOLUllEJ •
llEO lAN l'OllE OlAllETElt ( .U:(A) •
AVfltAGE l'OllE OlAllETElt ( 4V / A) •
flUU(

A,,AAEHT

1l0.0 Mg

"UCUIT SUllFACE TENSION : 485 . 0 ityn/ ePIEllCUllY DENSITY :
1l . SllS g / ..._

68. 0736 g
0 . 4120 111..

OEHStTY •

(~LfT.t.U O~.HSlTY

•

0 . ]352 -.. l g

ZB.67'0 1<1-• / g
0 . 041l i •
0.0411 JI•
O.Ot.65 JI•
1 . 0127 g / 9l
l.53l0 g/91.

~SITY•

33.94%

useo •

33 :i:

STD! VOt.t.lltE
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Drug Load: 30.0 % w/w, Spheronization Time: 20.0 minutes, Run# 3

POllESllEll 9320 '12.07
SAM, LfDlllECTORY/NU..8£11 : DATA1

/S4

0'ERATOll : 11'.ETAH llEHTA
S.Ull'l.E IO; 3CJX20,. ; f'29dUK)

L'
H,

SU81UHER : KETA.11 llEHTA

RE' OS : S9 : ]1 02 /1 11 / 97

'fHETllOf!ETEll /lllllt8EJI; 13-0241
'fMETKlf!ETEll COMSfA.llT:

Qt, : 20 :1 9 02118/'17
OS : S9 : ]1 02/ 18 / 97

AOVAHCIHG COMTACT AHGLE : 130.0 de\)

10. 79 .. lip,

ltECEOING CONTACT Af!IGU :

130 . 0 d.g

'EIOETllOf!ETEll \!EIGHT :

68.6578 'ii

llEllCUllT SUU ACE TVISlo.I: 48S .0

STEl'I VOLUftE:

0.4120 Ill

,.EllCUltY DENSITY:

ayn/c.•

13 .5)35 g / lll

PIAXll'Ul'I HE.AO PUSSURE : 4 . 68(1) p 1 i

SAl'l'Lf VElGHT:

PEHETROPIETER VOLUllE;

SAl'IPLE+'E'"'Hi; WEIGHT : 110 . 9184 'ii

l . 5443 Ill

LOW PltESSUllE :
MUCUAY FILLING ,,IESSUAE :

a.sass

0 . '°22 9

p• i •

U.ST LOW PRESSURE l'OIHT ; 25 . 4901 p1i •

HIGHPRESSUllE ;
ltl.llTY": :

AUTOl'IATIC

~UH

EQIJILlllllAT'lO

llEThOO :

10 1KOnd1

ECIUlLl81lATIOH TlllE ;

TO TAL tNTRIJSIC»I VOl.Ul'!E •
TOTAL l'OlE AllEA •

0.3263 lll / g
l7 .170 aq-• / g

"ED!AH l'OllE OIAJIETU ('IOt.UflE> •

0.0480 11•

llED l A.11 '°41£ OUJIETER CAlEAJ •

0 .045] 11•

AVEIUGE P'O«E OIAllETU (4V/Al •

0 .04«> 11•

•

0 .8911 g/..._

Al'l'Alt [HT (SKfUT ALl DEHSlTY •

1 .2S64 ;/..._

9UUC.

D~SITl

l'OltOSlTY •

29.07 1

STEll\IOLl.1't[USEO•

321

223

Drug Load: 40.0 % w/w, Spheronization Time: 2.0 minutes, Run# l

POllESIZEll 9320 V2.07
SA"PLE OIRECTOl:T / NUfl8Elt : OATA1

155

OPEl\ATOll : KETAH llEHTA
S.u!Plfl0 :

00 : 44 : 16 02 / 19/97
01 : 2J : OJ 02 / 19tn
11£1' 01 : 23 :04 02 / 19/ 97

@2 • in2~1

SUEll!lTTU: UTAH llEHTA

l'EHETllOPIETEl NUfl8U: 13--0131
PENETllOPIETU COHSTAHT:

AOY.u!CIHG CONTACT AHGLE : 130.0 c!Of9

10 . 19 •L / pf

tECEOIHG CONTACT Al«ilE :

130 . 0

67 . 9958 g

llEllCUIY SUllfACE TUISlOft : 435 . 0 dyn/ea

STEii \'OlUflf;

0 . 4120 Ill.

.llEltCUllYOENSlTY :

IV.X{PU'I HOO PRESSURE : 4 . 6e00 pi i

PEHETllOltETElt YOLUflE :

].

sass

el.

1l . SllS9 / 11L

0 . 4011 g

SAAPLE WEIGHT :

S.utl'lf•l'EH+ltg WEIGHT : 111.)61.a g

LOW PRESSURE :

llUC\JIY '1LLIHG PllESSUAf: O.S30tl p1i a
LAST ll"" PllESSUllE l"OIHT : 25 . ~]J.4 p1 i a
Hl<il'l"llESSVllE:

ltt.INTil'E :

AUTOAAT1C

ltUN 11.ETHOO:

EQIJILIBltATJOH TUIE ;

.,.. /

°"9

PENETllOltETU WEIGHT :

10 Heond1

INTRUSION OAU. S.UPlf\AllT

TOTAL lHTlt\JSIOH VQllJfllf "
TOTAL il'Olt f .UU •
llEDIAH l'Oll:E OUJtETElt (VOLi.ME> •

0 . 3713 .t./ g
25 . 80' sq-a / 9
0.(l191.9 • •

llEOI.u4 l'Oll:E OJAAETU (AllU) .,

O . Ol64 11•

A\IU.AGE l'OAE 01.u!ETEll ( 4V/A) •

0 . 0586 11•

auu:

JEHStTY •

0 . 9716 g/9l

... ,,AllEIH (SKELETAL) OEMSlTY •

1.SlSO g/9l

POROSITY •
STEii VOlUlk USED•
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36 . 71 t

l7 %

Drug Load: 40.0 % w / w, Spheronization Time: 2.0 minutes Run# 2

l'OUS!Hll 9320 \12 . 07

156

SAllPLE OUECTOIY / JrCJf'l8Ell :

00: 44 : 16 02 / 19/ 97
HP 03 :00 : 44 02119/ 97
lllEP OJ :00 : 4S 02119/ 97

O'UATOI : (fTIJll llEMTA

SAllPU 10 : q..2• i n2~2
SU81HTTU : UT.lit llEHTA

PEJIETllOflETU

~II ;

AOVAH<U«:i CONTACT ANGLE : 130 . 0

13--0241

PEllETIOIETU: COHSTNIT:

10 . 7'1 11L/p'

llECEDIN6 CONTACT AHGLE :

d~

130 . 0 d<t!J

PEJIETltOflETU \/ElGtH :

68.7471 9

llUCUllY SUllfACE TUISIOH : ~s . o lfyfl / U

STUI VOLUMt: :

0 . 4120 ._

llUCUllT OUISITY ;
13 . SJ)S g /.i_.
S-'"'1.f llEIGMT :
0 . 40:19 g
SAllPLE•PEM+iti llElGMT : 110 . TJT] 9

IU.J:llUI llU.O "llESSUllE : 4 . 6800

PEHETM)flfTU VOLUME :

psi

l . 5443 -..

LOW PUSSUltE :

llUCUll:T FILLI NG PllESSUllE:

0 . 5JOl5 p• i •

UST LOW PUSSUllE l'OlllT ; 2S . Sll4 psi •

Hl!OHPRESSUU :
lt!JNTYl'E :

4UTOl'IAT1C

avH ltETl400 :

EQJILllAATED

EQJlltUATlOH TlltE :

10

••cond•

TOTAL lHTtuSIOH 'IOLLllE •

TOTAL '°41:£ AlEA •
llEDIAH l'OllE OIAllETH CVl"IU.lltE> •

0.31'91 -..19

26.0!IO sq-e/g
0.0952 11•

llEOlAH '°*E OIAllETH ( AllE.O •

0.0385 JI•

AVERAGE l'OllE OJAl'IETIElt (4¥/ A) •

0.0S81 JI•

BUU: OEMSlTY •

0.8S07 g / 9L

-"'UUfT CSKfLfTAU DENSlTY •

1 . 2557 g/9L

l'OltOSlT'Y •

32.25 X

STEJI V'OUMc:: USED •

r7 X
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Drug Load: 40.0 % w/w, Soheronization Time: 2.0 minutes. Run# 3

l'OlESUU 9320 '12 . 0 7

"'

SAll,Lf OUECTOIU' / HUMU :
0'EA.lTOlt : C.etan ,..,..u

U'

OO : l'il : 33 0212.Co/97

SAl\l'U I D: 4CT.t2-.2•1nltU"'3

"' 01 : 16:09 f12f2"97

SIJBIH nU : (.et8"1\eflU

REP01 : 16 : 1002./ 21.ffl

.t.0\1.f.llCIHG CONTACT AHGLE : 1l0 . 0 ffg

P(HETllOltHtlt 111..11180 : 1]-01]1

PVIETllOflUU CCNST.un :

10 . 79 JL/ pr

RECEOIHG CONTACT .......,LE :

130 . 0

~

PEHETIKIMETU t.IElGHT :

68 . 917& 9

llEltCUllT SIJl:F ACE TVISI OM : 485 . 0 dyr!. / u

STE.II YOl.Ul'IE :

0 . 4120 ...

llUCUU OOISITY :

13 . UlS 9 / 1111..

!V.XlU H[AO PltESSUllf ; 4 . 6800 psi

s.utl'lf llElGKT :

PEHETllCMETU YOLUllE :

SAl\Plf•POf<-MQ llEIGHT : 112 . 2T'il0 9

] • 5&55

111L.

0 . 4029 9

LOW PllESSUllE :
llUCUll:Y 'ILLJHG PllESSUllE :

0.8&6] p1 i •

UST LOW PltESSUU "'°lllT : 25 . 7454 p1 i 1
HlGlt"IESSUltf :
AUTOflATl C

ltUH TYPE :

EOUILUlllATO

fQUILIBU.TlCN THIE :

10

Heondl

l/HltUS !OH DA TA SVflfl.UY
TOTAL ! KTl:USIOH YOLUl'lf •

TOTAL l'Olf AltU •

0 . 1736 lllL. / 9

lS . 762 ~-. /9

llfDIAH P'Oltf 01.IJIETEI ( YOLUl'lU •
l'lfOIAM l'Olf OUJIETEI ( .U:U l •

0 . 09JJ 11•
0.0361 J•

.\VU.AGE ~f OIAllETU ( 4V/A ) "

0 .0580 1•

lllJUC. OEHStTY •
""AAEHT (SKELETAL> OEMSITY •
l'OtlOSITY •
STEJll\'Ol:.ltEUSEO•
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0 . 9723 9f lll
1.5270 9 / .._
36 . ]] t

37%

(

Drug Load: 40.0 % wlw. Spheronization Time: 10.0 minutes. Run# 1

'°RESIZEll 'H20 V2.07

/ S.S

S.llt,LE Ol llECTOll'r/NUl'l8U:: 0ATA1

00 : ]9 : ]] 02124 / 97

~U

MfllATOll: ic.tan

H' 01 : S0 :09 r:R. 12,.4191
RE' 02 : lS :47 02124197

SAll,LE 10: lo0%2• 10.1nlt\JIK.f1

SUMlTTEll : !Catan lleflU

ADYIJICIHG CONTACT AICilf : 130 .0 4ltQ

'EHETl!OftETfll Ht.NU : 13--0241
'EHETJIONETfll COHSTAllT;

130.0 d.;

IUCEOlHG CONTACT AHGU :

10 . 1'9 iL / p'

'EHET"°"ETU 11El<>HT :

67 . 7971 g

llfllCUllY SUllfACE TEMSlOH : "85 . 0 dy"'c •

STE.II VOllllE :

0 . 4120 Ill..

11.UCUllY DEHSlTY :

1l . Sll5 g / W..

"4.lllllJfl HE.lO ,llESSUllE : 4 . 68QJ pi t
'fNE~ETU

VOlUflE:

l . 544] ml.

LOW"tESSUllE :
ltUCU IY llLLI HG PllUSUllE :

0 . M6J p1 i a

U.ST LOW "l:fSSUllE il'OUtT : 2' . 7454. p1 i a
HlCiHl"llESSUlf ;

l:UNTYl'E ;

AUTOP\ATI C

in.N 11£'0400 :
fQIJILllU. TIOH TlllE :

fQJILtlSUTU
10 sec:oncl1

TOTAL

JllT~StON

YOUME •

TOT.ll. l'OllE UU. •

0.]]9;? .i.t ;

2S . 045 tq-a / g

llEDUH l'OllE DUJIITTI (VCUJftE) •

0 . 068S JI•

ltE DI Al'I l'Ol:E 01.utETU OAE.O •

0.0452 JI•

AYEIUGE il'OllE OUJUTU ( 4V / 0

•

lllJlX nOISITY •
.t.1',UEJfT ( S«'.£L£T.ll) OVfSITY •

0.0542 11•
0 . &&61 9/ 9l.
1.Z661 ia / 91..

l'OAOSITY•

l0 . 051:

STt:ll 'IOll.ll'IE USEO •

]3 I
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Drug Load: 40.0 % w/w. Spheronization Time: 10.0 minutes. Run# 2

"°ll:ESllU 9320 V2 . 07
S.tJ!PLE OlAECTOltT / Nl.1"8.U : OAU.l

/ 61

05 : 18 : 4902. / 24197
OS :SS : S9 02. / 24 / 97

Of'ElATOll: : Ket*" ltti'tt•

LI'

SAllPLE tO : i.ou- 10.i"a!.lllZ
SU9111TTU : ICet.,,NetlU

•EP 05 : 56 :00 02./24/97

PEMIETAOftETElt MUNEI :

HP

tl~ll

PENUAOMETD COHSTAMT:

PEH£TIKl'l£TU llEI<iHT:
STEii YCUllE :

AO'OJICIHG COfllTACT A'!GLE : ll0 . 0 d"Q

10 . 79 •l/ pF
67 . 8911 Q
0 . 4120 9l..

l'IUlNJllHEAOPllfSSUIE : 4 . 6llOOp1i

PEHEUOl'IETU VOl.LlllE :

lEUOING CONTACT oUIGU : ll0.0 deg
llEJICUllY SIJIHACE TUISlOH : 485 . 0 dyn/u
llUCUIY OOSlTY:
SAJlll'LE l/UGHT :

1l . 5ll5g/ ..
O.t.0019

l . Saas ....

LOllPllESSIJIE :

llfRCUllY fllllMG "IESSU•E :

0 . 6190 p1 i 1

LAST LOW PftfSSUllE l'OINT : 25 . 6197 pa i l
HlGH PltfSSUllE :

NII TYPE :

AUTOf'IATIC

fQUILllUATlOH TlllE :

11) H«W'lds

INTltUStOH OAU. SUM..O:T

,.. •.,.

TOTAL INTlllJSlOH YOU#IE •

TOU.L l'Oi!E .U£A •
llEDIAH l'OllE OIAllETU (VOl.Uf!E) •

AED1AM

0 . 3462 -..19

26 . 27'0 M1-1/9
0 . 06J9 11•

OIAllETU OIU.) •

0 . 0453 111

AVUAGE l'OitE 01.METU (4V/ A) •

0 . 0527 11•

~E

DEHSITT •
A,,UfHT (SKELETAL.) OEICStTY •
'<>f!OstTY •
STEllYOUlllEUSEO•
llJL(
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0 . 9718 QI ._
1 . "644 ;I._
Il . 64 t
341

Drug Load: 40.0 % w/w, Spheronization Time: 10.0 minutes. Run # 3

~ESIZEi

9320 V2 . 07
I~

SMPLEOlllECTOltT I NUl't!IU : OAU.1
Of'EllATOfl:!Ceun~u

Ll'

OS : 15 :49 02/24/ 97

SMPLE IO ; l,Q%.2-10. ;111WN']

HI"

06 : 31 : 09 02.124197

SUBIUTTU : Ket an

llEI" 10 : 1ii! :20 02124 / 97

ll~U

.lOVMClHG COHTACT AHGL.f : 130 . 0 d.g
PEHETllOf!ETU COHSTAHT ;

l"UIETllOllETU llUIOHT :

10 . 79 11L/ p,

68 . 9310 !1

IECEOIMG CONTACT ANGLE :

130.0 d.g

llUCUIY SIJllfACE TEHSIOH : t.aS.O dyn / o:•

0 . 4120 111..
IV.XllUI HE.AO PRESSOllE ; 4 . 6800 p1 ;

llUC1JltY DENSITY :
SAMl't.E I/EIGHT :

l"EHETllOllETU 't'OLLME :

SAAl"U•l"Vt+ttg llEIGHT ; 111 . 11'0l5 g

3 . 544] Ill..

13 . 53]5 !1/9l
0.'0X> g

LOW PIESSUIE :
llEltCUllV flllif'IG PllESSlJltE :

0 . 6190 p1ie

UST LOW PltESSOltE l"OlNT : lS . 6197 ps i e
HIGH l"JIESSUltE:
IWlfrYPE :

AUTOl'l.ATIC

ltUHllETltOO :

EQUt:,.JllAATEO

EQUlllBAATIOfll TUtE :

10 1econd1

IHTRUSIOICOATASUl!MltY
TOTAL llilfltUSION YOlUflE •
TOTAL l'OflE AUA •
llED ! AM l'O•E OIAMETU ('IOLU!fl •

0 . 1414 .Ug
lS . 649 1<1-•/ g
0 . 0682 ,_

llEOIAH l'OltE OlA.ltETU UREA) •

0 . 0453 11•

AVE!WiE l'OIE 01.\lllETU (411/A) •

0.0532 118

9Ut.X OU4SITY •

Af',.UEIH (Sl(fLETAL) OfHSlT'J •
ST'E,.V'OLUftfU5fO•
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O.Ml5 gt.i..
1.2651 gt .._
30 . 161
lll

Drug Load: 40.0 % wlw. Spheronization Time: 20.0 minutes. Run# I

l"ORUIZEI 9320 V2.07
SAltPU OUECTOlt'r/NUMU : OAT.ll

/ fl]

°"U..UOlt : IC•tan ill«'IU
SAlll"LE 10 : "°12-.20mo inltl.N1
SUMITIU : Ket81'1 !Wit•

HI"

00:02 :0] 02/25197
00: 49 : 07 02 / 2j / 97

llEP 00: 49 :09 02. / l51'7

'EllETllOMTU NUMU: U~54
l"EMETllONETO ct*STAKT: 10.19 n,Jpl
'EllETllOflETtll llflGHT:
61 . 99\l:l g
STVI \IOl..Ultt: :
0 . 4120 ._

AOVAHCIHG CONTACT ANGLE : 130 . 0 cl..;
130 . 0 d"'i1

lECUIHG CONTACT ANGLE :

"EltCUltT SUllfACE TENSION : "5$ . 0

llEll:CUllY OUISITY :

lOlill"lltESSUllE ;

MEll:CUltY FILLING ,.ESME :

0 . 6073 ps i a

L..UT ~ l"ltfSSllllE l'OINT : 2S . 7l27 psb

HIGH "IESSUllE :
AUTOIUTIC

11:1.M NETltOO :

ECIUILIHATt:D
10 Heondl

EQIJILlllAATlOH TlME :

TOTAL JNTlt\JSIOH 'IOLUl'IE
TOTAl l'OllE .UU
llEDIAH l'OllE 01All£TEll: (YQ.J..91£)
llEDIAfll l'Ot!E OUl'IETEil (.lllfA)

•

0 . 3615 111../ g

•

21 . 265 ..:,-a/ g

•

o.osn ,,.

•

0 . 0453 ¥ •

AVOAGE l'OllE OIAllET£1t (4'U.l) •

0 . 0S12 11•

euu::

OEMSITY •

.UOl'.UENT ( SU:UTAL) OVtSIT'I' •

l'O'tOSlTY •
SfVIYOU.ll'IEUSEO•

230

0 . 866' g / lll.
, . 2614 g / 111.
31 . 32 :C
lSI

Jto/fl/c•

13 . Sns g/..

IUJ:llUt HEAD "ESSUIE : 4 . 61!CO ps i
l"EJrjfT.otlETElt \IOl.LME :
3 . 5541 .i.

Drug Load: 40.0 % wlw. Spheronization Time: 20.0 minutes Run # 2

l'OllESIZU 9320 V2 .07

'AGE

S.vlPLE Ol llE CTOC 'f/ HUll!IU : OAT.1.1

1

/ 64

00 :02 :03 02/25 / 97

O'EU.Tott : !Cetan llehU

01 :25 : 12 02/25 / 97
REP OZ : JJ : t.2 0212'5/97

S>JIPL£ 10 : i.o:t:2..Z0.1t11tl!M12
SUl!l\I TT Ell : Ko:un lleftt•

.OVAHCUIG CONTACT AllGU: : 130 . 0 d91jl

'EHIETltOftETElt COHst.u n :

10 . 79 /IL/ pf

IECEOUIG CCfllTAC:T AIGU :

130.0

~

PEMETIIOl'tETElt VUGHT :

68 . 4436 g

llUIC\ll'f SUUACIE TENSIOft : 485 . 0 tlyn / c•

STEii VOUME ;

0 . 4120 9'.

llEll:CUllY DEllSITY :

IWtl""'" HEAD ,llESSUllE : 4 . 6800 p1 i
'ENETllOl'IETU \IOLL.111£ :
J . 699'1 ._

SM'U llEIGHT:
SMM..E•'~

1].5]JS g/111.

0 . 4005 g
VUGHT : 112 . 6359 g

LOW 'l:ESSUllE:

0 . 6073 psi•
UST LOii ,llESSUU l'O l llT: 25 . 7l27 p1ie

llEltCUAT '1LLIH6 PlllESSUlllE :

HIGH PllESSUU :

AUTOfU.TIC

EClllLIWTt:D

NH llETHOO :
EQIJlLIWTIOH TUtE :

10

•e«ind•

I HTllUSICH D"TA Sl.IMAAT

TOTAL umtustON YOU.IP!£ •
TOTAL l'Ol:E AltE.& •

llEDUJI il'OAE OIJJIETEll CYOU#!El •
llEDIM l'04lE DIAl'IETEll '.tJtU.) •

AVEAAGE IJOlE 01.YIETU (4V/A) •

0. 3645 111./ g
29.09lfl aq-• / g
0 . 0574 ,_
0 . 0452 lf9

0 . 050'! p

llUl.l'. OOISITY •

0 . 86'5 g/ 9L

.t.P,,.llVIT CSKILETAU OVtSlTl' •

1 . 2621 g/ ._

l'OllOSlTl'•
STVt'tOLl"'£US£0 •

23 1

31.51 l
351

Drug Load: 40.0 % w / w, Spheronization Time: 20.0 minutes, Run# 3

~ESIZU

9320 VZ . 07

SAl"LE 0111E CTCM11' / Nl,"9U : 0ATA1

/ 65

O,Elt.UOll. : l(eten IMt'IU

L'

SAll,LE 10 : t.0%2-20a1nflUHl]

OJ : io] ; 43 02.f'ZS / 97
04 : 11! : 43 02. / lS / 97
U' 04 :1 5 : 49 OUZS/97

0

SU9'11TTElt ; l:•tWll'l<tf'tU

AOVAHClHG COHTACT .oc;U : 1l0 . 0 deg

'EllETllOfllETU COHSTAHT:

10.1'9 11L/pf

llECUUG COMTACT .t.llGU :

'EHETIOl'IETH I/EIGHT :

67.tl174 g

llEUUIT SUll,ACE TEHSIOfl :

STEtl 'IOLLlltE :

0 . 4120 ._

llEICUllY DENSI TY :

MlUILllt HUD 'llESSUltE : 4 . 6800 p.1

'EllETIOl'lffU 'IOLUltE :

].

S'-"'U 11£1GHT:

O. l.002 g

seas ....

LOW "l:ESSUll:E :
llflcutlY flllUG 'llESSUllE : 0 . 7903 p• i •
U.STLOW'llE5SUllEP'OIMT; 2' . 519'1ps i 1
HlGH 'llESSUAE :
llUH TYPE:
ltUN llETMOO :

AUTOMTIC
EOJIL181UT£D

EQIJlLlllU.TlOH TlllE ;

10 Heo:"ldl

TOTAL IHTltUSIOH VOi.Uit£ •

0 . ] 578 111.. / 9

fOT4L l'OIE UfA •

28 . lSI!

~-1/9

llEDUll PORE 01.tJIETElt (VOl..Ultf) •

0 .0580

1•

llEOlAH

~E

OlAllETEll ( .U:EA ) •

.I.VU.AGE l'OllE ldAltETEll (4V/.l) •

. . ,,uor

0.045] 11•
O. OS07 11•

9UlJC O!MSlTY •

0 . 97JS 9 191.

CSICEUTAL) 0£.ltSITY.

1 . 49399 / 111..

l'OIOSITY •

STEii YOt.l.ME USEO •

232

no .o deog
c.as .o cfyfo / c•

13 . 5]]5 9 / 91..

l4 .8J :
35 X

Appendix 3b

Determination of porosity parameters by mercury intrusion porosimetry. Pellets
formulated with different granulation water levels.

Granulation water level: 60 % w/w Run# l

"°llfSlZER 9120 V2 .07
n3

SAl!,U OIRECTOUll•.MU : OATA1

Ol"EIUiTOll: !C:tt«'I

~t•

Lt 06 : 21 : l0 OJ / 04 / '17
Kt 09 : 0 :04 03/04197
UP 09 : "3 : 05 Q] / 04 / 97

10U0.1n6Q: ~urlll.Ml1

SUBIUnU: htan fllettta

,EHET'°"ETU 1ueu: ll--OeS4
PEMUltOl'tHU COM STAAT :

.t.OVAHC1NG CONTACT NIGU : 1l0. 0
ltfCHIMG COlfTACT AHliU : 130. 0
llUC\ltT StMUCE TVISION : 485 .0
llUC\MT OEJISITY:
13 . SlJS
SANU WEHiHT:
0 . 4.024

10. 79 #Llpf

PEHETIKlflETU V£1GHT :
65 . 5228 'ii
STEii 't'CUMf :
0 . 4120 ._
l'IAlUUI HEAD PlUSURf : 4 . 68CC p•i
PEMETl!Of!fTU VOLL.It£ :

LOW "tESWRf :

1 • .0SO p1h

UST LOW PltESSUlE "'3JlllT : lS . 6.'41 p•i•

.WTOfl..TlC
fQUU.JUATU

IUM llfTHOO :
f<IUILtlliTJON Tl"E :

,... ..... ·

10

1ecord1

JMUUSIOM OATA SJ.M,U:T

TOTAL IHTllUSIOH YOltMf •

TOTAi. f"Ollf AIU. •

0.2643 Oll. / 9

24.&30 tq-e/ g

.ltfOIAM f"Ollf OlMETH (YCUJll(} •

0 . 0453 ,w

"EDIA.N l'OltE DlMETU (Al:E.l) •

0 .045) ,_

AVUAGE l'OltE DWlfTH (4V/A) •

0.0Q6 J1t1

MJC OatSlTY •

0.95Z7 9/ -.

A"UEKT CSK.ELETAL) 0£HSlTY •

1 . Z7ll g / ._

l'OflOSITY •

STD!

d<IQ
~I~

9 / 0ll.
'ii
SM,LE+'Vt+tl; WEIGHT : 111 . lOll.2 9

}.5541 11t.

l'IUCVlllT 'ILLIH& 'IESSUtl:f ;

deg

\IOU.If!(

USED•

234

2'.18 l

26 X

Granulation water level: 60 % w/w Run# 2

~ESUU

9l20 Vi!: . 07

m

S.Ul'lf OlltECTOll:Yll•.llBU: D.l.TA1

OfUATOI: : Kst.n Mf\U
SMl'lE 10 : 10X.ZO.i"6/J'Xw•t•rtuMl2

si.eunu :

(•un

01 : 09 :06 03 /05197
01 : 4S:44 03/05/"fl

Mhu

AEP' 01:45;"' CD/05197

llECEDING CONTACT AllGLf:

67.52S9 9

ltt:ltCUltY WltfACE TVISION: 415.0 dyn/c.

STV. 't'Ol.IAIE:

0.4120

a.

ltt:JICUllY DOISITY :

MXIIUI MEAD "l:ESSUll:E : 4 . 6«0 p• i
l'VltTllOl'IETU YOlt.11'1.E :

3.5541

ADVAHClNG CC»CTACT AHGLE : 130.0
130.0

~

POIETltOl'IETU Nl.'"8U : 1l--Oe54
10. 79 11Upf

l'OIETltOl'IETU WEIGHT:

l'ENETllOl'IETU CONSTAHT:

a.

1l . SSJi5

0 . 4007 Q

SUI"-! WEIGHT:

S.UrLE+l'EH+HQ WEIGHT: 110.6407 i

LOW Pll:ESSUll.E :

"UCUll:T' flUJHG "l:ESSUllE : 0 . 1'9M ~ i •
UST LOW PlESSUllE il'OUIT: 25 . 6147 p1 i •

HlliHP'lUSUIE:
AUTCN.TtC

EQJll.IMATU

lttM JllETMXI:

~

g/.._

fQIJllllAATIOM TI"E:

\Jaeconl1

TOTAL IJllTltUUCfo YCU.l!E •
TOTAL l'OltE AJIEl •

llf01AM l'OllE 01Alt£TU CYCU.l!E> •
llfDlA.K !'O«E OUllETU <AllEA) •

AVUAGE l'Oltf OlAllETEI (4V/l) •

0.2619

-..!;

24. 981 sq ..... /;
0.0467 ,.

0.ID81 119

0.()1.19 ,n

DENSITY •

0. 9Sl8 g/111..

...,.,...llEHT ( SIC!.LET.l.L) DEHSlTY •

, . 2ns ,,..

llUl.K

l'O'IOSITY •

24.98 X

STEJll 't'Oll.llE USED •

25 X

235

Granulation water level: 60 % w/w, Run # 3

l'OllESUU 9320 V2 .07
/ tlJ

SAA'U OlltfCTOl:Y/ lt..N.Elt : OAT.f.1

01 :09 : 06 Ql/05197

Of>ElATCMll : lt•tan ..tlta
SAAl"LE ID ; 1at20ll i n60XwterlUllJ
SUllfllTTElt : Ketan

HI"

..nt•

02:22:11 «1/05 /97

ltEI" 02 : 22 : 14 03/0S / 97

l"atETllOf!ETH HlNH : l3..Qll68

AOVAHCING C'OfllUCT AHIM..f :

l"fHETllOf!ETIEI CONSTMT :

IECEOIM& COHTACT NtCOLE :

l"OtETIICflETU llUGKT :
STE.II YOltME :

10. 79 11L/pf

no.a d<IQ
no .a ...

61. 92S9 g

MEltCUltY SUl:fACE TDISIOH : 485 . 0 d'fn / c.

0.4120 .._

ltf:ll:CUllY OOISITY :

1l . 5D5 g / li..

IU.XUUI HW l'ltlESSU1tE: 4 . 68((1 p• i

SNIL'U I/EIGHT:

PfMETIOMETU YOU.llE :

WU'U+l"Elf++t; 11£1GKT ; 11l.1'S79 g

" ].6991 ._

0.4003 'ii

l.OW l"l:ESSIJtf :
ltEllCUIY flUllG l'llESSUllE :

O: 7988

~11

LAST LOW l"ltESSUltE l'OUfT : 25 . 6147 i>ai•
HliH MIESSUlE :

ltUJllTYPE :
lltUM .llEn«:>O :

AUTOMTtC

EQJILIUATlOH TDIE :

10

1.eondl

IMTltUSlON OATA SlfftAllY

TOTAl. l.llTll\ISIOf4 'tOt..tM£ •
TOTAL il'OIE .UU •

0.2665 lllfg
lS.547 tq-ti/ g

MEOLUI l"OlE OIMETEJI : 'i'OllMU •

0.0476 ,,_

.llEDlM l'OllE DIAltETElt ( .lllf.A).

o.mro.,.

AVERAGf: P'OlE DINIETU C4V/A) •

0.0417 ,,.

HMSJTY •

0 . 9622 g/ lll.

Al"PAllEMT { SICEUTA.Ll DOfSITY •

l.2941 g/ lll.

llUU(

P'OllOSlTY •

2S.64 X

STOI VOUME USED •

26 X
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Granulation water level: 65 % wlw. Run# I

l"OltESIIU 9120 Y2 . 07

"'"'
/15

SMPU OUECTOIYl lllNEI : OATAl
ort:ltATOlll : ic.un

v

"-"'t•

SMl'U 1D : UJX20ll t n6SI-terlt\N1
sa..llTID : ICU., "-"t•

'lM:Till:lMTfl
'fNETICflfffl
PU9ETIIOM:Ttl
STDI WOl.Llltf:
MIUUI HEAD
l'fMTll<ltETEI

lEI' 04:05 : 31 03/04197

IU'8U : 1l-<JIS68
CONST Alff :

llUSHT:

Oll : 1l :56 03/03/97
°' :04 : 16 03/04197

ADYAHCJNli COKT.lCT AIQ.f : 130. 0 4eQ

10 . 79 •L./pf
67 . 9196 9

0 . 4120 ....
l'IESSUllE : 4 . 6800 ps i
YCIU.9IE :
l . 6991 Ill.

ltfC(OINli CDWTACT AIGU. :

1l . 5DS9/._
SNll'U llUGHT:
0 ,""10 g
S.U"Lf+I'~ Vf:tGHT: 112 . 0096 9

llfltCUllYDOIUn:

LOW l'tESSllltE :
llEla.T 'ILL.IN& ,.ESSUll:E : 0 . 1065 P• I•
UST LOW " IESSUU l'OINT : lS . 2'1 19 p. i e
HlGHl'IESSUIE:

lt\JllT'n'E :
ltl.ltJIEll«)O:

EQIJlllUATED

EQIJILIMATIC. flllf :

10 1ecorda

INTltUSIOlll DATA Sl.MMIT

TOTAL lMTIIUSJart YOU.ME •
TOTAL P'OllE .U:O. •
lff:OIAllll"OltEDlAAETf:l ( 'f'CIU.9!( ) •

iq;ou.x

l"OltE

ownu u.u.u •

.lYEIU6E l'Oltf OJNIETU (4Y / A) •

auuc

:>SISHY •

o.1m-.1g
34.803 1q-.J9

o.or.s1 1119
o.cnn ,.
0.0452 ...
0 . 8536 ,, ..
1. 2.&U ,,..

101tOS1n •

sm

130. 0 deQ

MICUlY SUlfACf TtlfSIOll ; '-IS . 0 tiyfttlc.

VOLLl'IE USH .

2 37

D . S4 X

,. '

Granulation water level: 65 % w/w Run# 2

l'OllESUU 9320 V2 .07
Ulll'LEDIJIE CTOllT/~l :

OATA1 ,

n6

OfEltATOll : Kott., Aef'tt•

SIJ"lf ID: 10X20ili "65XWl!terltl.N2
SUlli'llTTEI : K•t_,

HP

"""'t•

eu:

'DETl!OflETEt ....

1]-01]1

l'VIETltOPlffil COflSTAMT:

10.7'9 #l/pf

l'EHETllOflETU llEIGHT :

6& . 1962 g

STEii VOt..lME :

0.4120

a.

llAXUU• HEAD l'lfSSUll:E : 4 . 6l!IXI psi
PDIETJIOftfTU YOU.II.IE :

] . SISS ._

09 : 1J : 56 03/03197
04:51 : 31 aJ / 04197

JIEI' 04 : 51:32 03 104 / 97

ADVAltCING COHTACT AHGLE : 130.0 ~
IEC'EOlHG CONTACT AIGLE : 130.0 d4lg
MllCUllY SIJllFACE TENSION : 4M . O flyn / c•
MICURY DOISITY :
13 . S]JS <;1 / a.
SAM'1.E WEIGHT :
0 . 4015 g
SM'1.E+l'e.++IQ WEIGHT: 1l2 . 0Z19 g

l.DWl'llESSLlllf :

llUC\llY 11LLING l'ltfSSUllE :

0 .1"'165 p•l.t

UST LOW l'llESSl.UIE l'OINT : Z5 . 2189 P•il
IUGl'i l'IESSIJltE :
~TYPE :

EilJ I LISAATEO

--

EClJILIBllAT JOH TJM:

1'JaKCll'lda

/

UlntJSICll DATA SIM'UT
TOTAL UfTllUS l OH YOU.11.E •

TOTAi. l'Oll:E AlEA •

0 . J.!SO lllL/g

32 . 234 .ci-/ ;

/If.DIA.IC l'Ol:E OLUIETU ( \IOl.1.11£) •

0 . 0481 ,_

llEOIA.11 l"OltE 0 1.tl'IETU ( AIEA ) •

0 . rnit9 ,_

AVERAGE l'Ol:E OLUIITTI ( 4V/ A) •
19UUC D£>fSlTY •
A,,AIOIT CSICil.ETAl) DEXSITY •

f'OIOSlTY •
STIR vrou.N: USED •
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0.0473 111
0. 9465 9/ a.
1 . 4893 Q/ lll.

36 . 44 l:
38 l'

Granulation water level: 65 % w/w Run # 3

POAESIZElt 9320 V2 . 07

'4GE

06 :21 : 30 aJ/Olo/97
07 :01 :01 aJ/04/'77

SAll'LE ID: 10120lin6SXwiur....wl
SIJlllUTIU : Ket., lhtltl

ll:EI' 07 : 01 : 02 aJ/04/V1

l'OIET~I 11..1•0 : 13--0241
l'EKETil<l'ETU CCllSTAHT: 10 . 79 11Upf

l'MTACMTD llUGHT :
68 . 9<&4 9
STEM VOUME :
0.4120 . .
llAJllUI MUO UESME : 4 . 61DJ p1 1
l'VtETIIOMTtl '+'Ol.l.N :

3.544.l . .

.lOV,tJKl,.,; CCWTACT ANGU : 130 .0 O.g

no.a o.q

lECEDIHG COffTACT IJCiU :

llEltCUltY SUllfACE TOISIC. : 415 . 0

"'ICUl:T OOISITY:

s.vtl'U WEIGHT :
0. 4003 9
SAIU'U•l'Ot+ffl;l llUGHT : 110. 1945 9

UJ350 p• i•

LAST LOii nESsuttE l'OllH : 21 . 6.341 peh

AUTCMTlC

ltt.llltETMOO :
ECUillUAfJCN TUtE :

fl'fn/ea

1l . 5DS91-..

LOW l>USSUll£:

IH;1cun '1U.1Mi l'ltESSUH :

1

m

SAll'lf DllECTOCT / MNEl: DAU.1
Cf'H.lTOlt: JAt.,. ....,,.

fQJJLIUAftO
10 second•

TOTAL. IMTRUSICll 'l'Ol..Ul'tE
TOTAl ~E .U:U.
PIEDIAH l'OIE DIN!t:TU (VOLUflE)
ltt:DJ.AM l'Ollf DlAllETH U.AEA)
AVEIUiGE l'Otf DWt(TU (4V/A)

•
•
•

•

•

IUlJc: DOISITT •
Ul'.U:EMT (SKf:UTAl) OEHSITY •

O. J&6J 91..19
34 . 682 e,q.-e/ 9
0.0453 _.
0 . 0372 ,_

0 . °"'6 ,.

0 . 8464 9/ L
1 . 2175 9 / ._
3.2.691

STEii YOU.l'!E USED •

239

38 1

Granulation water level: 70 % w/w, Run # I

Ull".f ' l O: CTOIT f ......eEl :
Ol'E U TCMI ; ll•t.,

..,,ti

03 :09 : 15 1l/QV96
04 : 41 : 16 12102 196

UJVt.£ UI : 10U0.•n.2..it!M1
~ lrT U ; ll•t., .nu

•t:, 04 : 41 : 17 12/02/ 96

'0•£Tll011UU•ll.••U : 13-0111
'01(fltO!t: Ttl CC* ST.Ult : 10 . 1'9 #1./ pf
llf.lGMT :
61 . 6Jl8 1
ST Eii VQ.LIU :
0 . ,120 Ill..
1'.UlllUltMUO ••USUlt: : 4 . 6a1Xip• 1
't:HUllOIUU VOl.IME :
l . 6417 ._

AO'WAllCllG CORT.I. CT .uGU : 130. 0

O:CHUG tcllTlCT .wil..f :

'fNf T~TU

s.t.#UWl l lOMT:

O. liQl59

lll lGMT : l11 . 1144 9

LOW ,.fSSUtlf :

llUCUIT 'IU.1111& 'ltUSUl( :
L.AST lOW•ffSSIJlll'OUtT :

0 . 6790 ps 1•
2' . ~p• 1 •

"IGM ,.USUlf :
It.MM! :

M.l'fQU.fl C

~Mn«» :

IGUlLIMATID

fQUlllMAflOll TI M :

10 aec.ond•

TOTAl IKTIIUS1C*~•
TOTAL. JOltt: .UU •
"'Ol.&ill IOI( OUMTH C~J •
IW:OlA.11 ll'Oll:( OL&Mnl ( .UU. l •

4VEIMK li'Oll:f D!Mfl'tl 14V/AJ
au Ot>ISIT'r
A"HVIT ( SK!lfTAl) OOISITY
l'OIOSITY

sm

..o.J.N

•
•
•
•

uso •

240

~/ca

13 . 541] gl -.

lttl(IJIT HflSJTY;
SAMt.f•"~

~

130.0 deo;

llUCUIT SOllUC! TOSIC* : ""' .0

0 ."°"'-.19
11 . Ml ~/ 9
0.0il.a'I , .
0 . 0426 ,_

0.°"24
O. UAO
1 . 2664
34 . 14

'°

,.
91.._
9 / 111.
l
i

Granulation water level: 70 % w/w, Run# 2

.... '

"OIUIUI 9120 '12 . 0'7
/~

l.UW Lf OllfCTOIY /ll,,l•U : OAU.1

QllU.Uot : tetM Wlt1

06 : 49 : 22 1i2/ QZ/96

SAll'LI to: 1 C:U0. 1 ~
W.ITTll : tnmn ..t\U

~f'

a1' : JS : 44 12/Cl/ '6
09 : 19 : 21 12/Ql/ 96

'EMlr.:lMTtl lll.llRI : 1]...Q1]1

•O'+'.ut<:U.. CClllU. CT .UCLf : 1](1 . 0 dilllJ

'fMfTllClllTll (QlllSTUIT : 10 . 1'9 •L/ pl
'OllT...-Tll llfllHT :
67 . 6SSO t
UP Y'CUlll :
0 . 4120 ._

llCHIMi CC-TACT Allil.I :
0.,
1tUCUIT 1Ul'o\Cl l'VISlCM : 4e . O ~lc.
..rtC\.lllY OQl1tn :
1] . S41] 9/ . .

IU.Uiut MUI 'llU"-'11 : 4. 6im0 1M 1
'fJIET..-rEI 'l'OIJ,lll :
J . 6417 ._

UMU '1(18'1' :

no.o

SAMU•'~

0 . liO'IO 9
Wl lGHT : 110. M76 'ii

UM "1S3llll :

.._tc\WI'

'ILlt• fl'US11Af : 0 . ml p.1 \1
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Appendix 3c

Determination of porosity parameters by mercury intrusion porosimetry. Nifedipine and
nifedipine :pluronic® F-68 (!: l) solid dispersion pellets after different dissolution time
intervals.
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Nifedipine pellets, dissolution time : 0 hours
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SA/'1PLE OIRE CTOR Y/NU"BER : lh\TA1

1

/ 81

OPERATOR : Ke tan /1ehta

LP

07 : 42 : 00 04 / 06 / 97

SAMPLE IO: 20Y.nlfedipine beads 2u Ohours

HP

08 : 17 : 40 04 / 06 / 97

SUB/1ITIER : Ketan l"lehta

REP 08:17 : 41 04 / 06 / 97

PENETR°"ETER NUHBER : 13-()868
PENETROl!ETER COHSTAHT :

ADVANCING CONTACT ANGLE: 130 . 0 deg

10, 79 pl/ pf

130 . 0 deg

RECEDING CONTACT ANGLE:

PENETROf1ETER WEIGHT:

68 . 1624 g

11ERCURY SURFACE TENSION : 485 . 0 dyn / c•

STE" VOLU11E :

0 . 4120 •L

11ERCURY DENSITY :

"AXI"U/1 HEAD PRESSURE: 4 , 6800 psi
PENETRO•ETER VOLU•E :

3 . 6991

13 . 5335 g/ •L
0 . 3010 g

SAllPLE WEIGHT :

•L

SAllPLE+PEN+Hg WEIGHT : 114.2917

l°" PRESSURE :

11ERCURY FILLING PRESSURE:

0.7450 psia

LAST LO\I PRESSURE POINT: 25 . 4604

psia

HIGH PRESSURE:
RUN TYPE:

AUTOf!ATIC

RUN 11ETHOO :

EQUILIBRATED

EQUILIBRATION Tl"E:

10 seconds

INTRUSION DATA SU"AAAY
TOTAL INTRUSION VOLUME

=

TOTAL PORE AREA

=

11EOIAN PORE DIA"ETER : voLU/1E) =

0.2815 oL / g
27. 425 sq-o / g

AVERAGE PORE OIA"ETER (4V/A)

=
=

BULK DENSITY

=

0 . 0480 '"'
0.0330 µ•
0 . 0411 11•
0. 962.2 g/ oL

APPARENT (SKELETAL) DENSITY .:

1 . 3198 g/ oL

KEDIAN PORE OIA"ETER

~ AREA)

POROSITY

=

STE/'1 YOLU/'1E USED .:

244

27 . 09

x

21 X tttt

g

(

Nifedip ine pellets, disso lution time: 2. 0 hours
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SAMPLE DIRE CTORY/ NUMBE R: l:fATA1
OPERATOR: le.et an Mehta

SAMPLE ID :

201. n lt ~ i pine b ead's2~hr ~

SUBl"IITTER : Ketan Mehta

LP

00 : 13 : 47 04 / 07 / 97

HP

00 : 48 : 22 04 / 07 /97

REP 00 : 48 : 23 04 / 07/ 97

PENETRottETER NUMBER : 13-o868
PENETRot'IETER CONSTANT :

1

/ 83

ADVANCING CONTACT ANGLE: 130 . 0 deg

10 . 79 µL/pF

no .a deg

RECEDING CONTACT ANGLE :

PENETRottETER UE I GHT :

67 . 9982 g

MERCURY SURFACE TENSION: 485 . 0 dyn / c11

ST EM VOLUME :

0 . 4120 •L

f'\ERCURY DENSITY:

13.5335 g / 11L

11AX I /1Uf'\ HEAD PRES SURE : 4. 6800 ps i

SA•PLE WEIGHT :

PENETRO!'tETER VOLU11E :

SAP1PLE+PEN+Hg UEIGHT : 113 . 3140 g

L®

3 . 6991 ml

0 . 3016 g

PRESSURE :
MERCU RY F I LLI NG PRESSURE :

0 . 6052

psia

LAS T LO\I PRESSURE POINT : 2 5 . 5137 ps i a

HIGH PRE SSURE :
RUN TYP E :

AUTOMATIC

RUN ME THOD:

EQU! LI BRATED

EOU!LIBRAT!ON Tl •E :

10

second~

INTRUSION DA TA SUl1P1ARY
TOTAL INTRUSION YOLUPiE =
TOTAL PORE AREA=

0 . 4650 11L/g
27 . 813

sq-• / g

P1EDUN PORE DUP1ETER ( VOLUP1E ) =

0 . 0814 I'•

P1EDIAN PORE DIAMETER ( AREA ) =

0 . 0318 I'•

AVERAGE PORE OIAP1ETER ( 4Y / A) =

0 . 0669 I'•

BULK DENSITY

=

APPARENT ( SKELETAL) DENSITY =

0 . 8086 g / ol
1 . 2960 g / • l

POROSITY=

37 . 61 X

STEK VOLL KE USED =

34 X
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Nifedipine pellets. dissolution time: 4.0 hours
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SAMPLE DIRECTORY/NUP18ER: DATA1

1

/ 85

OP ERATOR: Ketan caehta

LP

05 :42 :1 6 04/07/97

SAMPLE ID: 207.nifedipine beads 2M , 4 hours

HP

06:18:05 04 / 07/ 97

SUBfHTTER: Ketan 11ehta

REP 06 : 18 : 06 04 / 07/97

PENE TROKETER NU118ER: 13-0868

PENETR°"ETER CONSTANT :

ADVANCING CONTACT ANGLE : 130.0 deg

10 . 79 ,uL/pF

RECEDING CONTACT ANGLE :

130.0 deg

PENETROf1ETER WEIGHT:

68 . 1666 g

MERCURY SURFACE TENSION: 485.0 dyn/ca

STEl't VOLUf1E:

0 . 4120 •L

MERCURY DENSITY:

13.5335 g/oL
0 . 3017 g

11AXIl'1U/1 HEAD PRESSURE : 4.6800 psi

SAP'llPLE !JEIGHT:

PENETROf1ETER VOLUME :

SAMPLE+PEll+Hg VEIGHT: 113 .4587 g

3.6991 11L

LQIJ PRESSURE:
MERCURY FILLING PRESSURE:

0.8105 psia

LAST Lexi PRESSURE POINT: 28 .~ 694 psia

HIGH PRESSURE :
RUN TYP E :

AUTOMATIC

RUN METHOD :

EQUILIBRATED

EQUILIBRATION Til'IE :

10 seconds

INTRUSION DATA SUP11'tARY

TOTAL INTRUSION VOLUf1E

=

TOTAL PORE AREA

=

MEDIAN PORE OIAl1ETER (VOLUl'tE )

26. 559 sq-•/g
0. 1530 ••

MEDIAN PORE DIAMETER (AREA) =
AVERAGE PORE DIAMETER ( 4V/Al =
BULK DENS 1TY =
APPARENT ( SKELETAL) DENSITY

0. 4904 oL/g

=

0 . 0305
0 .0739

jf•

0 . 8051 g/oL
1.3303 g / oL

PO'tOSITY =

39 . 48

STE" VOLU"E USED =

36
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Nifedipine pellets. dissolution time : 6.0 hours
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SAMPLE OIRECTORY/ NUl'IBER : DATA1

OPERATOR: Ket an • eh ta

2u,

SAMPLE ID: 20Xnifedipine beads

6 hrs

SUBMITTER: Ketan f1chta

04 : 37:01 04/08/97
05:12:02 04/08/97

ADVANCING COllTACT ANGLE : 130 .0 deg

10. 79 11Llpf
67. 9340

STEM VOLUME:

0.4120 ML

!1AXll'tUt1 HEAD PRESSURE : 4.6800

RECEDING COllTACT ANGLE:

g

PENETROttETER \IEIGHT:

PENETROf1ETER VOLU"'E:

LP
HP

REP 05:12:02 04/ 08/97

PENETROf'IETER NUMBER : 13-Q868

PENETROf'IETER CONSTANT:

1

/ 87

130 .0 deg

MERCURY SURFACE TENSION: 485 .0 dyn /cM
"ERCURY DENSITY :

ps i

13.5335 g /•L

SA"PLE WEIGHT :

0 . 2671 g

SMPLE+PEN+Hg WEIGHT: 113.6380 g

3 . 6991 •L

LOW PRESSURE:
MERCURY FILLING PRESSURE:

0.5458

psia

LAST LOW PRESSURE POINT : 28.4n1 psia

HIGH PRESSURE:
RUN TYPE:

AUTOf'IATIC

RUN METHOD:

EQUILIBRATED

EQUILIBRATION Til'IE:

10 seconds

INTRUSION DATA SUHMRY
TOTAL INTRUSION VOLUf1E
TOTAL PORE AREA

!1EDIAN PORE OIA11ETER (VOLUKE)

=

0. 5038

aL/g
sq-•/g

=

25. 529

=

0 .4056 JI•

"EOIAH PORE DIAMETER (AREA) ;:

0.0296 Jl•

AVERAGE PORE DIA"ETER (4V/A)

.=:

0.0789 Jl•

BULK DENSITY

=

0. 7816 g / •L

APPARENT (SKELETAL) DENSITY
POROSITY
STE" VOLU"E USED
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=
=
=

1 . 2893 g / •L
39 . 38 X
33 X

Nifedipine pellets. dissolution time : 8.0 hours
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SA!1PLE OIRECTORY/NU11BER: DATA1

1

/89

OPERATOR: l<etan 11ehta

LP

00:04 : 47 04 109197

SMtPLE IO : 20Xnifec:hpine beads, 2.u , Bhours

HP

00 : 39 : 37 04 / 09 197

SUBIHTTER: Ketan Mehta

REP 00:39:37 04 / 09 197

PENETR011ETER NU118ER: 13-()868

ADVANCING CONTACT ANGLE: 130.0 deg

PENETROPtETER CONSTANT:

RECEDING CONTACT ANGLE :

10 . 79 JJL/pf

130.0 deg

PENETROMETER WEIGHT:

68 . 2047 g

11ERCUAY SURFACE TENSION : 485.0 dyn /ca

STEl1 VOLU11E:

0 . 4120 •L

11ERCURY DENSITY:

13 . 5335 g / aL

0.2549 g

f'tAXIl1U11 HEAD PRESSURE: 4.6800 psi

SA11PLE WEIGHT:

PENETROl1ETER VOLU"E:

SA"PLE+PEN+Hg OEIGHT : 114 . 1119 g

3.6991 oL

LOii PRESSURE:
MERCURY FILLING PRESSURE:

0.6518 psia

LAST LOY PRESSURE POINT: 28 . 4637 psia

HIGH PRESSURE:
RUN TYPE:

A.UTOKATIC

RUN METHOD :

EQO I LIBRA TEO

EQUILIBRATION TI•E:

1J seconds

INTRUSION DATA SUl1KARY
TOTAL lHTRUSIOf- VOLU11E =

TOTAL PORE AREA

=

0.4950 11L/9

26.074 sq-a/g

MEDIAN PORE DIA11ETER CVOLUl'tE) ""

0.5036 1111

"EDIAN PORE DIA"ETER (AREA) =
AVERAGE PORE DIA"ETER C4V/A) =
BUU< DENSITY =
APPARENT (SKELETAL) DENSITY

0.0290 11•

=

POROSITY •

248

0.0759 11•
0 . 7823 g/ oL

1 . 2768 g/•L
38 . 73 X

Nifedipine:Pluronic® F-68 solid dispersion pellets. disso lution time: 0 hours
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SAMPLE OIRECTORY / NUP1BER: OATA1
OPERATOR: Ketan P1ehta

LP

07:42:00 04 / 06 /97

SAMPLE IO : 1 :1 NFD SD Ohours

HP

08 : 52:13 04 / 06 / 97

SUBMITTER : Ketan l'lehta

REP 08 : 52 : 14 04 / 06 /97

PEHETROf'1ETER NUMBER: 13-Q854
PEHETROf'IETER CONSTANT:

ADVANCING CONTACT ANGLE: 130.0 deg

10 . 79 µL/pr

RECEDING CONTACT ANGLE :

130 . 0 de<J

PEHETROl'IETER WEIGHT:

68 . 3914 g

MERCURY SURFACE TENSION: 485 .0 dyn/ea

STEM VOLUME:

0.4120 •L

MERCURY DENSITY:

HAXIP1UP1 HEAD PRESSURE: 4.6800

PENETROPtETER VOLUME :

13.5335 g / oL

ps i

0.3004 g
SAltPLE+PEH+Hg WEIGHT : 112 . 9926 g

3. 5541 •l

LO\I PRESSURE :

MERCURY FILLING PRESSURE:

0. 7450 psi a

LAST LOW PRESSURE POINT: 25 . 4604 psia

HIGH PRESSURE :

......... ·

1

/ 82

RUN TYPE:

AUTOl'IATIC

RUN METHOD:

EQUILIBRATED

EQUILIBRATION TH•E:

10 seconds

INTRUS IOH DAU SUMMARY

TOTAL INTRUSION WOLU11E

=

TOTAL PORE AREA

=

18 . 159

11EOIAN PORE DIMETER (VOLUME)

=
=

0.0518 11•
0.0164 11•

11EDIAH PORE OIAMTE11 (AREA)

0.1636 •Llg

sq-•/ g

AVERAGE PORE DIAMETER (4V/A) =

0 .0360 11• '

=

1.0702 g/oL

BULK DENS I TY

POROSITY

=
=

STEM VOLUME USED

=

APPARENT (SKELETAL) DENSITY

249

1.2974 g / oL
17 . 51

x

12% tttt

Nifedipine:Pluronic® F-68 solid dispersion pellets. dissolution time : 2.0 hours
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SAMPLE O!RECTORY / HUP18ER: IMTA1

1

/ 84

OPERATOR : Ketan P1eht:a

LP

00:13 : 47 04/07/97

SAP1PLE IO : 1 :1Hifedipine SO , . 2- , 2 hrs

HP

02 : 16 : 35 04/07/97

SUBMITTER : Ketan P1ehta

REP 02 : 16 : 36 04 / 07/ 97

ADVANCING CONTACT ANGLE : 130 . 0 deg

PEHETROf'1ETER NUP1BER : 13-Q854
PEHETR°"ETER CONSTANT :

RECEDING CONTACT ANGLE :

10 . 79 pL/ pF

130 .0 deg

PENETROltETER OEIGHT :

68 . 3229 g

MERCURY SURFACE TENSION: 485.0 dyn/c•

STEl'I VOLUME :

0 .4120 •L

NERCURY DENSITY :

13.5335 g / oL

"A.Xll1Uf1 HEAD PRESSURE : 4 . 680C'I psi

SAP1PLE WEIGHT :

PENETROl1ETER VOLUNE :

SAN PLE+PEN+H<J OEIGHT : 112. 7089 g

3.5541 oL

0 . 2612 g

LOW PRESSURE :

P1ERCURY FILLING PRESSURE :

0 .6052 psia

LAST LOU PRESSURE POINT: 25.5137 ps i a

HIGH PRESSURE :
RUH TYPE:

AUTOf'IATIC

RUN P1ETHOO:

EQUIUSRATEO

EQUILIBRATION

TH~E :

10 seconds

INTRUSION DATA SUP1P1ARY

TOTAL INTRUSION VOLUME

=

TOTAL PO"C: AREA =
l'IEO IAN PORE 0 I.METER (VOLUME)

=

0 .3527 •L/g

12 . 105 sq-•/ g
11 .4396 JI•

NEDIAN PORE DIAMETER ( AREA) =

0.0109 po

AVERAGE PORE DI.METER (4V/A) "'

0 . 1166 JI•

BULX ~<NSITY •

APPARENT (SKELETAL ) DENSITY

=

POROSITY =
STHI VOUJftE USED =

250

0 . 8894 g / oL
1 .2960 g/oL
31 . 37 x

22 Xtttt

Nifedipine:Pluronic® F-68 solid dispersion pellets, dissolution time: 4.0 hours
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SAMPLE OIRECTORY/ NU"BER : QATA1

1

/ 86

OPERATOR : Ketan "eh ta

LP

05:42:16 Ol.107197

SA/"IPLE IO: 1 :1 nif edipine beads , 2•, 4 hours

HP

22 :52:28 Ol.107197

SUBMITTER: Ket en eehta

REP 22 : 52 : 29 Ol. 107197

PENETRO/"IETER NU118ER : 13-0854
PENETROIOETER CONSTANT:

ADVANCING CONTACT ANGLE : 130 . 0 deg

10. 79 •L/pF

RECEDING CONTACT ANGLE:

130 . 0 deg

PENETROPtETER WEIGHT :

68.4334 g

/"IERCURY SURFACE TENSION : 485.0 dyn/c•

STE/"I VOLU/"IE:

0 .4120 •L

•ERCURY DENSITY:

/"IAXIl'IU" HEAD PRESSURE : 4 . 68CX)
PENETR°"ETER VOLU/"IE:

psi

3. 5541 el

13. 5335 g / ol

SA•PLE WEIGHT:

0 . 1880 g

SAltPLE+PEN+Hg WEIGHT: 113.5487 g

LOii PRESSURE:
MERCURY FILLING PRESSURE:

0 . 8105 ps i a

LAST LOU PRESSURE POINT: 28 . 5694 psia

HIGH PRESSURE:
RUN TYPE:

AUTCftATIC

RUH /"IETHOO :

EQUILIBRATED

EQUILIBRATION TI ME :

10 seconds

IHTRUS IOH DATA SUl1MRY
TOTAL INTRUSION VOLU/"IE =
TOTAL PORE AREA

=

MEDIAN PORE DIAMETER (VOLUME) =

11EOIAN PORE DIAptEffR CA.REA)

2

AVERAGE PORE DI.METER C4V/A) ,.
BULK DENSITY =
APPARENT (SKELETAL) ~r::NSITY ::1
POROSITY ..
STEpt YOlUptE USED •

25 1

0 . 4689 oL/g
15. 734 sq-o/g
12.2373 11•
0 . 0112 ••

0 . 1192 11•
0 . 8021 g/ •L
1 . 2856 g/ oL
37 . 61

x

21 Xtttt

Nifedipine:Pluronic® F-68 solid dispersion pellets, disso lution time: 6.0 hours
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SA"PLE 01RECTORY/HU'18ER: DATA1

/88

OPERATOR: ketan ffhta

LP

04:37 : 01 04 / 08 / 97

SA'1PLE ID: 1:1nifedipine SO , _2M, 6 h:-s
SUBIHTIER: Ketan Mehta

HP

06 :05:40 04 / 08 / 97

PENETR°"ETER CONSTANT:

REP 06 :05:40 04 / 08 / 97

ADVANCING COHTACT ANGLE : 130.0 deg

PENETROftETER NU"BER: 13-()241

130. 0 deg

RECEDING COHTACT ANGLE:

10 . 79 µL / pF

PENETROllETER WEIGHT :

69 . 0044 g

"ERCURY SURFACE TENSION : 485 . 0 dyn /c •

STE" VOLUME:

0 . 4120 •L
ps i

"ERCURY DENSITY :

MA.XU~U" HEAD PRESSURE: 4.6800

SA,.PLE WEIGHT:

PEHETROllETER VOLU•E:

3. 5443 oL

SA!IPLE+PEH+Hg WEIGHT: 114 . 3570 g

13 . 5335 g / •l
0 . 1489 g

LOW PRESSURE :

"ERCURY FILLING PRESSURE :

0 . 5458 psia

LAST L°" PRESSURE POINT : 28.4"/31 ps i a

_.... ·

1

HIGH PRESSURE :
RUN TYPE :

AUTOf'IATIC

RUN ftETHOO:
EQUILIBRATION

EQIJIL!BRATED
TU~E :

10 seconds

INTRUSION DATA SUMMARY
TOTAL INTRUS!OH VOLU•E

=

TOTAL PORE AREA =
•ED!AN PORE DIA!IETER CVOLU•E>

=

•EDIAN PORE DIA•ETER ( AREA) =
AVERAGE PORE DIA!IETER (4V/A) =

BULK DENSITY
APPARENT (SKELETAL) DENSITY

=
=

POROSITY =
STE• VOLU•E USED

252

=

0. 5703 ol/g

18. 161 sq-•/g
13 . 7318 ••
0 . 0118 ••
0 . 1256 ••

0 . 7293 g/oL
1 . 2487 g / oL
41 . 59 %
21 Xtttt

(

Nifedipine:Pluronic® F-68 solid dispersion pellets, dissolution time : 8.0 hours
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SAMPLE OIRECTORY / NUMBER: ~TA.1

/90

OPERATOR: Ketan ltehta
SAMPLE 10: 1 : 1 niff:'dipine SO~

2•,

8 hours

SUBl1ITTER: Ketan 11ehta

LP

00 : 04 : 47 04 / 09 197

HP

01:13:41 04/ 09/ 97

REP 01:13:42 04 / 09197

ADVANCING CONTACT ANGLE : 130 . 0 deg

PENETR°"ETER NUMBER: 13-Q241

PENETRO•ETER CONSTANT :

1

10 . 79 pl/ pf

RECEDING CONTACT ANGLE:

130 . 0 deg

PENETR°"ETER WEIGHT:

68 . 3024 g

11ERCURY SURFACE TENSION : 485 .0 dyn /c11

STE/'t VOLU11E:

0 . 4120 11L

•ERCU RY DENSITY:

13 . 5335 9 / ol
0.0753 g

11AXU'IUl1 HEAD PRESSURE: 4.6800 psi

SAl'!PLE WEIGHT:

PENETROftETER VOLUl'IE :

SAP1PLE+PEN+Hg WEIGHT: 114.8735

3. 5443 11L

LOU PRESSURE :

11ERCURY FILLING PRESSURE:

0 . 6518 psia

LAST LOU PRESSURE POINT: 28.4637 ps i a

HIGH PRESSURE :
RUN TYPE :

AUTOftATIC

RUN 11ETHOO :

EQUILIBRATED

EQ4JILIBRATIOH TI/'tE:

~O

seconds

INTRUSION DATA SUl1'1ARY
TOTAL INTRUSION VOLUl'IE

=

TOT Al P0 RE AREA

=

"EOIAH PORE DIA"ETER (VOLU"E) =
"EDIAH PORE DIAMETEf (AREA) =
AVER.AGE PORE DlAAETER C4V/A) =
BULK DENS I TY

=

APPARENT (SKELETAL) DENSITY =
POROSITY

=

STEM VOLUME USED ,.

253

0. 5925 ol/9
20 . 711 sq-•/g
16.7441 ,,.
O.CIJ97 11•
0.1144 11•
0 . 6928 g / ol
1. 1752 9 / •l
41 . 05

x

,, %

****
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Appendix 4

Determination of nifedipine in plasma after oral administration of nifedipine erosion matrix
pellet capsule and Adalat® soft gelatin capsule in fasted dogs.

__,..·
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!-!PLC METHOD VALIDATION:

DETERMINATION OF NIFEDIPINE IN PLASMA AFTER ORAL
ADMINISTRATION OF NIFEDIPINE EROSION MATRIX PELLETS AND
ADALAT® SOFT GELATIN CAPSULES IN FASTED DOGS.

l.

TEST ARTICLES :

Nifedipine erosion matrix pellets (30 mg capsules, Lot #KM 280/2).
Adalat® soft gelatin capsules (I 0 mg and 20 mg, Lot # 6 EAB and 5 HAX respectively
manufactured by Bayer Corporation, West Haven, CT, USA).

2.

!-!PLC METHOD:

System:
Pump:

Waters 600 E Multi Solvent Delivery System (Waters Corporation,
Milford, MA, USA) .

Injector:

Waters 717 Plus Auto Sampler (Waters Corporation, Milford, MA, USA).

Column:

Zorbax ODS , 4-6 microns reverse phase, 25 cm X 4.6 mm (I. D., Dupont
Inc., Wilmington, DE).

Heator:

Column Heator Model Code 600 (Waters Corporation, Milford, MA,
USA).

Detector:

Variable wavelength detecto r, Model Spectra Physics 100, UV/VIS
(Spectra Physics, USA) .
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Parameters:
Flow Rate:

0.8 rnUmin

Injection Vol: 20 µL
Col Tempt:

55°C

Col Pressure: 1200 Psi
Detector:

A..,,., 237 nm, 0.001 AUFS

Run Time:

30 minutes

Solutions:
Mobile Phase:
0.01 M disodium hydrogen phosphate buffer : methanol (45 :55) was mixed for 30 minutes
Before mixing the buffer was brought to pH 6. I with 50% v/v phosphoric acid . This
solution was then sonicated for IO minutes and was filtered through a 0.5µ filter.

Extraction Solvent:
Chloroform : acetone were mixed in ratio of I : I for 30 minutes and was used as the
extraction solvent for nifedipine from the plasma.

3.

LINEARITY:

Linearity of nifedipine in methanol and plasma samples spiked with standard methanolic
solution of nifedipine was determined by simple linear regression method . Figure I
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depicts the standard curve and linear regression of nifedipine in methanol and plasma. The
following concentrations were used for linearity determinations.

Solution#

Concentration in methanol and plasma (µg/mL)

I.

0.05014

2.

0.10028

3.

0.20050

4.

0.40010

5.

0.60480

6.

0.80220

7.

1.00280

8.

10.02800

Correlation coefficient for linearity determinations in methanol was 0.9998 and in plasma
was 0.9940. Extraction ratio of drug from plasma to organic phase at all concentrations
was not less than 95 % .

4.

PRECISION:

Assay precision was determined by plotting the peak height ratios of triplicate injections of
nifedipine samples of known concentrations against the standard curves generated in the
previous section. The mean % difference between the actual concentration of the samples
and that determined by the standard curve were always below 5% during the entire
analysis period.
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5.

REPRESENTATIVE CHROMATOGRAMS:

Figures 2 through 41 are the chromatograms of plasma samples after injection, obtained
from four dogs each administered with nifedipine erosion matrix pellet capsule (30
mg/dog/day) at 0, l , 2, 4, 6, 8, 12, 16, 20 and 24 hours. Figures 42 through 73 ar_e the
chromatograms of plasma samples after injection , obtained from four dogs each
administered with Adalat® soft gelatin capsule (10 + 20 mg/dog/day) at 0, 0.5, I, 2, 4, 6,
8 and 12 hours.
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Calibration graph of nifeipine in methanol and plasma.
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Figure 2
Chromatogram of plasma sample obtained from dog# I administered with nifedipine
erosion matrix pellet capsule at 0.0 hours.
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Figure 3
Chromatogram of plasma sample obtained from dog # I administered with nifedipine
erosion matrix pellet capsule at I. 0 hours.
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Figure 4
Chromatogram of plasma sample obtained from dog # I administered with nifedipine
erosion matrix pellet capsule at 2.0 hours.
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Chromatogram of plasma sample obtained from dog # I administered with nifedipine
erosion matrix pellet capsule at 4.0 hours .
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Chromatogram of plasma sample obtained from dog # I administered with nifedipine
erosion matrix pellet capsule at 6.0 hours.
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Figure 7
Chromatogram of plasma sample obtained from dog # 1 administered with nifedipine
erosion matrix pellet capsule at 8.0 hours.
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Figure 8
Chromatogram of plasma sample obtained from dog # I administered with nifedipine
erosion matrix pellet capsule at 12.0 hours.
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Figure 9
Chromatogram of plasma sample obtained from dog# I administered with nifedipine
erosion matrix pellet capsule at 16.0 hours .
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Chromatogram of plasma sample obtained from dog # 1 administered with nifedipine
erosion matrix pellet capsule at 20. 0 hours.
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Figure 11
Chromatogram of plasma sample obtained from dog # I administered with nifedipine
erosion matrix pellet capsule at 24.0 hours.
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Figure 12
Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 0.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at I. 0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 2.0 hours.
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fulill...12
Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 4.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 6.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 8.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 12.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 16.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 20.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with nifedipine
erosion matrix pellet capsule at 24 .0 hours.
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Chromatogram of plasma sample obtained from dog# 3 administered with nifedipine
erosion matrix pellet capsule at 0.0 hours.
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Figure 23
Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at I. 0 hours.
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at 2.0 hours .
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Figure 25
Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at 4.0 hours.
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Figure 26
Chromatogram of plasma sample obtained from dog# 3 administered with nifedipine
erosion matrix pellet capsule at 6.0 hours.
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Figure 27
Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at 8.0 hours.
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at 12.0 hours.
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Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at 16.0 hours.
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1. 1.. 1

Chromatogram of plasma sample obtained from dog # 3 administered with nifedipine
erosion matrix pellet capsule at 20.0 hours.
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Chromatogram of plasma sample obtained from dog# 3 administered with nifedipine
erosion matrix pellet capsule at 24.0 hours .
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 0.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at I. 0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 2.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 4.0 hours .
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l • l"I

Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 6.0 hours.
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Figure 37
Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 8.0 hours.
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Chromatogram of plasma sample obtained from dog# 4 administered with nifedipine
erosion matrix pellet capsule at 12.0 hours .
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 16.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 20.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with nifedipine
erosion matrix pellet capsule at 24 .0 hours.
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Figure 42
Chromatogram of plasma sample obtained from dog # I administered with Adalat soft
gelatin capsules at 0.0 hours.
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Figure 43
Chromatogram of plasma sample obtained from dog # I administered with Adalat soft
gelatin capsules at 0.5 hours.
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Figure 44
Chromatogram of plasma sample obtained from dog # l administered with Adalat soft
gelatin capsules at I. 0 hours.
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Figure 45
Chromatogram of plasma sample obtained from dog# I administered with Adalat soft
gelatin capsules at 2.0 hours.
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Chromatogram of plasma sample obtained from dog# 1 administered with Adalat soft
gelatin capsules at 4.0 hours.
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Chromatogram of plasma sample obtained from dog # I administered with Adalat soft
gelatin capsules at 6.0 hours.
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Chromatogram of plasma sample obtained from dog # I administered with Adalat soft
gelatin capsules at 8.0 hours.
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Chromatogram of plasma sample obtained from dog # I administered with Adalat soft
gelatin capsules at 12.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 0.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 0.5 hours.
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Chromatogram of plasma sample obtained from dog# 2 administered with Adalat soft
gelatin capsules at I. 0 hours .
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 2.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 4.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 6.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 8.0 hours.
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Chromatogram of plasma sample obtained from dog # 2 administered with Adalat soft
gelatin capsules at 12.0 hours.

3 15

Chromatogram of plasma sample obtained from dog# 3 administered with Adalat soft
gelatin capsules at 0.0 hours.
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Figure 59
Chromatogram of plasma sample obtained from dog# 3 administered with Adalat soft
gelatin capsules at 0.5 hours.
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Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft
gelatin capsules at I. 0 hours.
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Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft
gelatin capsules at 2.0 hours.
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Figure 62
Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft
gelatin capsules at 4.0 hours.
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Chromatogram of plasma sample obtained from dog # 3 administered with Adalat soft
gelatin capsules ~t 8.0 hours.
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Figure 65
Chromatogram of plasma sample obtained from dog# 3 administered with Adalat soft
gelatin capsules at 12.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 0.0 hours .
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Figure 67
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 0.5 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with Ad al at soft .
gelatin capsules at 1.0 hours.
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Figure 69
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 2.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 4.0 hours.
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Figure 71
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 6.0 hours.
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Figure 72
Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 8.0 hours.
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Chromatogram of plasma sample obtained from dog # 4 administered with Adalat soft
gelatin capsules at 12.0 hours .
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